

Efficacy and Mechanism Evaluation

Volume 8 • Issue 10 • July 2021

ISSN 2050-4365

Defining phenotypes and treatment effect heterogeneity to inform acute respiratory distress syndrome and sepsis trials: secondary analyses of three RCTs

Manu Shankar-Hari, Shalini Santhakumaran, A Toby Prevost, Josie K Ward, Timothy Marshall, Claire Bradley, Carolyn S Calfee, Kevin L Delucchi, Pratik Sinha, Michael A Matthay, Jonathan Hackett, Cliona McDowell, John G Laffey, Anthony Gordon, Cecilia M O'Kane and Daniel F McAuley



Defining phenotypes and treatment effect heterogeneity to inform acute respiratory distress syndrome and sepsis trials: secondary analyses of three RCTs

Manu Shankar-Hari^{ID},^{1,2*} Shalini Santhakumaran^{ID},³
A Toby Prevost^{ID},³ Josie K Ward^{ID},⁴ Timothy Marshall^{ID},⁴
Claire Bradley^{ID},⁴ Carolyn S Calfee^{ID},^{5,6,7}
Kevin L Delucchi^{ID},⁸ Pratik Sinha^{ID},⁵ Michael A Matthay^{ID},⁵
Jonathan Hackett^{ID},⁹ Cliona McDowell^{ID},¹⁰
John G Laffey^{ID},¹¹ Anthony Gordon^{ID},⁴
Cecilia M O’Kane^{ID}¹² and Daniel F McAuley^{ID}^{9,10,12}

¹Department of Intensive Care Medicine, Guy’s and St Thomas’ NHS Foundation Trust, London, UK

²School of Immunology and Microbial Sciences, King’s College London, London, UK

³Imperial Clinical Trials Unit, School of Public Health, Imperial College London, London, UK

⁴Intensive Care Unit, Imperial College/Charing Cross Hospital, London, UK

⁵Department of Medicine, University of California, San Francisco, CA, USA

⁶Department of Anaesthesia, University of California, San Francisco, CA, USA

⁷Cardiovascular Research Institute, University of California, San Francisco, CA, USA

⁸Department of Psychiatry, University of California, San Francisco, CA, USA

⁹Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, UK

¹⁰Northern Ireland Clinical Trials Unit, Royal Victoria Hospital, Belfast, UK

¹¹Anaesthesia, School of Medicine and Regenerative Medicine Institute (REMEDI), CÚRAM Centre for Research in Medical Devices, National University of Ireland Galway, Galway, Ireland

¹²Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, Belfast, UK

*Corresponding author

Declared competing interests of authors: Manu Shankar-Hari is funded by a National Institute for Health Research (NIHR) Clinician Scientist Award (reference CS-2016-16-011). A Toby Prevost is a member of the Public Health Research Funding Board. Claire Bradley reports grants from the Wellcome Trust Institution Strategic Support Fund (London, UK) during the conduct of the study. Carolyn S Calfee reports grants from the National Institutes of Health (Bethesda, MD, USA) during the conduct of the study. Carolyn S Calfee also reports grants from GlaxoSmithKline plc (GlaxoSmithKline plc, Brentford, UK), grants and personal fees from Bayer AG (Leverkusen, Germany), personal fees from ProMetic Life Sciences Inc. (Laval, QC, Canada), CSL Behring (King of Prussia, PA, USA), Quark Pharmaceuticals, Inc. (Ness Ziona, Israel) and Roche Holding AG (Basel, Switzerland)/Genentech Inc.

(South San Francisco, CA, USA) outside the submitted work. Michael A Matthay reports grants from National Institutes of Health/National Heart, Lung, and Blood Institute (Bethesda, MD, USA), grants from the US Department of Defense (Arlington, VA, USA), Bayer AG, GlaxoSmithKline plc, and personal fees from Cerus Therapeutics (Concord, CA, USA) outside the submitted work. John G Laffey reports grants from the Health Research Board (Dublin, Ireland) during the conduct of the study. Anthony Gordon reports that he has received speaker fees from Orion Corporation (Espoo, Finland) and Amomed Pharma GmbH (Vienna, Austria). He has consulted for Ferring Pharmaceuticals (Saint-Prex, Switzerland), Tenax Therapeutics, Inc. (Morrisville, NC, USA), Baxter Healthcare (Deerfield, IL, USA), Bristol Myers Squibb (New York, NY, USA) and GlaxoSmithKline plc, and has received non-financial support from Orion Corporation, and grant support from Tenax Therapeutics, Inc. and HCA Healthcare International (London, UK), with funds paid to his institution. He reports grants from the NIHR Efficacy and Mechanism Evaluation (EME) programme, NIHR Research for Patient Benefit programme, NIHR Research Imperial Biomedical Research Centre and from the NIHR Research Professorship award (reference RP-2015-06-018). Cecilia M O'Kane reports grants from the EME programme during the conduct of the study. In addition, she reports personal fees from GlaxoSmithKline plc, C.H. Boehringer Sohn AG & Co. KG (Ingelheim am Rhein, Germany) and Bayer AG, and grants from the Wellcome Trust and Innovate UK (Swindon, UK) outside the submitted work. Daniel F McAuley reports grants from the NIHR EME programme, Health Research Board, Northern Ireland Public Health Agency Research and Development (Belfast, UK), Intensive Care Society of Ireland and REVIVE for the conduct of this work. Outside the submitted work, Daniel F McAuley reports personal fees from consultancy for GlaxoSmithKline plc, C.H. Boehringer Sohn AG & Co. KG and Bayer AG. His institution has received funds from grants from NIHR, Wellcome Trust, Innovate UK and others. In addition, Daniel F McAuley is a named inventor on a patent US8962032 covering the use of sialic acid-bearing nanoparticles as anti-inflammatory agents issued to his institution. Daniel F McAuley is a Director of Research for the Intensive Care Society (London, UK) and is the NIHR EME Programme Director. Daniel F McAuley is a member of EME Strategy Advisory Group and a member of the EME Funding Committee.

Published July 2021

DOI: 10.3310/eme08100

This report should be referenced as follows:

Shankar-Hari M, Santhakumaran S, Prevost AT, Ward JK, Marshall T, Bradley C, *et al.* Defining phenotypes and treatment effect heterogeneity to inform acute respiratory distress syndrome and sepsis trials: secondary analyses of three RCTs. *Efficacy Mech Eval* 2021;**8**(10).

Efficacy and Mechanism Evaluation

ISSN 2050-4365 (Print)

ISSN 2050-4373 (Online)

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nihr.ac.uk

The full EME archive is freely available to view online at www.journalslibrary.nihr.ac.uk/eme. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the *Efficacy and Mechanism Evaluation* journal

Reports are published in *Efficacy and Mechanism Evaluation* (EME) if (1) they have resulted from work for the EME programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

EME programme

The Efficacy and Mechanism Evaluation (EME) programme funds ambitious studies evaluating interventions that have the potential to make a step-change in the promotion of health, treatment of disease and improvement of rehabilitation or long-term care. Within these studies, EME supports research to improve the understanding of the mechanisms of both diseases and treatments.

The programme supports translational research into a wide range of new or repurposed interventions. These may include diagnostic or prognostic tests and decision-making tools, therapeutics or psychological treatments, medical devices, and public health initiatives delivered in the NHS.

The EME programme supports clinical trials and studies with other robust designs, which test the efficacy of interventions, and which may use clinical or well-validated surrogate outcomes. It only supports studies in man and where there is adequate proof of concept. The programme encourages hypothesis-driven mechanistic studies, integrated within the efficacy study, that explore the mechanisms of action of the intervention or the disease, the cause of differing responses, or improve the understanding of adverse effects. It funds similar mechanistic studies linked to studies funded by any NIHR programme.

The EME programme is funded by the Medical Research Council (MRC) and the National Institute for Health Research (NIHR), with contributions from the Chief Scientist Office (CSO) in Scotland and National Institute for Social Care and Health Research (NISCHR) in Wales and the Health and Social Care Research and Development (HSC R&D), Public Health Agency in Northern Ireland.

This report

The research reported in this issue of the journal was funded by the EME programme as project number 16/33/01. The contractual start date was in November 2017. The final report began editorial review in July 2019 and was accepted for publication in May 2020. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The EME editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the MRC, NETSCC, the EME programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the EME programme or the Department of Health and Social Care.

© Queen's Printer and Controller of HMSO 2021. This work was produced by Shankar-Hari *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).

NIHR Journals Library Editor-in-Chief

Professor Ken Stein Professor of Public Health, University of Exeter Medical School, UK

NIHR Journals Library Editors

Professor John Powell Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

Professor Andrée Le May Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals) and Editor-in-Chief of HS&DR, PGfAR, PHR journals

Professor Matthias Beck Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin Senior Scientific Advisor, Wessex Institute, UK

Dr Peter Davidson Consultant Advisor, Wessex Institute, University of Southampton, UK

Ms Tara Lamont Senior Scientific Adviser (Evidence Use), Wessex Institute, University of Southampton, UK

Dr Catriona McDaid Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads Emeritus Professor of Wellbeing Research, University of Winchester, UK

Professor James Raftery Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

Professor Jonathan Ross Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Ken Stein Professor of Public Health, University of Exeter Medical School, UK

Professor Jim Thornton Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk

Abstract

Defining phenotypes and treatment effect heterogeneity to inform acute respiratory distress syndrome and sepsis trials: secondary analyses of three RCTs

Manu Shankar-Hari^{1,2*} Shalini Santhakumaran³ A Toby Prevost³
Josie K Ward⁴ Timothy Marshall⁴ Claire Bradley⁴
Carolyn S Calfee^{5,6,7} Kevin L Delucchi⁸ Pratik Sinha⁵
Michael A Matthay⁵ Jonathan Hackett⁹ Cliona McDowell¹⁰
John G Laffey¹¹ Anthony Gordon⁴ Cecilia M O’Kane¹²
and Daniel F McAuley^{9,10,12}

¹Department of Intensive Care Medicine, Guy’s and St Thomas’ NHS Foundation Trust, London, UK

²School of Immunology and Microbial Sciences, King’s College London, London, UK

³Imperial Clinical Trials Unit, School of Public Health, Imperial College London, London, UK

⁴Intensive Care Unit, Imperial College/Charing Cross Hospital, London, UK

⁵Department of Medicine, University of California, San Francisco, CA, USA

⁶Department of Anaesthesia, University of California, San Francisco, CA, USA

⁷Cardiovascular Research Institute, University of California, San Francisco, CA, USA

⁸Department of Psychiatry, University of California, San Francisco, CA, USA

⁹Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, UK

¹⁰Northern Ireland Clinical Trials Unit, Royal Victoria Hospital, Belfast, UK

¹¹Anaesthesia, School of Medicine and Regenerative Medicine Institute (REMEDI), CÚRAM Centre for Research in Medical Devices, National University of Ireland Galway, Galway, Ireland

¹²Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, Belfast, UK

*Corresponding author manu.shankar-hari@kcl.ac.uk

Background: Sepsis and acute respiratory distress syndrome are two heterogeneous acute illnesses with high risk of death and for which there are many ‘statistically negative’ randomised controlled trials. We hypothesised that negative randomised controlled trials occur because of between-participant differences in response to treatment, illness manifestation (phenotype) and risk of outcomes (heterogeneity).

Objectives: To assess (1) heterogeneity of treatment effect, which tests whether or not treatment effect varies with a patient’s pre-randomisation risk of outcome; and (2) whether or not subphenotypes explain the treatment response differences in sepsis and acute respiratory distress syndrome demonstrated in randomised controlled trials.

Study population: We performed secondary analysis of two randomised controlled trials in patients with sepsis [i.e. the Vasopressin vs Noradrenaline as Initial Therapy in Septic Shock (VANISH) trial and the Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS) trial] and one acute respiratory distress syndrome multicentre randomised controlled trial [i.e. the Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP-2) trial], conducted in the UK. The VANISH trial is a 2 × 2 factorial randomised controlled trial of vasopressin (Pressyn AR®; Ferring Pharmaceuticals, Saint-Prex, Switzerland)

and hydrocortisone sodium phosphate (hereafter referred to as hydrocortisone) (Efcortisol™; Amdipharm plc, St Helier, Jersey) compared with placebo. The LeoPARDS trial is a two-arm-parallel-group randomised controlled trial of levosimendan (Simdax®; Orion Pharma, Espoo, Finland) compared with placebo. The HARP-2 trial is a parallel-group randomised controlled trial of simvastatin compared with placebo.

Methods: To test for heterogeneity of the effect on 28-day mortality of vasopressin, hydrocortisone and levosimendan in patients with sepsis and of simvastatin in patients with acute respiratory distress syndrome. We used the total Acute Physiology And Chronic Health Evaluation II (APACHE II) score as the baseline risk measurement, comparing treatment effects in patients with baseline APACHE II scores above (high) and below (low) the median using regression models with an interaction between treatment and baseline risk. To identify subphenotypes, we performed latent class analysis using only baseline clinical and biomarker data, and compared clinical outcomes across subphenotypes and treatment groups.

Results: The odds of death in the highest APACHE II quartile compared with the lowest quartile ranged from 4.9 to 7.4, across the three trials. We did not observe heterogeneity of treatment effect for vasopressin, hydrocortisone and levosimendan. In the HARP-2 trial, simvastatin reduced mortality in the low-APACHE II group and increased mortality in the high-APACHE II group. In the VANISH trial, a two-subphenotype model provided the best fit for the data. Subphenotype 2 individuals had more inflammation and shorter survival. There were no treatment effect differences between the two subphenotypes. In the LeoPARDS trial, a three-subphenotype model provided the best fit for the data. Subphenotype 3 individuals had the greatest inflammation and lowest survival. There were no treatment effect differences between the three subphenotypes, although survival was lowest in the levosimendan group for all subphenotypes. In the HARP-2 trial, a two-subphenotype model provided the best fit for the data. The inflammatory subphenotype was associated with fewer ventilator-free days and higher 28-day mortality.

Limitations: The lack of heterogeneity of treatment effect and any treatment effect differences between sepsis subphenotypes may be secondary to the lack of statistical power to detect such effects, if they truly exist.

Conclusions: We highlight lack of heterogeneity of treatment effect in all three trial populations. We report three subphenotypes in sepsis and two subphenotypes in acute respiratory distress syndrome, with an inflammatory phenotype with greater risk of death as a consistent finding in both sepsis and acute respiratory distress syndrome.

Future work: Our analysis highlights the need to identify key discriminant markers to characterise subphenotypes in sepsis and acute respiratory distress syndrome with an observational cohort study.

Funding: This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a MRC and National Institute for Health Research (NIHR) partnership. This will be published in full in *Efficacy and Mechanism Evaluation*; Vol. 8, No. 10. See the NIHR Journals Library website for further project information.

Contents

List of tables	xi
List of figures	xiii
List of abbreviations	xvii
Plain English summary	xix
Scientific summary	xxi
Chapter 1 Introduction	1
Sepsis	1
Acute respiratory distress syndrome	1
Hypothesis	2
Aims and objectives	2
Heterogeneity of treatment effect	2
<i>Conceptual approach for heterogeneity of treatment effect</i>	3
Latent class analysis to identify sepsis phenotypes	3
Latent class analysis to identify acute respiratory distress syndrome phenotypes	4
Chapter 2 Methods	5
Study approvals and randomised controlled trials data sets	5
<i>The VANISH trial</i>	5
<i>The LeoPARDS trial</i>	5
<i>The HARP-2 trial</i>	5
<i>Groups for comparison</i>	5
Heterogeneity of treatment effect	5
<i>Outcomes</i>	6
<i>Measures of baseline risk</i>	6
<i>Recalibrating APACHE II</i>	6
<i>Descriptive analysis</i>	8
<i>Regression modelling</i>	9
<i>Sensitivity analyses</i>	9
Determining sepsis subphenotypes using latent class analysis	10
<i>Biomarker measurements</i>	10
<i>Exploratory analysis</i>	10
<i>Latent class modelling</i>	10
<i>Non-technical description of latent class analysis methods</i>	11
<i>Description of subphenotypes</i>	12
<i>Clinical outcomes</i>	12
<i>Sensitivity analysis</i>	12
Determining acute respiratory distress syndrome subphenotypes using latent class analysis	13

CONTENTS

Chapter 3 Results	15
Heterogeneity of treatment effect	15
<i>Descriptive analysis</i>	15
<i>Modified APACHE II risk of death model recalibrated</i>	15
<i>The VANISH trial heterogeneity of treatment effect assessment</i>	26
<i>The LeoPARDS trial heterogeneity of treatment effect assessment</i>	26
<i>The HARP-2 trial heterogeneity of treatment effect assessment</i>	26
<i>Serious adverse events and baseline risk</i>	26
<i>Heterogeneity of treatment effect assessment on continuous scale using regression</i>	33
<i>Sensitivity analyses</i>	34
Determining subphenotypes using latent class analysis	34
<i>Exploratory analysis</i>	34
<i>Latent class analysis: the VANISH trial</i>	39
<i>Latent class analysis: the LeoPARDS trial</i>	48
<i>Latent class analysis: the HARP-2 trial</i>	55
Chapter 4 Discussion	63
Heterogeneity of treatment effect	63
<i>Main findings</i>	63
<i>Explanation of key findings</i>	63
<i>Comparison to published literature</i>	63
<i>Strengths and weakness</i>	64
Latent class analysis	64
<i>Main findings in the VANISH trial and the LeoPARDS trial</i>	64
<i>Comparison to published literature</i>	64
<i>Strengths and weakness</i>	65
<i>Main findings in the HARP-2 trial</i>	65
<i>Comparison with published acute respiratory distress syndrome literature</i>	65
<i>Strengths and weakness</i>	66
Chapter 5 Implications of future research	67
Heterogeneity of treatment effect analysis	67
Latent class analysis	67
Chapter 6 Conclusions	69
Grant applications to carry forward the hypothesis generated by this work	69
Acknowledgements	71
References	75
Appendix 1 Tables and figures	81

List of tables

TABLE 1 Calculation of APACHE II score in trial cohorts	7
TABLE 2 Trial-level summary characteristics	16
TABLE 3 Predictive performance of APACHE II score and <i>R</i>	24
TABLE 4 Area under receiver operating characteristic and DS for recalibrated models	25
TABLE 5 Estimated parameters from the logistic regression model M3	25
TABLE 6 Treatment–risk interaction using continuous APACHE II score from logistic regression analysis of 28-day mortality	33
TABLE 7 Results from multiple imputation analysis	36
TABLE 8 Patient characteristics at baseline for patients with some baseline sample data	36
TABLE 9 Biomarker data at baseline: the VANISH trial	37
TABLE 10 Biomarker data at baseline: the LeoPARDS trial	38
TABLE 11 Model fit statistics for all LCA models in the VANISH trial	41
TABLE 12 Baseline characteristics by assigned class in the LeoPARDS trial and the VANISH trial	44
TABLE 13 Biomarker data by class, with study participants assigned by highest posterior class probability	46
TABLE 14 Clinical outcomes by class in the LeoPARDS trial and the VANISH trial	48
TABLE 15 Model fit statistics for all models: the LeoPARDS trial	51
TABLE 16 Model coefficients from the multinomial regression model in the LeoPARDS trial	57
TABLE 17 Fit statistics for LCA model in the HARP-2 trial	57
TABLE 18 Clinical outcomes by subphenotype in the HARP-2 trial	58
TABLE 19 Estimated class distribution, indicator means and separation for stage 1: the VANISH trial	82
TABLE 20 Estimated class distribution, indicator means and separation for stage 2: the VANISH trial	83
TABLE 21 Estimated class distribution, indicator means and separation for stage 3a: the VANISH trial	84

TABLE 22 Estimated class distribution, indicator means and separation for stage 3b: the VANISH trial	85
TABLE 23 Estimated class distribution, indicator means and separation for stage 3c: the VANISH trial	86
TABLE 24 Differences in class assignment for main analysis and sensitivity analysis	86
TABLE 25 Estimated class distribution, indicator means and separation for stage 1, two- to four-class models: the LeoPARDS trial	87
TABLE 26 Estimated class distribution, indicator means and separation for stage 1, five latent classes: the LeoPARDS trial	88
TABLE 27 Estimated class distribution, indicator means and separation for stage 2: the LeoPARDS trial	89
TABLE 28 Estimated class distribution, indicator means and separation for stage 3a: the LeoPARDS trial	90
TABLE 29 Estimated class distribution, indicator means and separation for stage 3b: the LeoPARDS trial	91
TABLE 30 Estimated class distribution, indicator means and separation for stage 3c: the LeoPARDS trial	93
TABLE 31 Patient characteristics of the HARP-2 trial cohort	95
TABLE 32 List of class-defining variables used in the LCA in the HARP-2 trial	95

List of figures

FIGURE 1	Distribution of APACHE II score by study drug 1: the VANISH trial cohort	17
FIGURE 2	Distribution of APACHE II score by study drug 2: the VANISH trial cohort	17
FIGURE 3	Distribution of $R_{\text{calc.}}$ by study drug 1: the VANISH trial cohort	18
FIGURE 4	Distribution of $R_{\text{calc.}}$ by study drug 2: the VANISH trial cohort	18
FIGURE 5	Distribution of APACHE II score by treatment: the LeoPARDS trial cohort	19
FIGURE 6	Distribution of $R_{\text{calc.}}$ by treatment: the LeoPARDS trial cohort	19
FIGURE 7	Distribution of APACHE II score by treatment: the HARP-2 trial cohort	20
FIGURE 8	Mortality at day 28 (proportion) by APACHE II score: the VANISH trial cohort	20
FIGURE 9	Hospital mortality (proportion) by APACHE II score: the VANISH trial cohort	20
FIGURE 10	Mortality at 28 days (proportion) by APS-APII: the VANISH trial cohort	21
FIGURE 11	Hospital mortality (proportion) by APS-APII: the VANISH trial cohort	21
FIGURE 12	Mortality at day 28 (proportion) by $R_{\text{calc.}}$: the VANISH trial cohort	21
FIGURE 13	Hospital mortality (proportion) by $R_{\text{calc.}}$: the VANISH trial cohort	22
FIGURE 14	Mortality at day 28 (proportion) by APACHE II score: the LeoPARDS trial cohort	22
FIGURE 15	Hospital mortality (proportion) by APACHE II score: the LeoPARDS trial cohort	22
FIGURE 16	Mortality at 28 days (proportion) by APS-APII: the LeoPARDS trial cohort	23
FIGURE 17	Hospital mortality by APS-APII: the LeoPARDS trial cohort	23
FIGURE 18	Mortality at day 28 (proportion) by $R_{\text{calc.}}$: the LeoPARDS trial cohort	23
FIGURE 19	Hospital mortality (proportion) by $R_{\text{calc.}}$: the LeoPARDS trial cohort	24
FIGURE 20	Mortality at 28 days (proportion) by APACHE II score: the HARP-2 trial cohort	24
FIGURE 21	Forest plots for the RD and RR comparing 28-day mortality in treatment and control, by trial and APACHE II score subgroup	27
FIGURE 22	Forest plots for the RD and RR comparing 28-day mortality in treatment and control, by trial and APS-APII subgroup	28

FIGURE 23 Forest plots for the RD and RR comparing 28-day mortality in treatment and control, by trial and <i>R</i> subgroup	29
FIGURE 24 Forest plots for the RD and RR comparing 28-day mortality in treatment and control, by trial and R_{recal} . (recalibration model with only controls) subgroup	30
FIGURE 25 Forest plots for the RD and RR comparing 28-day mortality in treatment and control, by trial and R_{recal} . (recalibration model with whole cohort) subgroup	31
FIGURE 26 Forest plots for the RD and RR comparing related serious adverse events in treatment and control, by trial and APACHE II score subgroup	32
FIGURE 27 Heterogeneity of treatment effect assessment for APACHE II score as a continuous variable	33
FIGURE 28 Forest plots for the RD and RR comparing hospital mortality in treatment and control, by trial and APACHE II score subgroup	35
FIGURE 29 Plots of model fit indicators in the VANISH trial: (a) log-likelihood; (b) AIC; and (c) BIC	41
FIGURE 30 Box plot showing distribution of indicators by class for candidate models, assigning to modal class, in the VANISH trial	43
FIGURE 31 No evidence for treatment effect variation by class for any of the survival outcomes of the VANISH trial and the LeoPARDS trial	49
FIGURE 32 No evidence for treatment effect variation by class for any of the organ dysfunction outcomes of the VANISH trial and the LeoPARDS trial	50
FIGURE 33 Plots of model fit indicators in the LeoPARDS trial: (a) log-likelihood; (b) AIC; and (c) BIC	52
FIGURE 34 Box plot showing distribution of indicators by class for candidate models, assigning to modal class, in the LeoPARDS trial	54
FIGURE 35 Class-specific (a) sensitivity, (b) specificity and (c) c-statistics for multinomial logit models with increasing number of predictors in the LeoPARDS trial	55
FIGURE 36 Differences in standardised values of each continuous variable by subphenotype in the HARP-2 trial	58
FIGURE 37 Kaplan–Meier survival curves	59
FIGURE 38 Survival curves stratified by mean APACHE II score	61
FIGURE 39 Time to unassisted breathing over 28 days in the HARP-2 trial	62
FIGURE 40 Separation plot for the stage 2 two-class model: the VANISH trial	96
FIGURE 41 Separation plot for the stage 2 three-class model: the VANISH trial	97
FIGURE 42 Separation plot for the stage 3b two-class model: the VANISH trial	98

FIGURE 43 Separation plot for the stage 3 three-class model: the VANISH trial	99
FIGURE 44 Separation plot for the stage 2 model: the LeoPARDS trial	100
FIGURE 45 Separation plot for the stage 3a model: the LeoPARDS trial	101
FIGURE 46 Separation plot for the stage 3b model: the LeoPARDS trial	102
FIGURE 47 Separation plot for the stage 3c model: the LeoPARDS trial	103

List of abbreviations

AIC	Akaike information criterion	MPO	myeloperoxidase
ANG II	angiotensin II	NT-proBNP	N-terminal pro-B-type natriuretic peptide
APACHE II	Acute Physiology And Chronic Health Evaluation II	NYHA IV	New York Heart Association class IV
APS-APII	APACHE II physiology	OR	odds ratio
ARDS	acute respiratory distress syndrome	PaO ₂	partial pressure of oxygen
AUROC	area under receiver operating characteristic	PROWESS	PROtein C Worldwide Evaluation in Severe Sepsis
BIC	Bayesian information criterion	R	risk
BMI	body mass index	R _{calc.}	APACHE II-calculated risk of death
CCL2	C-C motif chemokine ligand 2	RCT	randomised controlled trial
CI	confidence interval	RD	risk difference
COPD	chronic obstructive pulmonary disease	RR	risk ratio
DS	discrimination slope	R _{recal.}	Modified APACHE II risk of death model recalibrated
EQuOR	extreme quartile odds ratio	SD	standard deviation
FiO ₂	fraction of inspired oxygen	SE	standard error
HARP-2	Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction	sICAM	soluble intercellular adhesion molecule
HTE	heterogeneity of treatment effect	SOFA	Sepsis-related Organ Failure Assessment
ICU	intensive care unit	SRS1	sepsis response signature 1
IL	interleukin	SRS2	sepsis response signature 2
IQR	interquartile range	sTNFR1	soluble tumour necrosis factor receptor 1
LCA	latent class analysis	VANISH	Vasopressin vs Noradrenaline as Initial Therapy in Septic Shock
LeoPARDS	Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis		

Plain English summary

In this project we studied two common conditions that often necessitate admission to an intensive care unit: sepsis and acute respiratory distress syndrome. We found that, although numerous medical treatments are used to treat patients with these two conditions, studies have shown that they have limited success in reducing the risk of dying.

We hypothesised that clinical trials have failed to show benefit because of differences between participants, such that the treatments benefit some patients but harm and/or show no benefit or harm in other patients. To test this theory, we obtained ethics approval to examine, in two separate analyses, clinical and laboratory data from two sepsis trials and one acute respiratory distress syndrome trial.

The first analysis explored whether or not trial participants' risk of dying affected how the treatments worked (referred to as heterogeneity of treatment effect analysis). The treatment effect of the drugs tested in the sepsis trials did not vary with differences in risk of dying, whereas the drug tested in the acute respiratory distress syndrome trial (simvastatin) probably benefited patients with the lowest risk of dying.

The second analysis explored whether or not patients with these conditions can be divided into subgroups in which the treatments have different effects (referred to as latent class analysis). In the case of sepsis, we identified two sepsis subgroups in one trial and three sepsis subgroups in the other trial but found no differences in treatment effect between subgroups in either trial. In the acute respiratory distress syndrome trial we identified two subgroups, and found that treatment was more beneficial in one subgroup.

Our analysis highlights the value of finding participants with greater similarities (subgroups) within sepsis and acute respiratory distress syndrome to help design future clinical trials.

Scientific summary

Background

Sepsis and acute respiratory distress syndrome are two heterogeneous acute illnesses associated with a high risk of death. Heterogeneity in this case means inter-individual variation in susceptibility to illness, illness manifestation (phenotype), response to treatment and outcomes, or combinations thereof.

Objectives

We hypothesised that negative randomised controlled trials in sepsis and acute respiratory distress syndrome are due to heterogeneity. A negative trial is one in which differences between the intervention and control arms are statistically non-significant. This hypothesis could be tested in two different ways: first, by assessing heterogeneity of treatment effect, that is whether or not treatment effect varies according to patients' pre-randomisation risk of outcome, and, second, by assessing whether or not distinct patient subgroups (subphenotypes) in which treatment effect differs can be identified in trial populations using clinical and biomarker data.

Methods

We tested our hypothesis using data from three recent randomised controlled trials: two sepsis trials [i.e. the Vasopressin vs Noradrenaline as Initial Therapy in Septic Shock (VANISH) trial and the Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis (LeoPARDS) trial] and one acute respiratory distress syndrome trial [i.e. the Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP-2) trial]. To test for heterogeneity of the effect on 28-day mortality of vasopressin (Pressyn AR[®]; Ferring Pharmaceuticals, Saint-Prex, Switzerland), hydrocortisone sodium phosphate (hereafter referred to as hydrocortisone) (Efcortisol[™]; Amdipharm plc, St Helier, Jersey) and levosimendan (Simdax[®]; Orion Pharma, Espoo, Finland) in patients with sepsis, and simvastatin in patients with acute respiratory distress syndrome, we used the total Acute Physiology And Chronic Health Evaluation II (APACHE II) score as the baseline risk measurement, comparing treatment effects in patients with baseline APACHE II scores above (high) and below (low) the median using regression models with an interaction between treatment and baseline risk.

Results

When we assessed heterogeneity of treatment effect using multivariable baseline risk of death models, we observed considerable within-trial variation in the baseline risk of death. We observed potential heterogeneity of the treatment effect of simvastatin in acute respiratory distress syndrome, but no evidence of heterogeneity of the treatment effect of vasopressin, hydrocortisone or levosimendan in the two sepsis trials. Our findings could be explained either by true lack of heterogeneity of treatment effect (i.e. no benefit of vasopressin, hydrocortisone or levosimendan relative to comparator in any patient subgroups) or by lack of power to detect heterogeneity of treatment effect.

To assess whether or not distinct phenotypes exist within sepsis and acute respiratory distress syndrome trial populations, we performed latent class analysis using clinical, laboratory and biomarker data. In the VANISH trial we identified two sepsis subphenotypes and found that subphenotype 2 individuals had more inflammation (higher concentrations of interleukin 1 beta, interleukin 6, interleukin 8, interleukin 10,

myeloperoxidase, angiotensin II, troponin, B-type natriuretic peptide and soluble tumour necrosis factor receptor 1) and shorter survival. There were no significant treatment effect differences between the two subphenotypes. In the LeoPARDS trial, we identified three sepsis subphenotypes and found that subphenotype 3 individuals had more inflammation (higher concentrations of interleukin 1 beta, interleukin 6, interleukin 8, interleukin 10, interleukin 17, angiotensin II, troponin, B-type natriuretic peptide, C-C motif chemokine ligand 2 and soluble tumour necrosis factor receptor 1) and were less likely to survive to 90 days. There were no significant between-class differences in the treatment effect of levosimendan, but among all subphenotypes survival was lower in the levosimendan group. A multinomial logit model with interleukin 6, interleukin 8, interleukin 10 and C-C motif chemokine ligand 2 as predictors gave a sensitivity of around 0.9 and a specificity of ≥ 0.9 for all subphenotypes. In the HARP-2 trial we again identified two subphenotypes of acute respiratory distress syndrome, and mortality was higher among those with the hyperinflammatory subphenotype than those with the hypoinflammatory subphenotype. Among those with the hyperinflammatory subphenotype, patients treated with simvastatin were more likely than those treated with a placebo to survive to 28 days.

Conclusions

We present a hypothesis-driven secondary analyses of three recent negative randomised controlled trials in sepsis and acute respiratory distress syndrome. Pre-randomisation risk of death varied in all three trial populations, and this variation was associated with differences in the treatment effect of simvastatin. We report three subphenotypes of sepsis and two subphenotypes of acute respiratory distress syndrome, with an association between an inflammatory phenotype and greater risk of death being a consistent finding. These phenotypes have discriminant markers that could form the basis point-of-care tests for future studies. A minimum set of markers to characterise phenotypes in sepsis and acute respiratory distress syndrome should be confirmed with an observational cohort study. Our analysis highlights the value of identifying sepsis and acute respiratory distress syndrome patients with similar marker profiles and the value of stratified medicine in these populations.

Funding

This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a MRC and National Institute for Health Research (NIHR) partnership. This will be published in full in *Efficacy and Mechanism Evaluation*; Vol. 8, No. 10. See the NIHR Journals Library website for further project information.

Chapter 1 Introduction

Sepsis

Sepsis and septic shock were defined in 2016.¹ Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection. The clinical criteria for sepsis are organ dysfunction [defined as an increase in the Sepsis-related Organ Failure Assessment (SOFA) score of ≥ 2 points] in the context of suspected or proven infection as the cause of acute illness. Septic shock is defined as a subset of sepsis, in which particularly profound circulatory, cellular and metabolic abnormalities are associated with a greater risk of mortality than sepsis alone. The clinical criteria for septic shock include vasopressor requirement to maintain a mean arterial pressure of ≥ 65 mmHg and a serum lactate level > 2 mmol/l (> 18 mg/dl) in the absence of hypovolaemia.^{1,2}

Sepsis is common. The extrapolated population incidence of Sepsis-3 sepsis and Sepsis-3 septic shock in England was 101.8 and 19.3 per 100,000 person-years, respectively, in 2015,³ and global incidence continues to increase every year.³⁻⁵ The mortality rate of patients admitted to critical care with sepsis remains high, at 30–40%. Since the first consensus definition of sepsis in 1992, although there has been a consistent reduction in sepsis mortality, there have been numerous statistically negative trials of potential interventions.⁶ Many of the interventions tested in late-phase trials had biological plausibility in preclinical studies and in early-phase trials, and some have even been tested in late-phase trials whose design was based on a priori-defined subgroup differences in the treatment effects observed in earlier Phase III trials.⁶ The often-cited reason for these statistically negative trial results is heterogeneity of sepsis cohorts.^{7,8} This has led to calls to identify subphenotypes among the overall (crude) sepsis and septic shock phenotype.⁸

Acute respiratory distress syndrome

Acute respiratory distress syndrome (ARDS) is a syndrome defined by acute onset of respiratory failure within 7 days of the inciting insult. The clinical criteria include acute onset of hypoxaemia [with three mutually exclusive categories of the ratio of the arterial partial pressure of oxygen (P_{aO_2}) to the fraction of inspired oxygen (F_{iO_2}), namely mild (200–300 mmHg), moderate (100–200 mmHg) and severe (≤ 100 mmHg)], bilateral chest radiographic opacities not fully explained by effusions, lobar/lung collapse or nodules, and exclusion of cardiac failure or fluid overload as the sole cause of the syndrome.⁹

Acute respiratory distress syndrome is a common and frequently fatal cause of respiratory failure among critically ill patients, with an incidence of nearly 200,000 cases per year in the USA alone, an estimated prevalence of 10% among all critically ill patients worldwide and a mortality rate of 30–40%.^{10,11} Since the first consensus definition of ARDS in 1988, experts have debated if patients should be subdivided on the basis of natural history, clinical features, biology or some combination thereof.¹² During the ensuing three decades, positive trials of several supportive care interventions, including most notably lung-protective ventilation, have led to decreases in ARDS mortality. However, over the same time period, dozens of pharmacotherapies that seemed to show great promise in preclinical studies have failed in clinical studies. One of the often-cited reasons for this discouraging failure rate has been the considerable clinical and biological heterogeneity within ARDS; however, objective data have been lacking to guide a more precision approach to clinical trials.

Hypothesis

We hypothesised that negative sepsis and ARDS randomised controlled trials (RCTs) are due to between- and within-patient differences in susceptibility, illness manifestation (phenotype), illness biology, response to treatment and risk of outcomes (heterogeneity).^{13,14} A negative trial is one in which differences between the intervention and control arms are statistically non-significant.

To test our hypothesis we use data from three recent RCTs: (1) the Vasopressin vs Noradrenaline as Initial Therapy in Septic Shock (VANISH) trial,¹⁵ (2) the Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS) trial¹⁶ and (3) the Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP-2) trial.¹⁷

This hypothesis could be tested by assessing if:

- the treatment effect varies according to patients' risk of outcome prior to randomisation [referred to as heterogeneity of treatment effect (HTE)]
- distinct patient subgroups (subphenotypes) in whom treatment effect differs can be identified in trial populations using clinical and biomarker data.

Aims and objectives

- What is the variation in baseline risk of death in the VANISH,¹⁵ LeoPARDS¹⁶ and HARP-2¹⁷ trials?
- Does the treatment effect of vasopressin (Pressyn AR®; Ferring Pharmaceuticals, Saint-Prex, Switzerland) and hydrocortisone sodium phosphate (hereafter referred to as hydrocortisone) (Efcortisol™; Amdipharm plc, St Helier, Jersey) in the VANISH trial,¹⁵ of levosimendan in the LeoPARDS trial¹⁶ and of simvastatin in the HARP-2 trial¹⁷ vary according to baseline risk of death?
- Can subphenotypes of participants in the VANISH,¹⁵ LeoPARDS¹⁶ and HARP-2 trials¹⁷ be identified?
 - What are the key discriminant variables that differentiate these subphenotypes?
- Does the treatment effect of vasopressin and hydrocortisone in the VANISH trial,¹⁵ of levosimendan in the LeoPARDS trial¹⁶ and of simvastatin in the HARP-2 trial¹⁷ vary among the subphenotypes identified in these trials?

Heterogeneity of treatment effect

Non-random variation in the treatment effect of an intervention due to differences in the baseline risk of death between patients in a population represents one form of HTE.^{18,19} In critical care settings, sepsis¹ and ARDS⁹ are acute illnesses with significant clinical and biological heterogeneity.²⁰⁻²³ Therefore, it is expected that RCTs that are enrolling patients who meet generic sepsis or ARDS eligibility criteria would generate heterogeneous trial populations. This heterogeneity occurs both within a trial and between trials.¹³ The resulting variation in risk of outcomes and response to treatments may result in clinically important HTE in such trial populations. This heterogeneity is one possible explanation for RCT results.^{13,24}

Recently, Iwashyna and colleagues²⁴ simulated RCTs using observational cohort data and reported that the magnitude of HTE may be such that the average benefit (or harm) from the tested treatment in critical care RCTs may not be valid for all individual patients meeting the trial eligibility criteria. Therefore, exploring HTE with data from completed RCTs, aside from explaining the RCT results, could also inform future trial design and trial efficiency by targeting a trial population with a higher risk of

the outcome and/or a specific baseline measure associated with either the highest treatment benefit or the greatest treatment response (enrichment).^{8,13,25}

In this context, we explored the presence of HTE for vasopressin and hydrocortisone in the VANISH trial,¹⁵ for levosimendan in the LeoPARDS trial¹⁶ and for simvastatin in the HARP-2¹⁷ trial, using multivariable risk-based models with individual patient data. The VANISH trial¹⁵ is a 2 × 2 factorial, double-blind RCT in adult patients with sepsis who required vasopressors carried out in 18 general adult intensive care units (ICUs) in the UK. The LeoPARDS trial¹⁶ is a two-arm, parallel-group, double-blind, placebo-controlled RCT in adult patients with sepsis who required vasopressors carried out in 34 ICUs in the UK. The HARP-2 trial¹⁷ is a two-arm, parallel-group, double-blind, placebo-controlled RCT in adult patients (within 48 hours after the onset of ARDS) carried out in 40 ICUs in the UK and Ireland. We hypothesised that within these RCTs an individual patient's baseline risk of death modifies the direction and magnitude of the treatment effects of vasopressin,¹⁵ hydrocortisone,¹⁵ levosimendan¹⁶ and simvastatin.¹⁷ Several recent studies support our hypothesis. In a previous RCT, it was found that the treatment effect of vasopressin differed with severity of septic shock.²⁶ The treatment effect of hydrocortisone differs between trials,²⁷ with potential benefit seen in trials with higher control group mortality.²⁸⁻³⁰ The treatment effect of simvastatin differs between ARDS subphenotypes³¹ and potentially with illness severity in critically ill patients.³²

Conceptual approach for heterogeneity of treatment effect

Our aim was to assess whether or not an individual patient's baseline risk of death modifies the treatment effect of an intervention (HTE). The Acute Physiology And Chronic Health Evaluation II (APACHE II) model has been proposed as a potential model for HTE evaluation.^{24,33,34} We assessed HTE using the APACHE II score³⁴ as the primary measure of baseline risk. In addition, we assessed three secondary measures based on the APACHE II model: (1) the APACHE II physiology score (APS-APII), (2) the APACHE II-calculated risk of death ($R_{calc.}$), as originally proposed by Knaus and colleagues,³⁴ and (3) a modified APACHE II risk of death model recalibrated ($R_{recal.}$) using data from the VANISH trial¹⁵ and the LeoPARDS trial.¹⁶ The rationale for using the APS-APII was that the total APACHE II score determines a non-modifiable risk of death based on age and severe comorbidity, but the physiological derangement most likely mediates the relationship between treatment effect and outcome.³⁵ We also investigated whether or not any HTE could be driven by adverse events: if low-risk patients have similar exposure to treatment-related harms as high-risk patients, but do not have the same exposure to benefits, this would result in a net harm signal.²⁴ Furthermore, irrespective of whether the treatment effects of interventions varied or remained constant over the range of baseline risk, HTE may manifest because of differences in treatment-related adverse events over the range of baseline risk.

Latent class analysis to identify sepsis phenotypes

Identifying subphenotypes in critically ill patients could be achieved using latent class analytic approaches or clustering approaches, as shown in ARDS cohorts³⁶ and sepsis cohorts.³⁷⁻³⁹ Calfee and colleagues²³ applied latent class analysis (LCA) data from patients enrolled into National Institutes of Health/National Heart, Lung, and Blood Institute ARDS Network randomised controlled trials, and reported two distinct and consistent subphenotypes of ARDS in five trials. In all trials, a hyperinflammatory subphenotype accounting for roughly 30% of the ARDS population was associated with higher levels of inflammatory biomarkers, more profound shock, worse acidosis, significantly worse clinical outcomes and potentially different treatment response to randomly assigned positive end-expiratory pressure and fluid management strategy than a hypoinflammatory subphenotype.^{23,31,40-42} In contrast, LCA on data from the PROtein C Worldwide Evaluation in Severe Sepsis (PROWESS) Shock study identified six different sepsis phenotypes and found no treatment effect differences between classes.³⁹ Furthermore, LCA on sepsis cohorts identified using electronic health records reported four different sepsis phenotypes,^{37,38} which appear different from sepsis phenotypes identified using PROWESS

Shock study-level data. It is important to note that, unlike Calfee and colleagues' ARDS analyses,²³ none of the sepsis subphenotype studies use cytokines, markers of endothelial or end organ injury.

In this context, we conducted an a priori-defined secondary analysis of the VANISH trial¹⁵ and the LeoPARDS trial¹⁶ using clinical and biomarker data to identify sepsis subphenotypes. Based on the available evidence from ARDS studies, we hypothesised a priori that LCA of the VANISH trial¹⁵ and LeoPARDS trial¹⁶ cohorts would identify at least two distinct subphenotypes of sepsis, and that patients with these subphenotypes might respond differently to corticosteroids, vasopressin and levosimendan (Simdax®; Orion Pharma, Espoo, Finland).

Latent class analysis to identify acute respiratory distress syndrome phenotypes

Latent class analysis is a well-validated statistical approach that seeks to use objective criteria to identify subgroups within a broader population. We have previously applied LCA in independent analyses of three cohorts of patients derived from three National Institutes of Health/National Heart, Lung, and Blood Institute ARDS Network RCTs. In all three cohorts, summing to over 2000 patients, we observed strong evidence for two distinct and consistent subphenotypes of ARDS.^{23,42} In all three cohorts, one subphenotype, representing roughly 30% of ARDS patients, was consistently characterised by higher levels of inflammatory biomarkers, more profound shock and acidosis, and significantly worse clinical outcomes. Of particular interest, we found that this hyperinflammatory subphenotype was associated with a significantly different response to randomly assigned positive end-expiratory pressure and randomly assigned fluid management strategy than the hypoinflammatory subphenotype.^{23,42} Therefore, identifying subphenotypes may be critical to future success in ARDS clinical trials.⁴³ It remains unknown, however, whether or not these ARDS subphenotypes are generalisable to non-US populations, whether or not they can be identified using less extensive data sets and, most importantly, whether or not they may respond differently to pharmacotherapies.

To test these questions we designed a secondary analysis of a Phase IIB RCT of simvastatin for ARDS (i.e. the HARP-2 trial).¹⁷ Based on our prior research, we hypothesised a priori that LCA of the HARP-2 trial cohort would identify two distinct subphenotypes of ARDS, with the hyperinflammatory subphenotype and showing better treatment response to simvastatin.

Chapter 2 Methods

Study approvals and randomised controlled trials data sets

We obtained ethics approval for this study (reference 18/LO/1079). No patients were directly recruited into this study. Data from the VANISH,¹⁵ LeoPARDS¹⁶ and HARP-2¹⁷ trials were used in this study. All trials were randomised and double blind. Further details can be found in the original study protocols.

The VANISH trial

The VANISH trial¹⁵ is a 2 × 2 factorial, double-blind RCT in adult patients with sepsis who required vasopressors and was carried out in 18 general adult ICUs in the UK. In the VANISH trial, patients were randomly allocated to vasopressin and hydrocortisone ($n = 101$), vasopressin and placebo ($n = 104$), noradrenaline and hydrocortisone ($n = 101$) or noradrenaline and placebo ($n = 103$). Patients received the second study drug (i.e. hydrocortisone/placebo) only if the maximum infusion of the first study drug (i.e. vasopressin/noradrenaline) had been reached. The 28-day mortality was 63 of 204 (30.9%) patients in the vasopressin group and 56 of 204 (27.5%) patients in the noradrenaline group [a difference of 3.4%, 95% confidence interval (CI) -5.4% to 12.3%].

The LeoPARDS trial

The LeoPARDS trial¹⁶ is a two-arm, parallel-group, double-blind, placebo-controlled RCT in adult patients with sepsis who required vasopressors, carried out in 34 ICUs in the UK. In the LeoPARDS trial, patients were randomised to receive either levosimendan ($n = 258$) or placebo ($n = 257$) over 24 hours, in addition to standard care. The 28-day mortality was 89 of 258 (34.5%) patients in the levosimendan group and 79 of 256 (30.9%) patients in the placebo group (a difference of 3.6%, 95% CI -4.5% to 11.7%).

The HARP-2 trial

The HARP-2 trial¹⁷ is a two-arm, parallel-group, double-blind, placebo-controlled RCT in adult patients (within 48 hours after the onset of ARDS), carried out in 40 ICUs in the UK and Ireland. In the HARP-2 trial, patients were randomised to receive either once-daily simvastatin or identical placebo tablets enterally for up to 28 days. The 28-day mortality was 57 of 259 (22.0%) patients in the simvastatin group and 75 of 280 (26.8%) patients in the placebo group [risk ratio (RR) 0.8, 95% CI 0.6 to 1.1].

Groups for comparison

Treatment effects were assessed primarily on an intention-to-treat basis, except for hydrocortisone compared with placebo (i.e. the second comparison in the VANISH trial¹⁵). Patients were eligible to receive hydrocortisone/placebo only if they had reached the maximum infusion of the first study drug, which occurred for around three-quarters of patients. This eligibility criterion was applied post randomisation, but before the administration of the second (blinded) study drug. As there was no interaction between the study drugs, and given the limited power of the analysis, only patients eligible to receive the second drug were included in this comparison (hydrocortisone, $n = 148$; placebo, $n = 148$). A sensitivity analysis on the per-protocol population was conducted for the other drug comparisons. Each trial was analysed separately.

Heterogeneity of treatment effect

This chapter includes text reproduced from Santhakumaran and colleagues⁴⁴ [this article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium,

provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated. The text below includes minor additions and formatting changes to the original text]. Parts of this section, which presents data on ARDS subphenotypes from the HARP-2 trial,¹⁷ includes information based on our previous publication by Calfee and colleagues.³¹

Outcomes

The primary outcome is mortality at 28 days after randomisation. The secondary outcome is hospital mortality during the initial hospital stay (i.e. ignoring readmissions). The rationale for this is that patients in these trials who left hospital alive were either well enough to be discharged or still sick but transferred elsewhere (e.g. social care). Therefore, hospital mortality is not a true binary outcome, as those alive at discharge are not a consistent group; hence landmark mortality at 28 days was preferred.

Measures of baseline risk

The primary analysis examined HTE for 28-day mortality, with the APACHE II³⁴ as the measure of baseline risk, comparing treatment effect in patients with an APACHE II score above (high) or below (low) the overall median score of 25 points. This score has already been suggested a measure over which HTE could be evaluated.^{24,33} The APACHE II score is the sum of the points from three elements: (1) acute physiology, (2) age and (3) chronic health. The calculation of APACHE II score is given in *Table 1*.

As secondary analyses we examined three other baseline risk measures. The first is the acute physiology element of the APACHE II score, which we denote APS-APII. The rationale for using the APS-APII was that the total APACHE II score includes non-modifiable risk of death attributable to age and comorbidity, but the physiological components are more likely mediators of the effect of treatment on outcome.³⁵ The second additional baseline risk measure we considered was the risk of death in hospital (i.e. R_{calc}), calculated based on APACHE II score using a formula originally proposed by Knaus and colleagues³⁴ as follows:

$$\text{Logit}(R) = -3.517 + 0.146 \times \text{APACHE II} + 0.603 \times \text{post emergency surgery} + \text{diagnostic category weight.} \quad (1)$$

Post-emergency surgery is a binary indicator, and diagnostic category weights relate to the principal reason for admission for a patient. The third baseline risk measure was R_{recal} , given by recalibrating R (risk) to the study population to see whether or not an improved prediction yielded a different estimate of HTE. Methods for developing R_{recal} are given in *Recalibrating APACHE II*.

Recalibrating APACHE II

The following logistic regression models were estimated, with each subsequent model recalibrating with finer detail:

$$\text{Model 1: } \text{logit}(R_1) = \alpha + \beta_A \times \text{APACHE II} + \beta_E \times \text{post-emergency surgery} + \beta_D \times \text{diagnostic category weight,} \quad (2)$$

$$\text{Model 2: } \text{logit}(R_2) = \alpha + \beta_{\text{AP}} \times \text{AP points} + \beta_{\text{Age}} \times \text{age points} + \beta_{\text{CH}} \times \text{CH points} + \beta_E \times \text{post-emergency surgery} + \beta_D \times \text{diagnostic category weight,} \quad (3)$$

$$\text{Model 3: } \text{logit}(R_3) = \alpha + \sum_i^{12} (\beta_{\text{AP}_i} \times \text{AP}_i \text{ points}) + \beta_{\text{Age}} \times \text{age points} + \beta_{\text{CH}} \times \text{CH points} + \beta_E \times \text{post-emergency surgery} + \beta_D \times \text{diagnostic category weight,} \quad (4)$$

TABLE 1 Calculation of APACHE II score in trial cohorts

Element	Low abnormal range				Normal	High abnormal range				
	4	3	2	1	0	1	2	3	4	
Acute physiology										
Temperature (°C)	≤ 29.9	30.0–31.9	32.0–33.9	34.0–35.9	36.0–38.4	38.5–38.9		39.0–40.9	≥ 41.0	
Mean arterial pressure (mmHg)	≤ 49		50–69		70–109		110–129	130–159	≥ 160	
Heart rate (beats/minute)	≤ 39	40–54	55–69		70–109		110–139	140–179	≥ 180	
Respiratory rate (breaths/minute)	≤ 5		6–9	10–11	12–24	25–34		35–49	≥ 50	
Oxygenation (kPa)										
FiO ₂ ≥ 0.5: A–a gradient					< 26.7		26.7–46.6	46.7–66.6	> 66.6	
FiO ₂ < 0.5: PaO ₂	< 7.33	7.33–7.99		8.00–9.32	≥ 9.33					
Arterial pH	< 7.15	7.15–7.24	7.25–7.32		7.33–7.49	7.50–7.59		7.60–7.69	≥ 7.70	
Serum sodium concentration (mmol/l)	≤ 110	111–119	120–129		130–149	150–154	155–159	160–179	≥ 180	
Serum potassium concentration (mmol/l)	< 2.5		2.5–2.9	3.0–3.4	3.5–5.4	5.5–5.9		6.0–6.9	≥ 7.0	
Serum creatinine concentration (µmol/l)			< 53		53–133		134–176	177–308	≥ 309	
Haematocrit (g/dl)	< 6.7		6.7–9.9		10.0–15.3	15.4–16.6	16.7–19.9		≥ 20.0	
White blood cell count (× 10 ³ /mm ³)	< 1.0		1.0–2.9		3.0–14.9	15.0–19.9	20.0–39.9		≥ 40.0	
Points assigned										
Glasgow Coma Scale score	15									
Age (years)										
≤ 44	0									
45–54	2									
55–64	3									
65–74	5									
≥ 75	6									
Chronic health										
History of severe organ system insufficiency or immunocompromised (including NYHA IV, severe COPD and cirrhosis)	2 points if elective postoperative and 5 points if non-operative or emergency postoperative									
A–a, alveolar–arterial; COPD, chronic obstructive pulmonary disease; NYHA IV, New York Heart Association class IV.										

where AP is acute physiology and AP_{1,...,12} is temperature, mean arterial pressure, heart rate, respiratory rate, oxygenation, arterial pH, serum sodium concentration, serum potassium concentration, serum creatinine concentration, haematocrit, white blood cell count and Glasgow Coma Scale score, respectively, and CH is chronic health. These elements were entered into the model on the points scale described in *Table 1*, as were age and chronic health. Mortality at 28 days was used as the outcome, as this was the outcome of interest, although predictive performance for hospital mortality was also assessed. Three additional models were estimated by adding the number of organ dysfunctions at baseline (respiratory, renal, hepatic, coagulation and cardiovascular), based on a SOFA score of ≥ 2 points.⁷ The number of organ dysfunctions was treated as a continuous variable. The coefficients for the diagnostic categories were kept in proportion to the existing weights, rather than re-estimating the weights for each category because of sparse data.

The discriminatory performance of the models for the whole cohort was compared using the area under receiver operating characteristic (AUROC) curve and the discrimination slope (DS), which is the mean difference in prediction comparing those with the event and those without.⁴⁵ We did not use Cox recalibration [i.e. the prediction resulting from a logistic regression of the outcome of interest against the logit (R)], as this would not change the discrimination of the model. If the patients were ordered with respect to their score after Cox recalibration then their rank would remain the same and therefore the HTE pattern would also be the same.

The AUROC curve was calculated for both hospital and 28-day mortality. As some of the data on which performance is assessed were also used to build the model, bootstrapping was used to correct the AUROC curve for overoptimism.⁴⁶ For this method, a bootstrap sample is taken and the model is estimated on the sample to obtain new coefficients. In addition, the AUROC curve (for example) is calculated (AUROC_{boot.}).

Next, the same model and coefficients are applied to the original data set and the AUROC curve calculated (AUROC_{orig.}). Then, AUROC_{boot.} - AUROC_{orig.} gives an estimate of the optimism and this is repeated for many bootstrap samples and the average optimism taken. The averaged optimism is subtracted from the optimistic AUROC to give a corrected AUROC. This process was modified because the model was estimated on only a sample of the data. A bootstrap sample of the whole data set was taken, stratifying on treatment (control vs. active, taking any active treatment for the VANISH trial¹⁵) to ensure that the proportion of placebos is the same in the bootstrap sample. AUROC_{boot.} is calculated by estimating the model on the placebo groups and applying it to the whole bootstrap sample and AUROC_{orig.} is calculated by applying the same model to the original data set. The same approach was applied to the DS. The model with the best corrected discriminatory performance was used as an additional measure of baseline risk.

Models were estimated using the control groups from the VANISH¹⁵ (noradrenaline + placebo, $n = 103$) and LeoPARDS¹⁶ trials (placebo, $n = 257$) to avoid using post-randomisation outcomes to calculate baseline risk. However, in a simulation study, Burke and colleagues⁴⁷ found that using the whole cohort slightly reduced bias, overfitting and risk of a false-positive finding for HTE, and so in addition the recalibration was performed using the whole cohort.

Descriptive analysis

Distributions of the baseline risk measures in the trial populations were described with histograms, including by treatment group, to check whether or not the distribution was balanced. APACHE II score was grouped in increments of 5 points, with those scoring ≥ 35 points in one category (this is the same categories used by Knaus and colleagues³⁴) and risk of death was grouped into 10% increments. The relationship between risk measures and mortality in the trial cohorts was described using bar charts showing the proportion of patients who died in each category. The discriminatory performance was assessed using the AUROC curve. We estimated the extreme quartile odds ratio (EQuOR) (i.e. the ratio of the odds of death in the highest vs. lowest quartile for risk) as an estimate of how the risk of death varies between patients in the same trial.⁴⁸

Statistical methods for heterogeneity of treatment effect

This chapter includes text reproduced from Santhakumaran and colleagues⁴⁴ [this article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated. The text below includes minor additions and formatting changes to the original text.].

Heterogeneity of treatment effect was examined by comparing the treatment effect in those with high and low baseline risk, splitting the population at the median. Forest plots illustrated the absolute risk difference (RD) and RR for 28-day mortality by treatment group, comparing high- and low-APACHE II groups. HTE was quantified on both the absolute and relative scales via additive and multiplicative interactions, respectively. The difference in the RD and associated 95% CI was estimated assuming a linear model for the probability of death, with treatment, a binary indicator for APACHE II subgroup and the interaction between them as covariates, using robust standard errors (SEs). The ratio of the RR and 95% CI was estimated assuming a log-binomial model with the same covariates. For the HARP-2 trial,¹⁷ only the primary baseline risk measure of the total APACHE II score was available.

Iwashyna and colleagues²⁴ argued, using simulated data, that low-risk patients may have similar exposure to treatment-related harms as the high-risk patients, but not to the benefits, resulting in a net harm for these patients. We therefore investigated heterogeneity of harms using forest plots by APACHE II subgroup similar to the primary analysis. Interactions were not estimated for heterogeneity of harms because of low number of events.

Regression modelling

We also considered heterogeneity over the range of APACHE II as a continuous variable. A logistic regression model was constructed with 28-day mortality as the outcome, and treatment, APACHE II score and an interaction between the two as covariates to test whether or not treatment effect varies over baseline risk. Logistic regression was chosen over Cox regression as the outcome is short term (i.e. 28 days) and there was no censoring. The model is given by:

$$\text{Logit}(p) = \alpha + \beta_R \times \text{risk} + \beta_T \times \text{trt} + \gamma + \text{risk} \times \text{trt}, \quad (5)$$

where p is the predicted probability of death before 28 days, risk is the mean-centred APACHE II and trt is the binary treatment indicator. The effect of a unit increase in baseline risk on mortality in the placebo group is given by β_R and the treatment effect for someone with mean baseline risk is given by β_T . HTE is described by the interaction term (i.e. the additional treatment effect for each unit increase in baseline risk) denoted by γ [i.e. all effects are log-odds ratios (ORs)]. Relative HTE was quantified by the interaction between APACHE II score and treatment, expressed as a ratio of ORs. Additive HTE was illustrated by plotting the estimated absolute difference in mortality between treatment groups across the range of APACHE II.

In the first instance, APACHE II was treated linearly, with residual plots used to determine if any transformations or non-linear terms were necessary. This would occur if, for example, the high-risk patients are too sick to benefit from the treatment, resulting in a n-shaped pattern of treatment effect. The non-linearity of the effects of baseline risk and of the interaction was investigated by grouping risk measures into quartiles and comparing nested models with linear and categorical associations using likelihood ratio tests.

Sensitivity analyses

Two sensitivity analyses for the main baseline risk measure (APACHE II score) were performed. First, we used hospital mortality as the outcome instead of mortality at 28 days, as the APACHE II score was

originally devised as a prediction tool for hospital mortality. Second, we investigated the potential impact of missing data on the results. There were 47 patients in the VANISH trial¹⁵ for whom at least one element of the acute physiology score was missing (and 61 patients in the LeoPARDS trial¹⁶). In the main analysis, normal scores were assumed for these elements, as for the main trial. Total APACHE II scores were missing for 66 patients in the HARP-2 trial,¹⁷ and these patients were omitted from the main analysis, but are included in the forest plot. Missingness occurred pre randomisation and hence is independent of treatment effect; however, it may affect the precision of the results. In the sensitivity analysis we assumed that patients with missing data were (1) equally likely to be in the high-risk group as those with complete data, (2) 10% more likely or (3) 10% less likely. The APACHE II category was imputed 20 times under these assumptions, and the difference in RD and ratio of RR was computed as for the main analysis, combining results across imputations using Rubin's rules.⁴⁹

Determining sepsis subphenotypes using latent class analysis

Latent class analysis is used to estimate a latent (i.e. unobserved) categorical variable that assigns individuals to groups (i.e. classes) when we have a set of observed data (i.e. indicators) that we believe is distributed differently for each class. LCA is a type of finite mixture model that jointly estimates a model for each of the indicators, with each indicator distribution being a mixture of class-specific distributions. Simultaneously, a multinomial logistic model for probabilities of class membership is estimated. The number of classes is specified in the model, but models with different numbers of classes can be compared. We used LCA to identify latent subphenotypes in adults with sepsis based on observed biomarker data.

Biomarker measurements

We measured three groups of markers to help delineate specific biological effects and illness characteristics. First, a limited cytokine profile was carried out to assess the balance between pro- and anti-inflammatory states using interleukins [i.e. interleukin 1 beta (IL-1 β), IL-6, IL-8, IL-10, IL-17 and IL-18], soluble tumour necrosis factor receptor 1 (sTNFR1) and C-C motif chemokine ligand 2 (CCL2). The state of neutrophil and endothelial injury was assessed using myeloperoxidase (MPO), soluble intracellular adhesion molecule and angiotensin II (ANG II). For organ dysfunction, in addition to the SOFA variables,⁵⁰ which were collected as part of trial data, we measured troponin and N-terminal pro-B-type natriuretic peptide (NT-proBNP) for cardiac dysfunction. These measurements used enzyme-linked immunosorbent assay-based methods. We had laboratory-specific standard operating procedures for these measurements prior to starting any measurements.

Exploratory analysis

Histograms and pairwise correlations were used to assess distributions, outliers and skewness (highly likely for the cytokine data). For assay data, the number and percentage of values below or above the limits of detection were recorded. Normal distributions were used for the continuous indicators, applying natural log transformations as necessary. Observations above or below the limits of detection were included in the analysis but treated as censored and all variables were standardised to have a mean of 0 and standard deviation (SD) of 1, with parameters taken from the data within the limits of detection. The number and proportion of missing observations were described for all biomarkers, clinical variables and demographic characteristics. If a patient has any missing individual indicators then LCA still allows the rest of the complete data to be included, implicitly assuming that the data are missing at random (i.e. the probability of missingness depends on only the observed data and not any missing data). This is reasonable for the biomarker data, as missing individual indicators are likely to be due to a technical issue.

Latent class modelling

Analysis was carried out separately for the LeoPARDS trial¹⁶ and VANISH trial¹⁵ cohorts. All measured biomarkers [i.e. PaO₂/FiO₂ ratio, creatinine, platelets, bilirubin, IL-1 β , IL-6, IL-8, IL-10, IL-17, IL-18, MPO,

soluble intercellular adhesion molecule (sICAM), ANG II, troponin, NT-proBNP, sTNFR1, lactate and CCL2] were included as indicator variables characterising the latent classes. Other baseline clinical and demographic variables {i.e. age, ethnicity, body mass index (BMI), comorbidities [any of New York Heart Association class IV (NYHA IV), severe chronic obstructive pulmonary disease (COPD), chronic renal failure, cirrhosis, immunodeficiency], site of infection (i.e. lung, abdomen, urine, other), SOFA score, APS-APII and post-surgical admission} that may be predictive of subphenotype were included in the model as class predictors. We also included APS-APII as a covariate in the submodel for each indicator based on a priori expectation of associations within classes. Only pre-randomisation data were used to develop the latent class model. All biomarkers were log-transformed and standardised because of skewness. Observations outside the limits of detection were included but treated as censored.

Latent class analysis models were fitted in three stages. First, conditional independence was assumed (i.e. all covariances constrained to zero) and no covariates predicting class membership were included. Second, prespecified clinical and demographic variables measured at baseline were included as covariates predicting class membership. Third, variance assumptions concerning indicators were relaxed to allow (1) non-constant residual variance across classes, (2) non-zero covariances and (3) both of these. It was not possible within the software used to model covariances between censored variables. For each stage we first fitted a one-class model, and then increased the number of classes by 1 until convergence could not be achieved. A number of strategies were used to achieve convergence, namely (1) for a k -class model, using starting values from a $k - 1$ class model; (2) using alternative integration methods; (3) reducing the number of censored indicators by treating values outside the limits as having values equal to the limit, for indicators with fewer than five such values; and (4) reducing the number of class predictors, selecting covariates that improved model fit based on likelihood ratio tests. Models were fitted using the *gsem* package in Stata[®] 15 (StataCorp LP, College Station, TX, USA).

The class means were estimated for each LCA model and differences across classes compared to determine which indicators showed the most separation across classes. For each model and each participant, the probability of an individual being in each class is predicted, with the probabilities for a participant summing to 1 across the classes. Each participant can then be assigned to the class for which they have the highest class probability. The Bayesian information criterion (BIC) was the primary measure of model selection,¹ with smaller values indicating better fit. We also considered the Akaike information criterion (AIC), log-likelihood, entropy (i.e. a measure of class separation between 0 and 1), class sizes (with very small classes being indicative of overfitting) and the mean probability of class assignment, averaged over participants in the class.⁵¹ We also assessed the class means and sized to see if the substantive interpretation of the classes differed across models. Additionally, plots of the change in fit statistics with the number of classes were used to determine where additional classes gave limited improvement in fit.⁵² If models of different complexity gave a similar fit, then the simplest model was favoured.

Non-technical description of latent class analysis methods

Latent class analysis of the baseline variables aimed to replicate the previous publications using data from published ARDS trials.^{23,42} We used data variables from subjects in all trial arms, without the influence of arm. The baseline variables consisted of clinical data, cytokine, and epithelial and endothelial injury marker profiles. For ARDS, the resulting subphenotypes were compared with the two subphenotypes derived independently in three trials previously.^{23,42}

The inclusion of variables, and any adaptation to their form, will depend on their robustness for their multivariate purpose, which was assessed by screening the univariate and bivariate data distributions for influential outliers, marked skewness and multicollinearity, for categorical variables with extreme prevalence and for variables contributing to the accumulation of missing data. This led to establishing the principal data set for the LCA of each trial, where the variables are further standardised to the z-scale to have mean of zero and unit variance, accounting for their differing units of measurement.

The latent class modelling stage involved the estimation of linear combinations of the standardised variables to identify a number of underlying classes. The number of classes will be determined formally by using the BIC and other model selection criteria, and by assessing the clinical interpretability of the classes as subphenotypes. With high probabilities of class membership, participants were assigned to their most likely phenotype. Regression methods with likelihood ratio tests were used to assess the association of classes with clinical outcomes, with randomisation kept intact and extended to compare response among randomised treatments. Given the factorial nature of the VANISH trial,¹⁵ this will involve a sequence of interactions tests respecting the design.

Description of subphenotypes

Once the most suitable model was selected, the estimated class means of each standardised indicator and their relative importance in class separation were shown by plotting the means, ordered by the magnitude of the largest difference between classes. Trial participants were assigned to the class for which they had the highest posterior probability of class membership for subsequent analysis. The median and interquartile range (IQR) of the observed biomarker values by class were tabulated, along with baseline clinical characteristics.

Clinical outcomes

For this study the primary clinical outcome was survival at 3 months in the LeoPARDS trial¹⁶ cohort, as this is the time point at which treatment differences stabilise.⁵³ Mean total SOFA score over 28 days (or ICU stay, whichever is shorter), which was the primary outcome in the LeoPARDS trial,¹⁶ and survival to 28 days were examined as secondary outcomes. For the VANISH trial¹⁵ we examined survival to 28 days (as survival to 3 months was not available), survival free of renal failure to 28 days among patients not in renal failure at baseline, and days alive and free of renal failure up to 28 days for all other patients (i.e. those who died or experienced some renal failure by day 28).

All outcomes were first compared between classes, irrespective of treatment, then treatment differences were compared between classes. For binary outcomes we presented the proportion of patients having the event in each class and performed a chi-squared test for the difference across classes. Treatment effects were expressed as a RD and the difference in treatment effects across classes as the a difference in RD. Ninety-five per cent CIs for the RD and difference in RD were calculated using linear regression with robust SEs.⁵⁴ For mean total SOFA score we presented the mean and SD, with differences between classes or treatment arms expressed as a difference in means. As mean total SOFA score is skewed, 95% CIs were calculated with bootstrapping, as was done in the main trial analysis. The median and IQR was presented for days alive and free of renal failure, again with bootstrap CIs. For continuous variables permutation tests were used to calculate *p*-values for the treatment–class interaction. Treatment effects by class were displayed using forest plots.

For the LeoPARDS trial,¹⁶ the first trial we analysed for identifying subphenotypes, we constructed a model to predict latent class, using a reduced set of indicators. A series of multinomial logit models were estimated, with latent class as the outcome and an increasing number of biomarkers as predictors, added in the order of greatest separation between classes. The probability of being in each class was predicted for each patient and patients were assigned to the class with the highest probability (similarly to the LCA). The class-specific sensitivity, specificity and *c*-statistics for each model were calculated by comparing the ‘gold-standard’ class of the latent class model with the ‘test’ class of the multinomial model. The final number of markers was chosen as the model for which the addition of further variables would bring negligible increases in accuracy measures.

Sensitivity analysis

In the main analysis we drew a distinction between class-defining and class-predicting variables. As a sensitivity analysis, we compared the class groupings when including all variables as indicators in the latent class model, following earlier work by Calfee and colleagues.^{23,31}

Determining acute respiratory distress syndrome subphenotypes using latent class analysis

Parts of this section, which presents data on ARDS subphenotypes from the HARP-2 trial,¹⁷ includes information based on our previous publication by Calfee and colleagues.³¹

To estimate the optimal number of classes in the data, latent class models were fitted in *Mplus* v8 (Muthén & Muthén, Los Angeles, CA, USA), using baseline demographic characteristics, available clinical data, and IL-6 and sTNFR1 as class-defining variables. Outcome variables were not included in the modelling. Models ranging from one to four classes were estimated to identify the optimal number of classes in the studied sample. From the four models, best fit was evaluated using BIC, the Vuong–Lo–Mendell–Rubin likelihood ratio test (which compares fit of model k -classes to $k - 1$ classes), class size and entropy.^{55,56} Variables were examined for their distribution prior to beginning this modelling and continuous variables with significantly skewed distributions were log-transformed. To estimate the model parameters, continuous variables were placed on a z-scale with a mean of zero and SD of 1, as in our prior work.^{23,42} LCA is a form of finite mixture modelling. The basic idea is that the observed distribution of variables is due to a mixture of subgroups that are unknown (i.e. latent). To test this, a series of models are fitted to the data to see if a model with k -classes fits the observed distribution better than a distribution without any subgroups. Although the idea is conceptually the same as cluster analysis, it differs in one key aspect. LCA is model based, which means one can estimate the model fit. Clustering is based on simplifying joining points based on their distance from each other. Model fit is estimated via several metrics, including AIC, BIC and the test of whether or not a model with k -classes fits better than one with $k - 1$ classes. Other considerations include the size of the smallest class in a given model, the average probabilities of class membership and whether or not the resulting profiles of the classes have some substantive meaning.

Once the optimal number of classes was determined, study participants were assigned to their most likely class and their baseline characteristics were compared using t -tests, Pearson's chi-squared or Wilcoxon rank-sum test, depending on the nature of the variable. Associations between class assignment and clinical outcomes (i.e. 28- and 90-day mortality, and ventilator-free days) were tested using logistic regression for mortality and zero-inflated Poisson regression for ventilator-free days. We compared time-to-event Kaplan–Meier curves using Cox proportional hazard tests to test for a differential response to treatment by class for survival. For modelling time to unassisted breathing a competing risks model was estimated with death before day 28 as the competing risk.⁵⁷ All analyses other than LCA were carried out using SAS[®] version 9.4 (SAS Institute Inc., Cary, NC, USA). Some of these results have been previously reported in the form of an abstract.⁵⁸

Chapter 3 Results

Heterogeneity of treatment effect

This chapter includes text reproduced from Santhakumaran and colleagues⁴⁴ [this article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated. The text below includes minor additions and formatting changes to the original text.].

Descriptive analysis

In the VANISH,¹⁵ LeoPARDS¹⁶ and HARP-2¹⁷ trials, 28-day mortality was not significantly different between the intervention and control arms (see *Table 1*). The illness severity (using the total APACHE II score) was lower in the HARP-2 trial¹⁷ than in the VANISH¹⁵ and LeoPARDS¹⁶ trials (see *Table 1*). The EQUOR highlighted significant heterogeneity of risk of death in all three RCTs for all three risk measures. Trial-level summary characteristics are shown in *Table 2*.

Figures 1–4 show the distribution of APACHE II and *R* by treatment arm in the VANISH trial¹⁵ (vasopressin vs. noradrenaline and hydrocortisone vs. placebo, shown separately). *Figures 5 and 6* show the distribution of APACHE II and *R*, respectively, by treatment arm in the LeoPARDS trial¹⁶ cohort. The distribution of APACHE II in the HARP-2 trial¹⁷ cohort is shown in *Figure 7*.

As expected, mortality, in general, increased with increasing baseline risk measures for all trials. *Figures 8–13* show the relationship between mortality and baseline risk measures in the VANISH trial,¹⁵ both for 28-day and for hospital mortality. *Figures 14–19* show the same associations in the LeoPARDS trial¹⁶ and *Figure 20* shows these associations for the HARP-2 trial.¹⁷

Modified APACHE II risk of death model recalibrated

The predictive performance of APACHE II and *R* are shown in *Table 3*. After correction for overoptimism, model M3 without including the number of organ dysfunctions yielded the highest AUROC and DS (*Table 4*). The estimated parameters from the model are given in *Table 5*. In the original equation for *R*, a unit increase in the APACHE II score was associated with a 16% increase in the odds of hospital mortality, with scores from each variable having the same contribution to the prediction. In comparison, in model M3, the effect of unit increases in the APACHE II score on the odds of mortality ranged from a 17% decrease (temperature) to a 76% increase (pH). The baseline odds (i.e. the odds of mortality for a patient with an APACHE II score of zero and diagnostic category weight who was not admitted following emergency surgery) was lower for model M3 than in the original model for *R* (0.008 vs. 0.03). Therefore, the same OR would produce a much smaller absolute difference in model M3 than in the original model for *R*.

TABLE 2 Trial-level summary characteristics

Characteristic	VANISH trial ¹⁵				LeoPARDS trial ¹⁶		HARP-2 trial ¹⁷	
	Vasopressin	Noradrenaline	Hydrocortisone	Placebo	Levosimendan	Placebo	Simvastatin	Placebo
28-day mortality, n/N (%)	63/204 (31)	56/204 (27)	52/147 (35)	47/148 (32)	89/258 (35)	79/256 (31)	57/259 (22)	75/279 (27)
Related AE, n/N (%)	23/205 (11)	16/204 (8)	18/148 (12)	18/148 (12)	41/258 (16)	16/257 (6)	36/259 (14)	25/279 (9)
Related SAE, n/N (%)	13/205 (6)	10/204 (5)	11/148 (7)	12/148 (8)	13/258 (5)	2/257 (1)	3/259 (1)	4/279 (1)
APACHE II score (points), median (IQR)	24 (19–29)	24 (19–30)	25 (19–32)	25 (20–30)	25 (21–31)	25 (21–30)	18 (14–24)	18 (14–23)
APS-APII, median (IQR)	20 (14–24)	20 (15–25)	21 (15–26)	20 (16–25)	20 (16–26)	21 (16–24)		
R_{calc} , median (IQR)	0.41 (0.24–0.63)	0.42 (0.25–0.66)	0.48 (0.25–0.69)	0.44 (0.28–0.67)	0.56 (0.36–0.72)	0.53 (0.39–0.70)		
EQuOR APACHE II, OR (95% CI)	4.85 (2.49 to 9.46)				7.35 (4.09 to 13.20)		5.92 (2.99 to 11.73)	
EQuOR APS-APII, OR (95% CI)	3.58 (1.88 to 6.83)				5.39 (3.06 to 9.51)			
EQuOR R_{calc} , OR (95% CI)	5.66 (2.83 to 11.31)				4.64 (2.63 to 8.17)			

AE, adverse event; SAE, serious adverse event.
Shading in the table indicates that data were not available.




FIGURE 1 Distribution of APACHE II score by study drug 1: the VANISH trial¹⁵ cohort. (a) Noradrenaline; and (b) vasopressin.




FIGURE 2 Distribution of APACHE II score by study drug 2: the VANISH trial¹⁵ cohort. (a) Placebo; and (b) hydrocortisone.

RESULTS




FIGURE 3 Distribution of $R_{\text{calc.}}$ by study drug 1: the VANISH trial¹⁵ cohort. (a) Noradrenaline; and (b) vasopressin.




FIGURE 4 Distribution of $R_{\text{calc.}}$ by study drug 2: the VANISH trial¹⁵ cohort. (a) Placebo; and (b) hydrocortisone.




FIGURE 5 Distribution of APACHE II score by treatment: the LeoPARDS trial¹⁶ cohort. (a) Placebo; and (b) levosimendan.




FIGURE 6 Distribution of $R_{calc.}$ by treatment: the LeoPARDS trial¹⁶ cohort. (a) Placebo; and (b) levosimendan.

RESULTS




FIGURE 7 Distribution of APACHE II score by treatment: the HARP-2 trial¹⁷ cohort. (a) Placebo; and (b) simvastatin.




FIGURE 8 Mortality at day 28 (proportion) by APACHE II score: the VANISH trial¹⁵ cohort.




FIGURE 9 Hospital mortality (proportion) by APACHE II score: the VANISH trial¹⁵ cohort.




FIGURE 10 Mortality at 28 days (proportion) by APS-APII: the VANISH trial¹⁵ cohort.




FIGURE 11 Hospital mortality (proportion) by APS-APII: the VANISH trial¹⁵ cohort.




FIGURE 12 Mortality at day 28 (proportion) by R_{calc} : the VANISH trial¹⁵ cohort.




FIGURE 13 Hospital mortality (proportion) by R_{calc} : the VANISH trial¹⁵ cohort.




FIGURE 14 Mortality at day 28 (proportion) by APACHE II score: the LeoPARDS trial¹⁶ cohort.




FIGURE 15 Hospital mortality (proportion) by APACHE II score: the LeoPARDS trial¹⁶ cohort.




FIGURE 16 Mortality at 28 days (proportion) by APS-APII: the LeoPARDS trial¹⁶ cohort.




FIGURE 17 Hospital mortality by APS-APII: the LeoPARDS trial¹⁶ cohort.




FIGURE 18 Mortality at day 28 (proportion) by R_{calc} : the LeoPARDS trial¹⁶ cohort.




FIGURE 19 Hospital mortality (proportion) by R_{calc} : the LeoPARDS trial¹⁶ cohort.




FIGURE 20 Mortality at 28 days (proportion) by APACHE II score: the HARP-2 trial¹⁷ cohort.

TABLE 3 Predictive performance of APACHE II score and R

Performance	VANISH trial ¹⁵	LeoPARDS trial ¹⁶	^a HARP-2 trial ¹⁷
AUROC APACHE II, mean (95% CI)			
28-day mortality	0.67 (0.62 to 0.73)	0.71 (0.66 to 0.75)	0.68 (0.62 to 0.73)
Hospital mortality	0.69 (0.64 to 0.75)	0.70 (0.66 to 0.75)	
AUROC APS-APII, mean (95% CI)			
28-day mortality	0.62 (0.57 to 0.68)	0.67 (0.62 to 0.72)	
Hospital mortality	0.64 (0.58 to 0.70)	0.66 (0.61 to 0.71)	
AUROC R , mean (95% CI)			
28-day mortality	0.67 (0.61 to 0.73)	0.67 (0.62 to 0.72)	
Hospital mortality	0.69 (0.63 to 0.74)	0.66 (0.61 to 0.71)	
Predicted mortality (%)	45.6	53.7	

^a For the HARP-2 trial,¹⁷ the additional data to calculate R were not collected and so only the AUROC for APACHE II is presented.

TABLE 4 Area under receiver operating characteristic and DS for recalibrated models

Model	28-day mortality				Hospital mortality			
	AUROC		DS		AUROC		DS	
	Apparent	Corrected	Apparent	Corrected	Apparent	Corrected	Apparent	Corrected
M1	0.673	0.669	0.094	0.081	0.684	0.680	0.100	0.088
M1 + number of organ dysfunctions	0.687	0.680	0.115	0.091	0.693	0.687	0.118	0.095
M2	0.696	0.691	0.123	0.106	0.715	0.710	0.134	0.118
M2 + number of organ dysfunctions	0.715	0.698	0.151	0.088	0.728	0.713	0.160	0.103
M3	0.718	0.712	0.168	0.144	0.742	0.737	0.185	0.163
M3 + number of organ dysfunctions	0.728	0.712	0.189	0.133	0.748	0.734	0.207	0.156

M1, model 1; M2, model 2; M3, model 3.

TABLE 5 Estimated parameters from the logistic regression model M3

Covariate	Coefficient ^a	SE	OR	95% CI
Temperature	-0.189	0.149	0.828	0.619 to 1.108
MAP	-0.0567	0.141	0.945	0.716 to 1.247
Heart rate	-0.192	0.139	0.826	0.629 to 1.084
Respiratory rate	0.239	0.113	1.271	1.018 to 1.586
Oxygenation	0.120	0.101	1.127	0.925 to 1.374
pH	0.567	0.124	1.763	1.382 to 2.248
Sodium	0.124	0.145	1.132	0.852 to 1.505
Potassium	-0.162	0.128	0.851	0.662 to 1.094
Creatinine	0.119	0.0479	1.127	1.026 to 1.238
Haemoglobin	0.280	0.122	1.323	1.041 to 1.681
WBCC	0.0979	0.114	1.103	0.883 to 1.378
GCS	0.0545	0.0331	1.056	0.990 to 1.127
Age	0.338	0.0794	1.402	1.200 to 1.639
Chronic health	0.192	0.0707	1.211	1.054 to 1.391
Emergency surgery (yes/no)	-0.141	0.323	0.868	0.461 to 1.634
Diagnostic category weight ^b	-0.560	0.272	0.571	0.335 to 0.975

GCS, Glasgow Coma Scale score; MAP, mean arterial pressure; WBCC, white blood cell count.

a The coefficient for each covariate is the increase in the log-odds of hospital mortality for a 1-point increase in the APACHE II score for each element, unless otherwise stated.

b Per unit increase in the diagnostic category weight, as described in the original calculation of R.

The VANISH trial heterogeneity of treatment effect assessment

In the primary analysis with APACHE II score as baseline risk of death measure, there was no evidence of HTE for vasopressin in either absolute terms [low-APACHE II group, RD 0.02 (95% CI -0.09 to 0.13); high-APACHE II group, RD 0.05 (95% CI -0.08 to 0.19); difference in RD 0.04 (95% CI -0.14 to 0.21)] or relative terms [low-APACHE II group, RR 1.09 (95% CI 0.64 to 1.86); high-APACHE II, group RR 1.15 (95% CI 0.80 to 1.64); ratio of RR 1.05 (95% CI 0.55 to 2.00)] (Figure 21). In the case of the secondary risk measures, the estimates of HTE for vasopressin were larger with wider CI for APS-APII (Figure 22) and smaller in magnitude for R (Figure 23).

In the primary analysis with APACHE II score as baseline risk of death measure, there was no evidence of HTE for hydrocortisone in either absolute terms [low-APACHE II group, RD 0.02 (95% CI -0.12 to 0.17); high-APACHE II group, RD 0.06 (95% CI -0.10 to 0.21); difference in RD 0.03 (95% CI -0.18 to 0.25)] or in relative terms [low-APACHE II group, RR 1.11 (95% CI 0.62 to 1.99); high-APACHE II group RR 1.15 (95% CI 0.79 to 1.67); ratio of RR 1.04 (95% CI 0.52 to 2.08)]. In the case of the secondary risk measures, the estimates of HTE for hydrocortisone was similar for APS-APII (see Figure 22) and larger in magnitude for R (see Figure 23). Figures 21–23 were previously published by the authors in the paper by Santhakumaran and colleagues.⁴⁴

Heterogeneity of treatment effect was not observed when R was recalibrated either with controls only (Figure 24) or with the whole cohort (Figure 25), although subgroup differences were in the opposite direction for hydrocortisone.

The LeoPARDS trial heterogeneity of treatment effect assessment

For the primary analysis with APACHE II score as baseline risk of death measure there was no evidence of HTE for levosimendan in either absolute terms [low-APACHE II group, RD 0.05 (95% CI -0.04 to 0.15); high-APACHE II group, RD 0.04 (95% CI -0.08 to 0.16); difference in RD -0.02 (95% CI -0.17 to 0.14)] or in relative terms [low-APACHE II group, RR 1.34 (95% CI 0.78 to 2.31); high-APACHE II group, RR 1.09 (95% CI 0.84 to 1.41); ratio of RR 0.81 (95% CI 0.44 to 1.48)] (see Figure 21). For the secondary risk measures, the estimates of HTE for levosimendan were larger for APS-APII (see Figure 22) and in the opposite direction for R (see Figure 23).

Heterogeneity of treatment effect was not observed when R was recalibrated either with controls only (see Figure 24) or with the whole cohort (see Figure 25), although subgroup differences were in the opposite direction.

The HARP-2 trial heterogeneity of treatment effect assessment

For the primary analysis with APACHE II score as baseline risk of death measure, we observed HTE for simvastatin in absolute terms [low-APACHE II group, RD -0.15 (95% CI -0.22 to -0.07); high-APACHE II group, RD 0.19 (95% CI -0.01 to 0.39); difference in RD 0.34 (95% CI 0.12 to 0.55) ($p = 0.02$)] and in relative terms [low-APACHE II group, RR 0.45 (95% CI 0.28 to 0.72); high-APACHE II group, RR 1.61 (95% CI 0.95 to 2.71), ratio of RR 3.57 (95% CI 1.77 to 7.17)]. Simvastatin reduced mortality in the low-APACHE II group and increased mortality in the high-APACHE II group (see Figure 21). As raw data APACHE II score data were not available, we have not reported any secondary risk measures for the HARP-2 trial.¹⁷

Serious adverse events and baseline risk

We plotted the proportions of serious adverse events in the low- and high-APACHE II groups in each trial to explore whether or not the pattern of adverse event distribution could explain any HTE in mortality. In all three RCTs, both in the intervention and controls trial arms, there was no pattern in serious adverse events that could explain HTE in mortality (Figure 26).




FIGURE 21 Forest plots for the RD and RR comparing 28-day mortality in treatment and control, by trial and APACHE II score subgroup. Reproduced from Santhakumaran and colleagues.⁴⁴ This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated. The figure includes minor additions and formatting changes to the original figure.




FIGURE 22 Forest plots for the RD and RR comparing 28-day mortality in treatment and control, by trial and APS-APII subgroup. Reproduced from Santhakumaran and colleagues.⁴⁴ This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated. The figure includes minor additions and formatting changes to the original figure.




FIGURE 23 Forest plots for the RD and RR comparing 28-day mortality in treatment and control, by trial and R subgroup. Reproduced from Santhakumaran and colleagues.⁴⁴ This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated. The figure includes minor additions and formatting changes to the original figure.




FIGURE 24 Forest plots for the RD and RR comparing 28-day mortality in treatment and control, by trial and R_{recal} . (recalibration model with only controls) subgroup.




FIGURE 25 Forest plots for the RD and RR comparing 28-day mortality in treatment and control, by trial and R_{recal} (recalibration model with whole cohort) subgroup.




FIGURE 26 Forest plots for the RD and RR comparing related serious adverse events in treatment and control, by trial and APACHE II score subgroup.

Heterogeneity of treatment effect assessment on continuous scale using regression

Differences were also smaller when HTE was assessed across the continuous range of APACHE II score [ratio of OR for 5-point increase in APACHE II 1.33 (95% CI 0.93 to 1.90)] (Table 6 and Figure 27).

TABLE 6 Treatment–risk interaction using continuous APACHE II score from logistic regression analysis of 28-day mortality

Trial	Ratio of OR for a 5-point increase in APACHE II score	95% CI
VANISH ¹⁵ (vasopressin vs. noradrenaline)	0.96	0.71 to 1.29
VANISH ¹⁵ (hydrocortisone vs. placebo)	0.93	0.67 to 1.29
LeoPARDS ¹⁶	1.00	0.74 to 1.34
HARP-2 ¹⁷	1.33	0.93 to 1.90




FIGURE 27 Heterogeneity of treatment effect assessment for APACHE II score as a continuous variable. Figures shows the estimated treatment effect with 95% CI bands from regression models for 28-day mortality including a treatment \times APACHE II score interaction with (a) the VANISH trial¹⁵ (vasopressin); (b) the VANISH trial¹⁵ (hydrocortisone); (c) the LeoPARDS trial,¹⁶ and (d) the HARP-2 trial.¹⁷ (continued)




FIGURE 27 Heterogeneity of treatment effect assessment for APACHE II score as a continuous variable. Figures shows the estimated treatment effect with 95% CI bands from regression models for 28-day mortality including a treatment \times APACHE II score interaction with (a) the VANISH trial¹⁵ (vasopressin); (b) the VANISH trial¹⁵ (hydrocortisone); (c) the LeoPARDS trial;¹⁶ and (d) the HARP-2 trial.¹⁷

Sensitivity analyses

The results from sensitivity analyses were consistent with those from the main analyses for the VANISH trial¹⁵ and the LeoPARDS trial¹⁶ (see *Table 6* and *Figure 28*). HTE was attenuated in the sensitivity analyses for the HARP-2 trial¹⁷ under different assumptions for the missing data [e.g. ratio of RR was 2.86 (95% CI 1.47 to 5.57) when we assumed that patients with missing APACHE II data were more likely to be high risk; all other results were less attenuated] (*Table 7*). Differences were also smaller when hospital mortality was used as the outcome [difference in RD 0.25 (95% CI 0.03 to 0.48), ratio of RR 2.34 (95% CI 1.31 to 4.18)] (see *Figure 28*).

Determining subphenotypes using latent class analysis

Exploratory analysis

Biomarker data (at least one biomarker at baseline) were available for 176 of 409 patients in the VANISH trial¹⁵ and 493 of 516 patients in the LeoPARDS trial.¹⁶ Clinical characteristics at baseline are shown in *Table 8*. A summary of the biomarker data for both trials is shown in *Table 9* (the VANISH trial¹⁵) and *Table 10* (the LeoPARDS trial¹⁶), including details of values outside the limits of detection. As the limits varied by assay run, the mean limits for each biomarker are given.




FIGURE 28 Forest plots for the RD and RR comparing hospital mortality in treatment and control, by trial and APACHE II score subgroup.

RESULTS

TABLE 7 Results from multiple imputation analysis

Assumption for missing APACHE II score	APACHE II score \geq 25 points (%)	Difference in RD (95% CI)	Ratio of RR (95% CI)
VANISH trial ¹⁵ (vasopressin vs. noradrenaline)			
Same as complete data	50	0.03 (-0.16 to 0.21)	1.02 (0.51 to 2.04)
10% higher	60	0.03 (-0.16 to 0.21)	1.03 (0.51 to 2.07)
10% lower	40	0.01 (-0.17 to 0.20)	0.96 (0.49 to 1.90)
VANISH trial ¹⁵ (hydrocortisone vs. placebo)			
Same as complete data	50	0.03 (-0.19 to 0.25)	1.02 (0.49 to 2.14)
10% higher	60	0.03 (-0.20 to 0.25)	1.03 (0.48 to 2.19)
10% lower	40	0.02 (-0.21 to 0.25)	0.99 (0.47 to 2.09)
LeoPARDS trial ¹⁶			
Same as complete data	56	-0.01 (-0.17 to 0.17)	0.89 (0.47 to 1.69)
10% higher	66	-0.01 (-0.17 to 0.16)	0.86 (0.45 to 1.67)
10% lower	46	-0.02 (-0.17 to 0.17)	0.89 (0.47 to 1.69)
HARP-2 trial ¹⁷			
Same as complete data	19	0.31 (0.10 to 0.52)	2.99 (1.51 to 5.90)
10% higher	29	0.30 (0.08 to 0.52)	2.96 (1.43 to 6.10)
10% lower	18	0.30 (0.09 to 0.51)	2.86 (1.47 to 5.57)
Note			
For patients with missing APACHE II scores, we assumed the proportion in the high-risk category (i.e. an APACHE II score \geq 25 points) was the same as among trial participants with complete data, 10% higher or 10% lower.			

TABLE 8 Patient characteristics at baseline for patients with some baseline sample data

Characteristic	VANISH trial ¹⁵ (N = 176)		LeoPARDS trial ¹⁶ (N = 493)	
	Median (IQR) or n (%)	Missing (n)	Median (IQR) or n (%)	Missing (n)
Age (years)	65 (53.5–77)	0	68 (58–76)	0
Male	112 (63%)	0	274 (56%)	0
Ethnicity		0		0
White	146 (83%)		461 (94%)	
Black	14 (8%)		10 (2%)	
Asian	13 (7%)		19 (4%)	
Other	3 (2%)		3 (1%)	
BMI (kg/m ²)	26.1 (22.5–31.3)	6	27.1 (23.4–31.0)	9
Comorbidities		0		0
NYHA class IV	0 (0%)		5 (1%)	
Severe COPD	10 (6%)		23 (5%)	
Chronic renal failure	8 (5%)		35 (7%)	
Cirrhosis	11 (6%)		9 (2%)	
Immunocompromised	11 (6%)		45 (9%)	

TABLE 8 Patient characteristics at baseline for patients with some baseline sample data (continued)

Characteristic	VANISH trial ¹⁵ (N = 176)		LeoPARDS trial ¹⁶ (N = 493)	
	Median (IQR) or n (%)	Missing (n)	Median (IQR) or n (%)	Missing (n)
Site of infection		3		1
Lung	74 (43%)		192 (39%)	
Abdomen	35 (20%)		181 (37%)	
Urine	28 (16%)		29 (6%)	
Primary bacteraemia	3 (2%)		10 (2%)	
Neurological	4 (2%)		5 (1%)	
Soft tissue or line	6 (3%)		26 (5%)	
Other	23 (13%)		49 (10%)	
SOFA score (points)	7 (5–9)	22	8 (6–9)	16
APACHE II score (points)	24 (19–30)	1	25 (21–31)	0
Post-surgical admission	26 (15%)	0	180 (37%)	0

TABLE 9 Biomarker data at baseline: the VANISH trial¹⁵

Biomarkers	n ^a	Median (IQR) of values within limits	Lower limit		Upper limit		Missing (n)
			n (% ^b) below	Mean	n (% ^b) above	Mean	
Organ dysfunction							
PaO ₂ /FiO ₂ ratio (kPa)	169	26 (17.3–41.3)	0 (0)	NA	0 (0)	NA	7
Creatinine (µmol/l)	176	120 (78–198)	0 (0)	NA	0 (0)	NA	0
Platelets (× 10 ⁹ /l)	171	186 (118–287)	0 (0)	NA	0 (0)	NA	5
Bilirubin (µmol/l)	156	14.5 (9–28.5)	0 (0)	NA	0 (0)	NA	20
Inflammation (pg/ml)							
IL-1β	162	9.5 (5.7–15.6)	109 (67)	3.2	0 (0)	NA	14
IL-6	162	1419 (322–6385)	0 (0)	NA	15 (9.3)	59,149	14
IL-8	162	206 (55–1311)	16 (9.9)	10.2	0 (0)	NA	14
IL-10	162	47.1 (14.4–180.5)	16 (9.9)	3.0	0 (0)	NA	14
IL-17	162	16.7 (8.9–24.9)	108 (67)	5.3	0 (0)	NA	14
IL-18	162	475 (239–803)	3 (1.9)	2.2	0 (0)	NA	14
Leucocytes (pg/ml)							
Myeloperoxidase	168	433,826 (185,139–860,389)	1 (0.6)	31,250	2 (1.2)	5,600,000	8
sICAM	168	288,081 (183,124–466,634)	6 (3.6)	32,000	0 (0)	NA	8
Endothelial injury (pg/ml)							
ANG II	168	4658 (1983–8264)	2 (1.2)	375	1 (0.6)	48,000	8

continued

RESULTS

TABLE 9 Biomarker data at baseline: the VANISH trial¹⁵ (continued)

Biomarkers	n ^a	Median (IQR) of values within limits	Lower limit		Upper limit		Missing (n)
			n (% ^b) below	Mean	n (% ^b) above	Mean	
Cardiovascular							
Troponin (ng/l)	95	49 (12–428)	0 (0)	NA	0 (0)	NA	81
NT-proBNP (pg/ml)	168	5120 (2302–10,547)	3 (1.8)	480	0 (0)	NA	8
Other markers							
sTNFR1 (pg/ml)	168	5585 (3399–9254)	0 (0)	NA	2 (1.2)	40,000	8
Lactate (mmol/l)	172	2.4 (1.5–3.9)	0 (0)	NA	0 (0)	NA	4

NA, not applicable.
a Includes patients with values beyond limits of assay.
b As a percentage of non-missing values, including those beyond limits of detection.

TABLE 10 Biomarker data at baseline: the LeoPARDS trial¹⁶

Biomarkers	n ^a	Median (IQR) of values within limits	Lower limit		Upper limit		Missing (n)
			n (% ^b) below	Mean	n (% ^b) above	Mean	
Organ dysfunction							
PaO ₂ /FiO ₂ ratio (kPa)	491	28.8 (20.2–39.3)	0 (0)	NA	0 (0)	NA	2
Creatinine (μmol/l)	491	138 (91–213)	0 (0)	NA	0 (0)	NA	2
Platelets (× 10 ⁹ /l)	490	215 (141–307)	0 (0)	NA	0 (0)	NA	3
Bilirubin (μmol/l)	483	15 (8–26)	0 (0)	NA	0 (0)	NA	10
Inflammation (pg/ml)							
IL-1β	486	1.41 (0.84–2.97)	43 (8.8)	0.42	0 (0)	NA	7
IL-6	490	676 (222–2881)	0 (0)	NA	34 (6.9)	40,000	3
IL-8	490	166 (60–437)	0 (0)	NA	4 (0.8)	24,000	3
IL-10	490	79 (31–193)	0 (0)	NA	1 (0.2)	80,000	3
IL-17	486	8.4 (5.6–17.5)	9 (1.9)	1.64	0 (0)	NA	7
IL-18	486	732 (463–1176)	4 (0.8)	93.6	12 (2.5)	6000	7
Leucocytes (pg/ml)							
Myeloperoxidase	486	424,478 (251,550–786,731)	35 (7.2)	87,500	12 (2.5)	5,600,000	7
sICAM	486	310,426 (188,980–494,860)	1 (0.2)	22,400	22 (4.5)	1,400,000	7
Endothelial injury (pg/ml)							
ANG II	486	5673 (3113–12,112)	7 (1.4)	744	8 (1.6)	48,000	7
Cardiovascular							
Troponin (ng/l)	483	82.3 (20.9–481)	0 (0)	NA	0 (0)	NA	10
NT-proBNP (pg/ml)	492	10,462 (4540–21,149)	34 (6.9)	548	2 (0.4)	800,000	1

TABLE 10 Biomarker data at baseline: the LeoPARDS trial¹⁶ (continued)

Biomarkers	n ^a	Median (IQR) of values within limits	Lower limit		Upper limit		Missing (n)
			n (% ^b) below	Mean	n (% ^b) above	Mean	
Other markers							
sTNFR1 (pg/ml)	492	10,664 (5925–17,389)	0 (0)	NA	0 (0)	NA	1
Lactate (mmol/l)	490	2.2 (1.4–3.6)	0 (0)	NA	0 (0)	NA	3
CCL2 (pg/ml)	490	733 (423–1390)	0 (0)	NA	6 (1.2)	48,000	3

NA, not applicable.

a Includes values beyond limits.

b As a percentage of non-missing values, including those beyond limits of detection.

Latent class analysis: the VANISH trial

The latent class modelling was carried out in three stages. The first stage includes only indicator variables (the biomarkers) and assumes a common variance across classes and zero covariance between indicators within class. In the second stage, clinical and demographic characteristics are added as covariates. In the third stage, the variance assumptions are relaxed. We first present the model results and then compare the results and model fit across all the models. Finally, we compare detailed results for a selection of candidate models. For each model we present the estimated distribution of the latent classes and the estimated class means for each indicator. Important indicators are those that have good separation (high between-class variability). As a measure of separation, we present the variance of the estimated class means. All indicators have been log-transformed and standardised to have a mean of zero and a SD of 1.

Stage 1: no covariates, constant variance across classes and uncorrelated errors within classes

For indicators with fewer than five values outside the limits of detection (i.e. IL-18, MPO, ANG II, NT-proBNP and sTNFR1), values were replaced by the limit because of inability of models to converge. Models with more than four classes did not converge. *Table 19* shows the results for two-, three- and four-class models. In the two-class model, the inflammatory biomarkers showed the most separation between classes (i.e. low in class 1 and high in class 2). Other biomarkers followed a similar pattern, except for PaO₂/FiO₂ ratio and platelets, which were high in class 1 and low in class 2. A similar set of biomarkers showed the most separation in the three- and four-class models. Variables were standardised based on the observed data (excluding values outside the limits of detection). The estimated class means are calculated based on all the data, which for some indicators (e.g. IL-1 β) includes a large number of observations below the limit of detection, resulting in negative means in all classes.

Stage 2: model including biomarkers as above, demographic and clinical variables

Models did not converge when including all covariates specified a priori. Therefore, a reduced number of covariates were selected as follows. For each covariate we compared the two-class model derived in stage 1 with the same model plus the covariate in question in the logistic model for class membership, using a likelihood ratio test. This was repeated for the three- and four-class models. Any covariate that improved the fit (as indicated by a *p*-value < 0.05 from the likelihood ratio test) for any of the two-, three- or four-class models was included as a covariate. These covariates were age, source of infection (i.e. lung, abdomen, urine or other), APS-APII and post-surgical admission. APS-APII was also included as a covariate in the regression equations for each indicator, based on clinical plausibility. As in stage 1, the residual variance of the indicators was assumed to be constant across classes and with zero correlation between indicators within classes. The results are shown in *Table 20*. The same biomarkers contributed to class separation as in stage 1 (unadjusted for clinical covariates). In the three-class model, class 1 was larger, with higher class means for the inflammatory markers than the corresponding unadjusted stage 1 model. Classes 2 and 3 had lower class means than the stage 1 three-class model.

Stage 3: relaxing variance constraints

In stages 1 and 2 we assumed that the residual variance of each indicator did not change across classes and that the indicators were uncorrelated for individuals in the same class. In stage 3 these assumptions were relaxed in three sets of models. In stage 3a we allowed for non-constant variance across classes (see *Table 21*), in stage 3b no constraints were placed on covariance terms (see *Table 22*) and in stage 3c both these options were applied together (see *Table 23*). The four-class models did not converge if non-constant variance across classes was modelled, and so for these specifications only the two- and three-class models are presented.

A similar set of important biomarkers was identified in stage 3 as in the previous stages. The two-class models all had similar estimated class means to stage 2 for the important biomarkers, with the exception of IL-1 β . This marker was less important in models that allowed the variance to differ across classes (i.e. stage 3a and stage 3c), possibly because of the large number of observations below the limit of detection. In the stage 2 three-class model, the largest class had low values of the inflammatory markers. When the variance was allowed to differ across classes, the class with the highest values for inflammatory markers (i.e. class 3) was the largest, estimated to be nearly half the population. In the other stage 3 model (i.e. stage 3b), in which only the covariance restriction was relaxed, class 2 was the largest class.

Comparing models derived from stages 1–3

The log-likelihood, class distributions, entropy, mean class probability, AIC and BIC are given in *Table 11*. *Figure 29* shows how the log-likelihood, AIC and BIC change with the number of classes for each model stage. Across all models a similar set of indicators contributed to defining the classes. The estimated class means and class size were similar for the two-class models. Based on the AIC and BIC, the two-class stage 3b model (including covariates and allowing indicators to be correlated for individuals in the same class) appears to offer the best fit. We examined this model further, along with the three-class stage 3b model, which has a similar fit but an additional class, and the more parsimonious stage 2 models (two and three classes).

Figure 30 shows the distribution of each indicator by class for each of the candidate models, assigning individuals to their modal class (i.e. the class for which they had the highest posterior class probability). The indicators are ordered by the p -value from a Kruskal–Wallis non-parametric test comparing the distribution across the classes. The test was performed separately for each model and the average p -value taken to get an approximate ordering of importance of the indicators. The results are consistent across the models, with differences observed only for indicators with less separation across the classes. For example, NT-proBNP is highest in class 2 for the stage 2 three-class model, but highest in class 3 for the stage 3 three-class model. *Figures 41–43* show separation plots for each of the candidate models reported in stages 1–3. These show the distribution of each of the indicators, with one line representing an individual, coloured according to the modal class. They show how well separated the classes are for each indicator. Only the top few indicators are clearly separated. For the three-class models, stage 3b models appear slightly better separated than their stage 2 counterpart for the most important indicators. There is little difference between the two-class models.

In summary, these comparisons suggest that the simpler two-class model from stage 2 is appropriate, given the minimal differences in indicator distribution, separation and class assignment. The more complex three-class models create a ‘middle’ class that is a mixture of the other two classes, and so does not give a substantively different interpretation. Therefore, the two-class model from stage 2 is used for all our subsequent analysis.

Analysis by modal class: the VANISH trial

There was an almost even split between classes (90 individuals assigned to class 1 and 86 individuals assigned to class 2). The clinical characteristics by latent class in the VANISH trial¹⁵ are shown in *Table 12*, biomarker values are shown in *Table 13* and clinical outcomes by class are shown in *Table 14*. The classes in the final model will be referred to as subphenotype 1 (i.e. class 1) and subphenotype 2 (i.e. class 2) from hereon in the manuscript when referring to the VANISH trial.¹⁵

TABLE 11 Model fit statistics for all LCA models in the VANISH trial¹⁵

Stage	Number of classes	Log-likelihood	Class distribution		Entropy	Mean class probability ^a	AIC	BIC
			Estimated	Observed ^a				
1	1 ^a	-3937					7942	8049
	2	-3732	49/51	49/51	0.87	0.96/0.97	7568	7733
	3	-3673	29/44/27	29/45/26	0.82	0.93/0.89/0.94	7486	7708
	4	-3638	21/13/34/32	22/12/35/31	0.84	0.91/0.90/0.88/0.95	7451	7730
2	1 ^a	-3806					7714	7874
	2	-3596	51/50	49/51	0.88	0.97/0.96	7378	7671
	3	-3514	37/28/35	36/26/38	0.86	0.95/0.98/0.90	7298	7722
	4	-3465	36/17/24/23	35/17/23/24	0.88	0.95/0.95/0.93/0.91	7281	7838
3a	1 ^a	-3806					7714	7875
	2	-3573	51/49	49/51	0.89	0.97/0.96	7365	7711
	3	-3476	49/29/23	47/28/24	0.93	0.98/0.96/0.95	7290	7822
	4 ^b							
3b	1 ^a	-3621					7453	7787
	2	-3454	46/54	44/56	0.85	0.96/0.95	7025	7671
	3	-3375	32/46/22	31/45/24	0.89	0.95/0.94/0.98	7130	7729
	4	-3330	25/38/23/15	24/37/23/16	0.91	0.96/0.95/0.95/0.96	7125	7855
3c	1 ^a	-3621					7453	7787
	2	-3393	56/44	55/45	0.90	0.97/0.96	7226	7918
	3	-3307	48/23/29	48/22/31	0.93	0.97/0.99/0.97	7282	8333
	4 ^b							

a Class statistics not applicable for models with only one class.

b Model did not converge.




FIGURE 29 Plots of model fit indicators in the VANISH trial:¹⁵ (a) log-likelihood; (b) AIC; and (c) BIC. (continued)

RESULTS




FIGURE 29 Plots of model fit indicators in the VANISH trial:¹⁵ (a) log-likelihood; (b) AIC; and (c) BIC.

There was no evidence that treatment effects varied by subphenotype for any of the outcomes of the VANISH trial¹⁵ (Figures 31 and 32). The effect of vasopressin on renal failure-free survival at 28 days compared with noradrenaline was in opposite directions in class 1 [i.e. 10% reduction in survival (95% CI -31% to 11%)] compared with subphenotype 2 [i.e. 10% increase in survival (95% CI -16% to 35%)], but the CI for the subgroup difference was wide [difference in RD 20% (95% CI -13% to 53%)]. Point estimates for the treatment effect showed a consistent direction of subgroup differences (i.e. all RDs were positive, indicating that treatments were more likely to benefit participants in class 2). This was also seen for renal failure-free days. For subphenotype 1, the median in the vasopressin group was 10 days lower (95% CI -23 to 3 days) than in the noradrenaline group, whereas for class 2 those in the vasopressin group had a median of 6 more renal failure-free days (95% CI -8 to 20 days). The test for subphenotype-treatment interactions was not statistically significant. The sensitivity analysis gave very similar results, with 97% agreement in subphenotype assignment for the VANISH trial¹⁵ (see Table 24).




FIGURE 30 Box plot showing distribution of indicators by class for candidate models, assigning to modal class, in the VANISH trial.¹⁵ The box shows the 25th, 50th and 75th percentiles, the whiskers show the extent of data within $1.5 \times \text{IQR}$ and the dots show data points beyond these limits. P/F, $\text{PaO}_2/\text{FiO}_2$.

TABLE 12 Baseline characteristics by assigned class in the LeoPARDS trial¹⁶ and the VANISH trial¹⁵

Characteristic	LeoPARDS trial ¹⁶ (N = 493)				VANISH trial ¹⁵ (N = 176)		
	Class 1 (n = 191)	Class 2 (n = 247)	Class 3 (n = 55)	Missing (n)	Class 1 (n = 90)	Class 2 (n = 86)	Missing (n)
Age (years), median (IQR)	68 (57-77)	69 (62-76)	65 (51-73)	0	65.5 (54-77)	64.5 (53-76)	0
Male, n (%)	108 (56.5)	138 (55.9)	28 (50.9)	0	58 (64.4)	54 (62.8)	0
Ethnicity, n (%)				0			0
White	180 (94.2)	229 (92.7)	52 (94.6)		77 (85.6)	69 (80.2)	
Black	3 (1.6)	5 (2)	2 (3.6)		8 (8.9)	6 (7)	
Asian	7 (3.7)	11 (4.5)	1 (1.8)		4 (4.4)	9 (10.5)	
Other	1 (0.5)	2 (0.8)	0 (0)		1 (1.1)	2 (2.3)	
BMI (kg/m ²), median (IQR)	26.7 (23-30.8)	27.3 (23.4-30.7)	27.8 (24.2-33.6)	6	24.7 (22.2-31.6)	26.2 (22.6-31.1)	9
Comorbidities, n (%)							
NYHA IV	1 (0.5)	4 (1.6)	0 (0)	0	0 (0)	0 (0)	0
Severe COPD	10 (5.2)	11 (4.5)	2 (3.6)	0	7 (7.8)	3 (3.5)	0
Chronic renal failure	18 (9.4)	15 (6.1)	2 (3.6)	0	2 (2.2)	6 (7)	0
Cirrhosis	6 (3.1)	3 (1.2)	0 (0)	0	4 (4.4)	7 (8.1)	0
Immunocompromised	14 (7.3)	22 (8.9)	9 (16.4)	0	2 (2.2)	9 (10.5)	0

Characteristic	LeoPARDS trial ¹⁶ (N = 493)				VANISH trial ¹⁵ (N = 176)		
	Class 1 (n = 191)	Class 2 (n = 247)	Class 3 (n = 55)	Missing (n)	Class 1 (n = 90)	Class 2 (n = 86)	Missing (n)
Site of infection, n (%)				3			1
Lung	106 (55.5)	74 (30.1)	12 (21.8)		42 (48.3)	32 (37.2)	
Abdomen	45 (23.6)	111 (45.1)	25 (45.5)		17 (19.5)	18 (20.9)	
Urine	13 (6.8)	13 (5.3)	3 (5.5)		10 (11.5)	18 (20.9)	
Primary bacteraemia	0 (0)	6 (2.4)	4 (7.3)		2 (2.3)	1 (1.2)	
Neurological	3 (1.6)	2 (0.8)	0 (0)		4 (4.6)	0 (0)	
Soft tissue or line	10 (5.2)	10 (4.1)	6 (10.9)		3 (3.5)	(3.5)	
Other	14 (7.3)	30 (12.2)	5 (9.1)		9 (10.3)	14 (16.3)	
SOFA score (points), median (IQR)	7 (6–8)	8 (7–10)	9 (7–11)	22	6 (4–8)	8 (5–10)	16
APACHE II score (points), median (IQR)	24 (21–30)	26 (21–31)	27 (22–30)	1	24 (18–29)	23.5 (20–30)	0
Post-surgical admission, n (%)	49 (25.7)	114 (46.2)	17 (30.9)	0	17 (18.9)	9 (10.5)	0

TABLE 13 Biomarker data by class, with study participants assigned by highest posterior class probability

Parameter	LeoPARDS trial ¹⁶ (N = 493)				VANISH trial ¹⁵ (N = 176)		
	Class 1, median (IQR)	Class 2, median (IQR)	Class 3, median (IQR)	n (%) outside limits	Class 1, median (IQR)	Class 2, median (IQR)	n (%) outside limits
Organ dysfunction							
PaO ₂ /FiO ₂ ratio (kPa)	29.1 (22–39.7)	29.3 (20.2–39.4)	25.8 (16.6–36)	0/491 (0)	32.5 (21–43.5)	21.1 (14.6–34.9)	0/169 (0)
Creatinine (µmol/l)	107 (69–166)	151 (107–231)	173 (137–295)	0/491 (0)	91.5 (67–163)	140 (106–270)	0/176 (0)
Platelets (× 10 ⁹ /l)	243 (182–350)	203 (131–294)	136 (76–215)	0/490 (0)	206 (145–335)	150 (83–246)	0/171 (0)
Bilirubin (µmol/l)	12 (7–19)	17 (10–30)	17 (9–31)	0/483 (0)	12 (7–23)	16.5 (11–42)	0/156 (0)
Inflammation markers (pg/ml)							
IL-1β	0.915 (0.651–1.41)	1.53 (0.948–2.88)	7.96 (2.93–11.3)	43/486 (8.8)	4.9 (4.34–6.25)	11.2 (7.71–19.4)	109/162 (67.3)
IL-6	232 (92–481)	1588 (583–3874)	19,582 (11,926–27,584)	34/490 (6.9)	426 (175–1376)	6385 (2277–19,641)	15/162 (9.3)
IL-8	48.2 (30.4–84.8)	257 (159–516)	3015 (1252–7336)	4/490 (0.8)	64.8 (28.3–173)	1075 (225–3293)	16/162 (9.9)
IL-10	26.3 (17.4–49.8)	123 (66.1–205)	554 (314–1429)	1/490 (0.2)	15.1 (8.27–32.9)	159 (66–446)	16/162 (9.9)
IL-17	6.61 (4.71–10.1)	9.79 (6.52–19.5)	21.5 (8.1–49.9)	9/486 (1.9)	15.6 (7.36–22.6)	18 (10.6–38.8)	108/162 (66.7)
IL-18	559 (373–996)	804 (565–1278)	1065 (724–1759)	16/486 (3.3)	434 (163–595)	562 (331–836)	3/162

Parameter	LeoPARDS trial ¹⁶ (N = 493)				VANISH trial ¹⁵ (N = 176)		
	Class 1, median (IQR)	Class 2, median (IQR)	Class 3, median (IQR)	n (%) outside limits	Class 1, median (IQR)	Class 2, median (IQR)	n (%) outside limits
Leucocytes (pg/ml)							
Myeloperoxidase	332,192 (204,356–581,390)	489,569 (291,316–987,773)	541,091 (340,269–1,405,943)	47/486 (9.7)	264,802 (122,264–433,825)	675,769 (448,047–1,195,365)	3/168
sICAM	271,181 (168,034–414,706)	311,864 (187,557–515,209)	432,439 (298,658–886,124)	23/486 (4.7)	243,841 (165,654–326,461)	341,912 (208,505–550,529)	6/168
Endothelial injury (pg/ml)							
ANG II	3197 (1906–5419)	7487 (4491–14,867)	13,040 (7373–23,168)	15/486 (3.1)	3162 (1503–5551)	6592 (3681–11,564)	3/168 (1.8)
Cardiovascular							
Troponin (ng/l)	62 (16.8–536)	77.8 (23.7–381)	139 (45.2–589)	0/483	21 (6–94)	149 (31–729)	0/95
NT-proBNP (pg/ml)	9054 (3318–17,410)	10,269 (4922–23,317)	18,406 (9844–31,718)	36/492 (7.3)	3611 (1238–7416)	8130 (3590–16,890)	3/168 (1.8)
Other markers							
sTNFR1 (pg/ml)	5939 (3923–9802)	13,457 (8749–20,337)	18,099 (12,379–27,759)	0/492	3856 (2064–5555)	8315 (5743–12,645)	2/168 (1.2)
Lactate (mmol/l)	1.5 (1–2.1)	2.6 (1.8–4)	5.2 (3–7)	0/490	1.8 (1.2–2.5)	3.5 (2.3–5.3)	0/172
CCL2 (pg/ml)	384 (272–592)	995 (676–1590)	4049 (3105–5621)	6/490 (1.2)			

TABLE 14 Clinical outcomes by class in the LeoPARDS trial¹⁶ and the VANISH trial¹⁵

Trial outcome	Class			p-value for difference
	1	2	3	
LeoPARDS ¹⁶				
3-month survival, n/N (%)	132/189 (69.8)	155/246 (63.0)	23/55 (41.8)	0.001 ^a
28-day survival, n/N (%)	143/190 (75.3)	165/247 (66.8)	26/55 (47.3)	< 0.001 ^a
Mean daily SOFA score (points), mean (SD)	4.93 (2.88)	6.67 (3.94)	9.97 (4.60)	< 0.001 ^b
VANISH ¹⁵				
28-day renal failure-free survival, n/N (%) ^c	51/75 (68.0)	32/60 (53.3)		0.08 ^a
28-day survival, n/N (%)	72/90 (80.0)	57/86 (66.3)		0.04 ^a
Renal failure-free days, median (IQR) ^d	19 (3–26)	8 (0–23)		0.03 ^e

a Chi-squared test.

b Kruskal–Wallis test.

c In patients not in renal failure at baseline.

d In patients who die or experience some renal failure by day 28.

e Mann–Whitney U-test.

Latent class analysis: the LeoPARDS trial

Stage 1: no covariates, constant variance across classes and uncorrelated errors within classes

Models with more than five classes did not converge. *Table 25* shows the results for the two-, three- and four-class models, and *Table 26* shows the results for the five-class model. In the two-class model, the inflammatory biomarkers showed the most separation between classes (as with the VANISH trial¹⁵), with ANG II and CCL2 also being prominent. These biomarkers were low in class 1 and high in class 2. Other biomarkers followed a similar pattern, except for PaO₂/FiO₂ ratio and platelets, which were high in class 1 and low in class 2. Except for the five-class model, there was a consistent pattern across all prominent biomarkers (i.e. the order of the classes according to estimated class mean was almost identical).

Stage 2: model including biomarkers, demographic and clinical variables

All variables selected a priori were included as covariates in the models for the LeoPARDS trial.¹⁶ APS-APII was also included as a covariate in the regression equations for each indicator, based on clinical plausibility. As in stage 1, the residual variance of the indicators was assumed to be constant across classes and with zero correlation between indicators within classes. The model with five latent classes did not converge. The results are shown in *Table 27*. The same biomarkers contributed to class separation, as in stage 1 (i.e. unadjusted for clinical covariates). The two- and three-class models had similar estimated class means and class sizes to their stage 1 counterparts. The four-class model was slightly different, with fewer observations and lower class means in the class with the lowest biomarker values (i.e. class 1).

Stage 3: relaxing variance constraints

In stages 1 and 2 we assumed that the residual variance of each indicator did not change across classes and the indicators were uncorrelated for individuals in the same class. In stage 3 these assumptions were relaxed in three sets of models. In stage 3a we allowed for non-constant variance across classes (see *Table 28*), in stage 3b no constraints were placed on covariance terms (see *Table 29*) and in stage 3c both these options were applied together (see *Table 30*). The five-class models did not converge for any of the models in stage 3.




FIGURE 31 No evidence for treatment effect variation by class for any of the survival outcomes of the VANISH trial¹⁵ and the LeoPARDS trial.¹⁶ RF, renal failure.




FIGURE 32 No evidence for treatment effect variation by class for any of the organ dysfunction outcomes of the VANISH trial¹⁵ and the LeoPARDS trial.¹⁶

A similar set of important biomarkers was identified as in the previous stages. The two-class models all had similar estimated class means to stage 2 for the important biomarkers. For the three-class models the estimated class sizes were fairly similar to stage 2, with class 2 (i.e. middle values for important biomarkers) being the largest class. The estimated means differed slightly, but the ordering across the classes was consistent. For the four-class models, the class with the highest values of important markers (i.e. class 4) was consistently the smallest, as in stage 2; however, the distribution across the other classes varied. The estimated class means were slightly different, but showed similar patterns.

Comparing models derived from stages 1–3

A similar set of indicators were important for defining the latent classes, with some overlap with those found in the VANISH trial.¹⁵ The log-likelihood, class distributions, entropy, mean class probability, AIC and BIC are given in *Table 15*. We present plots showing how the log-likelihood, AIC and BIC change with the number of classes for each model stage in *Figure 33*.

With the exception of the stage 3c model, the information criteria continued to decrease as the number of classes increased. There was negligible improvement after three classes and the BIC for the stage 3c model increased. Fit statistics were close for stages 2–3c and so we examined the three-class model for all of these stages in more detail.

Figure 34 shows the distribution of each indicator by class for each of the candidate models, assigning individuals to their modal class (i.e. the class for which they had the highest posterior class probability). The results are very similar across the models. The most notable difference is for values of IL-6 in class 3, which are more dispersed in the models and allow for the variance to differ across the classes (i.e. stages 3a and 3c).

TABLE 15 Model fit statistics for all models: the LeoPARDS trial¹⁶

Stage	Number of classes	Log-likelihood	Estimated class distribution	Observed distribution ^a	Entropy	Mean class probability ^a	AIC	BIC
1	1 ^a	-13,058					26,188	26,339
	2	-12,285	61/39	61/39	0.89	0.98/0.96	24,681	24,912
	3	-11,942	33/14/53	32/14/54	0.89	0.95/0.97/0.95	24,031	24,342
	4	-11,800	35/23/13/29	35/23/13/30	0.86	0.95/0.89/0.98/0.88	23,787	24,178
	5 ^b	-11,676	22/30/17/10/20	22/30/17/10/20	0.86	0.93/0.89/0.91/0.98/0.90	23,576	24,047
2	1 ^a	-12,657					25,423	25,648
	2	-11,910	58/42	57/43	0.89	0.98/0.96	24,020	24,438
	3	-11,555	32/12/56	31/12/58	0.91	0.95/0.99/0.95	23,402	24,013
	4	-11,373	26/12/21/41	25/11/20/43	0.89	0.96/0.98/0.93/0.92	23,129	23,932
3a	1 ^a	-12,657					25,423	25,648
	2	-11,770	54/46	53/47	0.88	0.96/0.97	23,776	24,270
	3	-11,413	30/51/19	29/51/20	0.90	0.97/0.95/0.97	23,189	23,950
	4	-11,174	31/29/16/24	31/29/15/25	0.90	0.96/0.93/0.98/0.94	22,840	23,868

continued

RESULTS

TABLE 15 Model fit statistics for all models: the LeoPARDS trial¹⁶ (continued)

Stage	Number of classes	Log-likelihood	Estimated class distribution	Observed distribution ^a	Entropy	Mean class probability ^a	AIC	BIC
3b	1 ^a	-12,470					25,091	25,404
	2	-11,796	58/42	57/43	0.87	0.97/0.96	23,833	24,339
	3	-11,452	39/11/50	39/11/50	0.91	0.94/0.98/0.96	23,238	23,936
	4	-11,285	31/11/33/25	31/11/32/27	0.88	0.95/0.98/0.93/0.90	22,997	23,887
3c	1 ^a	-12,470					25,091	25,404
	2	-11,641	54/46	53/47	0.88	0.96/0.97	23,602	24,271
	3	-11,283	37/43/20	36/43/21	0.90	0.97/0.94/0.98	23,055	24,079
	4	-11,004	33/30/16/21	32/30/16/23	0.91	0.97/0.93/0.98/0.95	22,749	24,128

a Class statistics not applicable for models with only one class.
 b The five-class model did not converge in stages 2–3c.




FIGURE 33 Plots of model fit indicators in the LeoPARDS trial:¹⁶ (a) log-likelihood; (b) AIC; and (c) BIC. (continued)




FIGURE 33 Plots of model fit indicators in the LeoPARDS trial:¹⁶ (a) log-likelihood; (b) AIC; and (c) BIC.

Figures 44–47 show separation plots for each of the candidate models. These show the distribution of each indicators, with one line representing an individual, coloured in accordance with the modal class. They show how well separated the classes are for each indicator. For stages 3a and 3c there are a few low biomarker values that belong to subjects in class 3.

In summary, there are minimal difference in indicator distribution. Models 3a and 3c show some indication of poor separation, and model 2 may be of insufficient complexity, given what is known about the correlations between the indicators. Therefore, model 3b was selected.

Analysis by modal class: the LeoPARDS trial

The baseline clinical and demographic characteristics by classes are shown in *Table 12*. The final model assigned 191 individuals to class 1, 247 individuals to class 2 and 55 individuals to class 3. As standardised values can be difficult to interpret, the median and IQR for each indicator on the original scale are shown in *Table 13* for individuals assigned to each class, based on posterior class probability. The classes in the final model will be referred to as subphenotype 1 (i.e. class 1), subphenotype 2 (i.e. class 2) and subphenotype 3 (i.e. class 3) from hereon in the manuscript.

Survival varied by subphenotype ($p = 0.001$). In particular, survival was lower in subphenotype 3 (23/55, 41.8%) than in the other subphenotypes [subphenotype 1, 132/189 (69.8%); subphenotype 2, 155/246 (63.0%)]. Similar results were seen for survival to 28 days (see *Table 14*). The mean daily SOFA score also increased with subphenotype, with score almost twice as high in subphenotype 3 than it was in subphenotype 1.

There was no evidence that treatment effects varied by subphenotype for any of the outcomes of the LeoPARDS trial.¹⁶ Survival was lower in the levosimendan group for all classes (although the difference was not statistically significant in any subphenotype), with no apparent trend across the subphenotypes (see *Figure 31*). Mean daily SOFA score was higher in the levosimendan group than in the placebo group in subphenotype 1 (RD 0.84, 95% CI 0.02 to 1.65) and in subphenotype 2 (RD 0.88, 95% CI -0.08 to 1.83) (see *Figure 32*). There was no evidence of treatment difference in subphenotype 3 (RD -0.14, 95% CI -2.55 to 2.28). However, the differences in treatment effect comparing classes were not statistically significant.




FIGURE 34 Box plot showing distribution of indicators by class for candidate models, assigning to modal class, in the LeoPARDS trial.¹⁶ The box shows the 25th, 50th and 75th percentiles, the whiskers show the extent of data within $1.5 \times$ IQR and the dots show data points beyond these limits. P/F, PaO_2/FiO_2 .

A multinomial logit model with IL-6, IL-8, IL-10 and CCL2 as predictors gave a sensitivity of around 0.9 and a specificity of ≥ 0.9 for all subphenotypes (Figure 35). In particular, for subphenotype 3, which is perhaps of most interest for the purposes of identifying a trial population, the specificity was 0.98. The model coefficients are shown in Table 16. The sensitivity analysis gave very similar results, with 94% agreement in subphenotype assignment for the LeoPARDS trial¹⁶ (see Table 24).

Latent class analysis: the HARP-2 trial

Parts of this section, which presents data on ARDS subphenotypes from the HARP-2 trial,¹⁷ includes information based on our previous publication by Calfee and colleagues.³¹

Population characteristics

Baseline population characteristics of patients enrolled in the HARP-2 trial,¹⁷ including biomarker levels, are fully described in the original publication¹⁷ (see also Table 31). Pneumonia was the most common risk factor for ARDS (55%). The mean tidal volume was 8.1 ml per kilogram predicted body weight. Overall, median number of ventilator-free days was 13 days and 28-day mortality was 24.5%.

Two-class model optimally fits the HARP-2 trial population

For performing LCA using the HARP-2 trial¹⁷ data, we used fewer clinical and biomarker variables (14 vs. up to 37 variables in previous reports). Class-defining variables used in LCA are reported in Table 32. The two-class model was a better fit for the population than a one-class model (Vuong-Lo-Mendell-Rubin likelihood ratio test $p < 0.0001$). Additional classes did not improve model fit (Table 17), and class 3 in the three-class model had only 40 patients. The BIC decreased as the number of classes in the model increased, indicating improved model fit with additional classes. Entropy in all models was ≥ 0.75 , indicating adequate class separation. Consistent with previous reports,^{23,42} more patients were assigned to subphenotype 1 [class 1, $n = 354$ (65%)] than to subphenotype 2 [class 2, $n = 186$ (35%)]. Average latent class probabilities were 0.93 for class 1 and 0.92 for class 2.




FIGURE 35 Class-specific (a) sensitivity, (b) specificity and (c) c-statistics for multinomial logit models with increasing number of predictors in the LeoPARDS trial.¹⁶ (continued)




FIGURE 35 Class-specific (a) sensitivity, (b) specificity and (c) c-statistics for multinomial logit models with increasing number of predictors in the LeoPARDS trial.¹⁶

TABLE 16 Model coefficients from the multinomial regression model in the LeoPARDS trial¹⁶

Predictor	Class 2 vs. class 1		Class 3 vs. class 1	
	Log-OR for a 1 SD increase	SE	Log-OR for a 1 SD increase	SE
IL-6	1.404	0.356	3.803	0.771
IL-8	2.477	0.472	4.09	0.735
IL-10	1.942	0.346	2.514	0.639
CCL2	1.314	0.328	3.976	0.853
Baseline odds	2.236	0.301	-8.264	1.952

TABLE 17 Fit statistics for LCA model in the HARP-2 trial¹⁷

Number of classes	BIC	Entropy	Number of classes				p-value
			1	2	3	4	
1	16,532		540				
2	16,188	0.75	354	186			< 0.0001
3	16,147	0.82	339	161	40		0.08
4	16,104	0.82	262	128	109	41	0.07

Comparison with prior acute respiratory distress syndrome subphenotypes

In our prior studies of ARDS subphenotypes,²³ a three-variable model [comprising IL-6, sTNFR1 and vasopressor use (yes/no)] accurately classified patients into subphenotype 1 or 2. We used this model to classify the HARP-2 trial¹⁷ patients and found that the AUROC curve for classification was 0.97, compared with classification by latent class models. These findings suggest that the ARDS subphenotypes identified in this analysis are similar to those in our prior studies.

Comparison of phenotypic features and outcomes between subphenotypes

Subphenotype 2 had clinical and biological features similar to those found in our prior studies and consistent with a hyperinflammatory phenotype. Specifically, when compared with subphenotype 1, patients in subphenotype 2 had higher values of sTNFR1 and IL-6, lower platelet counts (*Figure 36*) and more vasopressor use ($p < 0.001$). Age and sex were similar across the subphenotypes. Although the distribution of direct and indirect ARDS risk factors was significantly different across the two subphenotypes ($p < 0.0001$), the most common ARDS risk factors of sepsis, pneumonia and aspiration were highly prevalent among both groups, as in our prior work.²³ In addition, subphenotype 2 patients had fewer ventilator-free days (median of 2 vs. 18 days; $p < 0.0001$), fewer non-pulmonary organ failure-free days (median of 15 vs. 27 days; $p < 0.0001$) and higher 28-day mortality (39% vs. 17%; $p < 0.0001$) than subphenotype 1 patients (*Table 18*).

Survival benefit observed with simvastatin in subphenotype 2

The original trial found no difference in 28-day survival curves between placebo and simvastatin ($p = 0.20$). The subphenotype 2 had a better 28-day survival ($p < 0.0001$) (*Figure 37*) and better 90-day survival ($p < 0.0001$) (*Figure 38*) for overall comparison ($p = 0.03$ for subphenotype 2 simvastatin vs. placebo and $p = 0.21$ with Bonferroni correction).

RESULTS




FIGURE 36 Differences in standardised values of each continuous variable by subphenotype in the HARP-2 trial.¹⁷ Standardised means by class. Variables with maximum positive separation are shown on the left (i.e. hyperinflammatory subphenotype higher than hypoinflammatory subphenotype) and variables with maximum negative separation on the right (i.e. hyperinflammatory subphenotype lower than hypoinflammatory subphenotype). The y-axis represents standardised variable values. A value of +1 for the standardised variable signifies that the mean value for a given subphenotype was 1 SD higher than the mean value in the cohort as a whole. The mean values are joined by lines to facilitate display of subphenotype profiles. P/F, PaO_2/FiO_2 .

TABLE 18 Clinical outcomes by subphenotype in the HARP-2 trial¹⁷

Outcome	Class		p-value
	1 (n = 354)	2 (n = 186)	
28-day mortality, n (%)	59 (17)	73 (3)	< 0.0001
90-day mortality, n (%)	78 (22)	87 (46)	< 0.0001
Ventilator-free days, median (25–75%)	2 (0–17)	18 (0–23)	< 0.0001
Non-pulmonary organ failure-free days, median (25–75%)	27 (21–28)	15 (0–25)	< 0.0001

In contrast to the curves stratified by subphenotype and treatment, survival curves stratified by ARDS severity (i.e. PaO_2/FiO_2 ratio) and treatment were not significantly different ($p = 0.12$). Survival curves stratified by APACHE II score (dichotomised at the median) and treatment revealed differences in survival by APACHE II score, but no differential effect of treatment in either the high- or low-APACHE II group (see *Figure 38*).

Mortality at 28 days was 13% lower in subphenotype 2 patients treated with simvastatin than in subphenotype 2 patients treated with placebo (32% vs. 45%). In contrast, 28-day mortality was similar in patients in subphenotype 1 regardless of treatment assignment (16% vs. 17%). The interaction between treatment and subphenotype for mortality was not statistically significant ($p = 0.14$).

In the original trial, time to unassisted breathing did not differ significantly between simvastatin- and placebo-treated patients, although a trend favouring simvastatin was observed (hazard ratio 0.84; $p = 0.09$). When stratified by subphenotype and treatment, time to unassisted breathing differed significantly ($p < 0.0001$) (*Figure 39*). However, the difference in the curves between subphenotype 2 patients treated with simvastatin and placebo was not statistically significant ($p = 0.10$). Among subphenotype 2 patients, median ventilator-free days were numerically higher in the simvastatin-treated patients than in placebo-treated patients (7 days vs. 0 days). This is in contrast to patients in subphenotype 1, among whom the median number of ventilator-free days was the same regardless of treatment (18 days in each). However, the interaction between treatment and subphenotype in regression models was not statistically significant ($p = 0.15$).




FIGURE 37 Kaplan–Meier survival curves. (a) 28-day patient survival; and (b) 90-day patient survival in HARP-2 trial,¹⁷ stratified by subphenotype and treatment (simvastatin vs. placebo). (continued)




FIGURE 37 Kaplan-Meier survival curves. (a) 28-day patient survival; and (b) 90-day patient survival in HARP-2 trial,¹⁷ stratified by subphenotype and treatment (simvastatin vs. placebo).




FIGURE 38 Survival curves stratified by mean APACHE II score. Product-limit survival estimates. (a) 28-day survival; and (b) 90-day patient survival in the HARP-2 trial,¹⁷ stratified by ARDS subphenotype and treatment (simvastatin vs. placebo).




FIGURE 39 Time to unassisted breathing over 28 days in the HARP-2 trial.¹⁷ Data are stratified by subphenotype and treatment condition, from Fine-Gray competing risks model.⁵⁹ HR, hazard ratio.

Chapter 4 Discussion

Heterogeneity of treatment effect

Main findings

We assessed whether or not HTE could contribute to the results in three recent ICU RCTs, using four different multivariable baseline risk of death models, which included well-established risk factors for acute mortality for sepsis and ARDS as covariates. There was considerable within-trial variation in the baseline risk of death in all three RCTs. We did not find consistent evidence for HTE as an explanation for the original trial results in all three ICU RCTs we assessed, as tests for HTE were inconclusive. We observed that detection of HTE in RCTs may be influenced by the baseline risk model specification, as illustrated by differences in HTE effects seen in the LeoPARDS trial.¹⁶ The lack of evidence of relative HTE may be in part due to low power to detect interaction effects, particularly for the HARP-2 trial,¹⁷ in which mortality was lower among those allocated to simvastatin in all risk quartiles except the highest. Parts of this section, which presents data on ARDS subphenotypes from the HARP-2 trial,¹⁷ includes information based on our previous publication by Calfee and colleagues.³¹

Explanation of key findings

There are a number of possible reasons why we did not observe HTE consistently in our analyses. All three trials we assessed have many features of explanatory trials,⁶⁰ which by their design limit HTE in comparison with pragmatic trials. Therefore, demonstrable HTE is less likely in these trials, although its evaluation remains important. Our findings may be true in that HTE may be less marked in sepsis and ARDS, in which many 'minimal causes' of mortality may be contributory,⁶¹ than in illnesses such as retroviral disease.⁶² It could be that the effects of the treatments we assessed are small and of limited variability, resulting in minimal HTE. In other words, when HTE is assessed for an intervention using data from a single trial we are unlikely to detect it unless HTE effects are large. This generates an argument to assess HTE using trials of the similar treatment-condition combination or of the same condition, and a broader group of treatments with similar enough mechanism of treatment effect or to consider intervention-specific multivariable models.

Comparison with published literature

A key comparison to consider is the contrasting results with RCT simulations by Iwashyna and colleagues.²⁴ Their simulations assumed that the trial participants' odds of 30-day mortality will be influenced by severity of acute respiratory failure, comorbid conditions, the extent to which the treatment reduces mortality from the primary illness and the treatment's fatal adverse effect rates. Although we used 28-day mortality for our primary analysis, we considered baseline risk as a function of acute illness severity using the total APACHE II score. The data in our trials do not follow the patterns described by Iwashyna and colleagues,²⁴ as we did not have constant relative treatment effects or constant harms, and mortality patterns differed from those predicted by their simulation model. Recently, Semler and colleagues⁶³ reported a pragmatic, cluster-randomised, multiple-crossover trial of saline compared with balance crystalloids in critically ill patients, and found no difference in the primary outcome of major adverse kidney events within 30 days, but a positive result in the composite secondary outcomes of death from any cause, new renal replacement therapy and persistent renal dysfunction. The authors then reported presence of HTE for the primary trial outcome, when assessed with a multivariable model specifically calibrated for the primary outcome.⁶⁴ Therefore, it is plausible that the closer a trial is to showing a difference, the greater the chance of finding HTE with multivariable models, which might also explain our findings of a lack of HTE.

Strengths and weakness

We explored HTE in sepsis and ARDS for four different treatments and using four different multivariable models. The primary baseline risk measure, APACHE II score, is an established, validated predictor of mortality in this population. Three variations on this measure were investigated to check the consistency of the results, along with several sensitivity analyses. We used a composite risk score (APACHE II) for its superior performance for baseline risk estimation, as highlighted by Kent and colleagues¹⁸ and as recommended for future studies of HTE assessment.²⁴ Furthermore, lead time bias may influence the impact that APACHE II score might have on the outcome. This may be less relevant here, as all the data sets were from RCTs. None of the RCTs included in this study had 28-day mortality as the primary outcome. Therefore, it is possible that we were underpowered to detect HTE, if it existed. The primary outcomes were not suitable for HTE analysis because they were continuous rather than binary and without an appropriate baseline measure, although the existing HTE framework could be adapted for some continuous outcomes, such as change from baseline organ dysfunction. Similarly, there may have been insufficient numbers to demonstrate non-linear risk and HTE effects that we investigated as sensitivity analyses.

Latent class analysis

Main findings in the VANISH trial and the LeoPARDS trial

The VANISH trial¹⁵ two-class (subphenotype) model best represented the data and generated two sepsis subphenotypes with a split of 90 (subphenotype 1) and 86 (subphenotype 2) individuals. The subphenotype 2 individuals had greater inflammation, with higher concentrations of IL-1 β , IL-6, IL-8, IL-10, MPO, ANG II, troponin, NT-proBNP and sTNFR1. The class 2 individuals also had reduced survival and fewer renal failure-free days. There were no treatment effect differences between the two classes for corticosteroids or vasopressin.

The LeoPARDS trial¹⁶ three-class (subphenotype) model best represented the data and generated three sepsis subphenotypes with a split of 191 individuals to class 1, 247 individuals to class 2 and 55 individuals to class 3. The subphenotype 3 individuals had greatest inflammation, with higher concentrations of IL-1 β , IL-6, IL-8, IL-10, IL-17, ANG II, troponin, NT-proBNP, CCL2 and sTNFR1. The subphenotype 3 individuals also had the highest SOFA score and reduced survival at 90 days. There were no treatment effect differences between classes for levosimendan, albeit survival was lower in the levosimendan group for all classes. A multinomial logit model with IL-6, IL-8, IL-10 and CCL2 as predictors gave a sensitivity of around 0.9 and a specificity of ≥ 0.9 for all classes. The differences in number of classes between the two trials may be related to differences in eligibility criteria, differences in sample sizes and the timing of measurements.

Comparison with published literature

Sepsis phenotypes can be categorised into clinical phenotypes that are identified using clinical and commonly acquired laboratory data (such as leucocyte count and C-reactive protein) and into molecular phenotypes that are identified using leucocyte gene expression data. This approach to classify phenotypes into clinical phenotype and molecular phenotypes has been reported in asthma.^{65,66} Studies to date have identified four^{37,38} to six³⁹ sepsis clinical phenotypes and two^{21,67} to four²⁰ sepsis molecular phenotypes.

Using clinical data from the PROWESS Shock RCT,⁶⁸ Gårdlund and colleagues³⁹ reported six different sepsis clinical phenotypes using LCA, which were (1) uncomplicated septic shock, (2) pneumonia with ARDS, (3) postoperative abdominal shock, (4) severe septic shock, (5) pneumonia with ARDS and multiple organ dysfunction syndrome and (6) late septic shock. They did not report any biomarker data in their LCA to make direct comparisons with our study. Knox and colleagues³⁸ reported four phenotypes using self-organising maps and grouped them into (1) shock with elevated creatinine; (2) minimal multiorgan dysfunction syndrome; (3) shock with hypoxaemia and altered mental status;

and (4) hepatic disease. Seymour and colleagues³⁷ reported four similar sepsis clinical phenotypes using observational cohort data and referred to them as (1) alpha (i.e. fewest abnormal laboratory test results, least organ dysfunction and lowest mortality), (2) beta (i.e. older patients, high prevalence of chronic illnesses and kidney dysfunction), (3) gamma (greater inflammation and pulmonary dysfunction) and (4) delta (i.e. with liver dysfunction and septic shock). In addition, Seymour and colleagues³⁷ correlated the phenotype data with biomarkers, validated these findings within RCT data and simulated for treatment effect heterogeneity. They neither did a direct interaction test with treatment effect nor used the biomarkers we used in their LCA models. Based on pan-leucocyte gene expression data, Davenport and colleagues²¹ present two sepsis molecular phenotypes named sepsis response signatures [i.e. sepsis response signature 1 (SRS1) and sepsis response signature 2 (SRS2)], with the SRS1 phenotype being more immunosuppressed and having greater mortality than SRS2. A two-subset model based on neutrophils gene expression was reported by Maslove and colleagues,⁶⁷ with subset 1 showing evidence of greater inflammation and toll-like receptor signalling. Based on pan-leucocyte gene expression data, Scicluna and colleagues²⁰ reported four sepsis molecular phenotypes and subphenotypes assessment, albeit they do not strictly meet the endotype definition. We cannot provide a direct comparison with these results as we do not use transcriptome data in our LCA. Recently, Antcliffe and colleagues⁶⁹ tested whether or not SRS1 and SRS2 sepsis molecular phenotypes respond differently to corticosteroids, using the VANISH trial¹⁵ data. The authors show that the relatively more immunocompetent phenotype (i.e. SRS2) may be harmed from corticosteroid therapy. In contrast, we did not observe any treatment effect differences between the two sepsis subphenotypes identified when using cytokines and clinical data in the VANISH trial.¹⁵

Strengths and weakness

This study has several strengths. First, the LCA plan was defined prior to knowing the results of biomarker measurements. Second, we used data from two high-quality sepsis trials.^{15,16} Last, the subphenotypes assessment followed a systematic plan and the model that best explained the heterogeneity within the trial cohorts was used.

The limitations are that this is a post hoc analysis, albeit with an explicit peer-reviewed hypothesis and an analysis plan that was set up prior to measurement of any biomarker data. We report two subphenotypes from the VANISH trial¹⁵ and three from the LeoPARDS trial,¹⁶ which is partly driven by the sample size. Not all patients in both trials had biomarker data. Some of the biomarker measurements were outside the measurement range. In addition, because of the nature of latent class models, there is uncertainty as to the similarities between two subphenotypes identified in the VANISH trial¹⁵ and the three subphenotypes identified in the LeoPARDS trial,¹⁶ although the key biomarkers appear similar between subphenotype 2 in the VANISH trial¹⁵ and subphenotype 3 in the LeoPARDS trial.¹⁶

Main findings in the HARP-2 trial

The HARP-2 trial¹⁷ analysis shows two novel findings. First, two distinct ARDS subphenotypes with features similar to those previously reported were identified for the first time in a non-US patient population. Importantly, this was achieved using a different and much smaller set of clinical and biomarker data than in previous studies. Second, and more importantly, these two subphenotypes of ARDS responded differently to randomly assigned simvastatin, with evidence of improved survival at both 28 and 90 days uniquely among patients with a 'hyperinflammatory' subphenotype of ARDS. The finding that patients with a hyperinflammatory ARDS subphenotype preferentially responded to randomly assigned simvastatin treatment has biological plausibility based on the presumed mechanism of action of statins in ARDS. Statins reduce lung inflammation and injury in both animal models of ARDS and pre-clinical human experimental studies,⁷⁰ and also have endothelium-stabilising properties. Therefore, patients with a higher degree of systemic inflammation, such as those in the hyperinflammatory subphenotype, would seem to be most likely to respond to this therapy.

Comparison with published acute respiratory distress syndrome literature

To date, there have been five RCT cohort reanalyses, including HARP-2 trial analysis^{23,31,40-42} and one observational cohort study.²² All RCT reanalyses were conducted using LCA.³⁶ All RCTs show two

phenotypes: (1) a non-inflammatory subphenotype that accounts for two-thirds of the trial population and (2) a less prevalent hyperinflammatory subphenotype that accounts for the remaining one-third of the population. The hyperinflammatory phenotype is associated with higher concentrations of inflammatory biomarkers (i.e. IL-6, IL-8 and sTNFR1), more acidosis and greater prevalence of shock, as suggested by vasopressor requirements.³⁶ Mortality is significantly higher among patients with the hyperinflammatory subphenotype than among those with the non-inflammatory phenotype. The observational cohort study also highlights a two-subphenotype model (i.e. equal prevalence of reactive and uninflamed populations).³⁶ When leucocyte gene expression was compared between the reactive and uninflamed subphenotypes in a cohort of 210 patients with sepsis and ARDS, 128 patients had a reactive phenotype and 82 patients had an uninflamed phenotype, with significant differences in 3332 of the 11,443 (29%) transcripts between the phenotypes. These findings highlight the need for a prospective study to validate the two ARDS subphenotypes using key discriminant markers.⁷¹ These findings indicate that these subphenotypes are consistent across geographical sites and are robust to variations in specific data collected, enhancing the generalisability of previous studies.

Strengths and weakness

The HARP-2 trial¹⁷ analysis is a post hoc analysis with attendant limitations, including lack of statistical power, as implied by the statistical test for interaction in the analyses of 28-day mortality ($p = 0.14$).⁷² We acknowledge that this analysis was not planned as part of the original trial design because the trial was designed before the descriptions of ARDS subphenotypes.⁷³ In addition, because of the nature of latent class models, it is not possible to prove that the two subphenotypes identified in the HARP-2 trial¹⁷ are 'the same' as the two subphenotypes identified in previous studies.^{15,16} However, because latent classes were identified using an unbiased, data-driven approach, the results are comparable to those of previous reports that use data from a RCT, allowing potential causal inferences regarding treatment effects and potential similarities to previously reported subphenotypes.³¹

Chapter 5 Implications of future research

Heterogeneity of treatment effect analysis

Aside from the ARDS or sepsis illness characteristics, it is likely that biological mechanisms determining differences in treatment effect will vary with the intervention tested. Therefore, studies considering prognostic enrichment (restricting to patients with higher risk of outcome) could consider supplementing a generic physiology-based multivariable model, such as APACHE II, with either illness-specific risk and/or intervention-specific approaches. For example, an ARDS subpopulation with greater inflammation and higher mortality is more likely to benefit from simvastatin^{31,74} and, aside from severity of septic shock, the treatment effect of vasopressin was associated with biological differences within the trial population.^{26,75} The Berlin ARDS definition⁹ and the Sepsis-3 definition¹ provide readily usable illness-specific enrichment criteria, contained within their predictive validity analyses.^{2,76} Therefore, identifying biomarkers that provide both prognostic and predictive enrichment or the use of intervention-specific predictive enrichment coupled with illness-specific prognostic enrichment is likely to be a better approach. For example, biomarkers derived from whole-blood transcriptomics could enrich paediatric septic shock patients for corticosteroid therapy^{77,78} or highlight potential harm adult septic shock subpopulations.⁶⁹ Our analysis also highlights the need for future studies to explore whether or not the intervention will have greater treatment effect with higher or lower baseline risk of outcome and whether or not the intervention effect is best assessed in a relative or absolute scale in the trial design stage. The reason for this is that, in our analysis, in the HARP-2 trial,¹⁷ simvastatin had a greater treatment effect in patients with a lower risk of death whereas, in the LeoPARDS trial,¹⁶ there was suggestion that the greatest benefit is likely to occur in the population with a higher risk of death. As suggested by Iwashyna and colleagues,²⁴ HTE assessment should perhaps form part of a priori analyses plans in future clinical trials. As HTE is about the variation in effectiveness, standardising the baseline risk measure between RCTs, including HTE assessment as a priori analyses, ensuring that the outcome used in HTE analyses is patient centred (such as mortality) and incorporating the proposals within the Core Outcome Measures in Effectiveness Trials guidelines will enable pooling of HTE analysis across future trials.⁷⁹

Latent class analysis

The sepsis subphenotypes from these two trials require prospective validation because consideration of these subphenotypes in enrichment trial designs, based on mechanisms of interventions, requires development of the capability to measure these biomarkers in real time. Moving forward, how might these findings be translated to future clinical trials in ARDS? Our findings suggest that identification of ARDS subphenotypes may be fundamentally important in future ARDS clinical trials and, more broadly, that targeting distinct subphenotypes of critical illness syndromes may finally yield progress after decades of negative pharmacotherapy trials in ICUs. As mentioned in *Heterogeneity of treatment effect analysis*, the hyperinflammatory ARDS subphenotype can be accurately identified using three variables.^{23,36,42} The development of the capability to measure these inflammatory markers in real time will be critical to conducting precision clinical trials in this setting.

Chapter 6 Conclusions

We assessed HTE in three recent ICU RCTs, using multivariable baseline risk of death models. Despite considerable within-trial variation in the baseline risk of death, we did not find consistent evidence that HTE explained the negative results seen with vasopressin, hydrocortisone and levosimendan in the two sepsis trials^{15,16} and simvastatin in the ARDS trial.¹⁷

Secondary LCA of the ARDS trial¹⁷ identified two subphenotypes. In the case of the two sepsis trials,^{15,16} two subphenotypes of sepsis were identified in the VANISH trial¹⁵ and three subphenotypes of sepsis were identified in the LeoPARDS trial.¹⁶ In both sepsis trials^{15,16} and in the ARDS trial¹⁷ the hyperinflammatory subphenotype was associated with higher mortality.

Grant applications to carry forward the hypothesis generated by this work

Findings from this work have led to the PHenotypes IN the Acute Respiratory Distress Syndrome (PHIND) study. This Innovate UK-funded multicentre, prospective, observational study aims to prospectively define hyper- and hypoinflammatory phenotypes in patients with ARDS and determine clinical outcomes associated with each phenotype.

Acknowledgements

Anthony Gordon is funded by a NIHR Research Professorship award (RP-2015-06-018) and by the NIHR Imperial Biomedical Research Centre. Manu Shankar-Hari is funded by a NIHR Clinician Scientist Award (CS-2016-16-011).

Contributions of authors

Manu Shankar-Hari (<https://orcid.org/0000-0002-5338-2538>) conceived and obtained funding for the study; developed the statistical analysis plan; performed the statistical analysis for the HTE analysis and LCA of the LeoPARDS trial¹⁶ and the VANISH trial;¹⁵ contributed to the interpretation of data, critical revision of the manuscript and approved the final manuscript; read the final draft of the manuscript and confirmed the accuracy/integrity of the work.

Shalini Santhakumaran (<https://orcid.org/0000-0003-0988-9339>) developed the statistical analysis plan; performed the statistical analysis for the HTE analysis and LCA of the LeoPARDS trial¹⁶ and the VANISH trial;¹⁵ contributed to the interpretation of data, critical revision of the manuscript and approved the final manuscript; read the final draft of the manuscript and confirmed the accuracy/integrity of the work.

A Toby Prevost (<https://orcid.org/0000-0003-1723-0796>) conceived and obtained funding for the study; developed the statistical analysis plan; performed the statistical analysis for the HTE analysis and LCA of the LeoPARDS trial¹⁶ and the VANISH trial;¹⁵ contributed to the interpretation of data, critical revision of the manuscript and approved the final manuscript; read the final draft of the manuscript and confirmed the accuracy/integrity of the work.

Josie K Ward (<https://orcid.org/0000-0003-3680-3043>) measured the biomarkers for the study; read the final draft of the manuscript and confirmed the accuracy/integrity of the work.

Timothy Marshall (<https://orcid.org/0000-0001-7214-7130>) measured the biomarkers for the study; read the final draft of the manuscript and confirmed the accuracy/integrity of the work.

Claire Bradley (<https://orcid.org/0000-0001-9184-103X>) measured the biomarkers for the study; read the final draft of the manuscript and confirmed the accuracy/integrity of the work.

Carolyn S Calfee (<https://orcid.org/0000-0001-9208-6865>) contributed to the LCA and reporting of the HARP-2 trial¹⁷ data; read the final draft of the manuscript and confirmed the accuracy/integrity of the work.

Kevin L Delucchi (<https://orcid.org/0000-0003-2195-9627>) contributed to the LCA and reporting of the HARP-2 trial¹⁷ data; read the final draft of the manuscript and confirmed the accuracy/integrity of the work.

Pratik Sinha (<https://orcid.org/0000-0003-3751-9079>) contributed to the LCA and reporting of the HARP-2 trial¹⁷ data; read the final draft of the manuscript and confirmed the accuracy/integrity of the work.

Michael A Matthay (<https://orcid.org/0000-0003-3039-8155>) contributed to the LCA and reporting of the HARP-2 trial¹⁷ data; read the final draft of the manuscript and confirmed the accuracy/integrity of the work.

ACKNOWLEDGEMENTS

Jonathan Hackett (<https://orcid.org/0000-0003-4965-2045>) contributed to the LCA and reporting of the HARP-2 trial¹⁷ data; read the final draft of the manuscript and confirmed the accuracy/integrity of the work.

Cliona McDowell (<https://orcid.org/0000-0002-7644-7197>) contributed to the LCA and reporting of the HARP-2 trial¹⁷ data; read the final draft of the manuscript and confirmed the accuracy/integrity of the work.

John G Laffey (<https://orcid.org/0000-0002-1246-9573>) contributed to the LCA and reporting of the HARP-2 trial¹⁷ data; read the final draft of the manuscript and confirmed the accuracy/integrity of the work.

Anthony Gordon (<https://orcid.org/0000-0002-0419-547X>) conceived and obtained funding for the study; contributed to the interpretation of data, critical revision of the manuscript and approved the final manuscript; read the final draft of the manuscript and confirmed the accuracy/integrity of the work.

Cecilia M O’Kane (<https://orcid.org/0000-0002-7138-5396>) conceived and obtained funding for the study; contributed to the interpretation of data, critical revision of the manuscript and approved the final manuscript; read the final draft of the manuscript and confirmed the accuracy/integrity of the work.

Daniel F McAuley (<https://orcid.org/0000-0002-3283-1947>) conceived and obtained funding for the study; contributed to the interpretation of data, critical revision of the manuscript and approved the final manuscript; read the final draft of the manuscript and confirmed the accuracy/integrity of the work.

Publications

Original manuscripts

Calfee CS, Delucchi KL, Sinha P, Matthay MA, Hackett J, Shankar-Hari M, *et al.* Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. *Lancet Respir Med* 2018;**6**:691–8.

Santhakumaran S, Gordon A, Prevost AT, O’Kane C, McAuley DF, Shankar-Hari M. Heterogeneity of treatment effect by baseline risk of mortality in critically ill patients: re-analysis of three recent sepsis and ARDS randomised controlled trials. *Crit Care* 2019;**23**:156.

Reviews and editorials

Shankar-Hari M, McAuley DF. Acute respiratory distress syndrome phenotypes and identifying treatable traits. The dawn of personalized medicine for ARDS. *Am J Respir Crit Care Med* 2017;**195**:280–1.

Shankar-Hari M, McAuley DF. Divide and conquer: identifying acute respiratory distress syndrome subphenotypes. *Thorax* 2017;**72**:867–9.

Shankar-Hari M, Fan E, Ferguson ND. Acute respiratory distress syndrome (ARDS) phenotyping. *Intensive Care Med* 2019;**45**:516–19.

Poster presentation

Ferris P, Boyle A, Conlon J, Gordon AC, Shankar-Hari M, O’Kane C, McAuley D. *Baseline NT-proBNP Predicts outcOme and Treatment Response to Statin Therapy in Patients with ARDS.* American Thoracic Society 2019 International Conference, Dallas, TX, USA, 17–22 May 2019.

Data-sharing statement

All data requests should be submitted to the corresponding author for consideration. Access to available anonymised data may be granted following review.

Patient data

This work uses data provided by patients and collected by the NHS as part of their care and support. Using patient data is vital to improve health and care for everyone. There is huge potential to make better use of information from people's patient records, to understand more about disease, develop new treatments, monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone's privacy, and it's important that there are safeguards to make sure that it is stored and used responsibly. Everyone should be able to find out about how patient data are used. #datasaveslives You can find out more about the background to this citation here: <https://understandingpatientdata.org.uk/data-citation>.

References

1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, *et al.* The third international consensus definitions for sepsis and septic shock (Sepsis-3). *JAMA* 2016;**315**:801–10. <https://doi.org/10.1001/jama.2016.0287>
2. Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, *et al.* Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (Sepsis-3). *JAMA* 2016;**315**:775–87. <https://doi.org/10.1001/jama.2016.0289>
3. Shankar-Hari M, Harrison DA, Rubenfeld GD, Rowan K. Epidemiology of sepsis and septic shock in critical care units: comparison between sepsis-2 and sepsis-3 populations using a national critical care database. *Br J Anaesth* 2017;**119**:626–36. <https://doi.org/10.1093/bja/aex234>
4. Fleischmann C, Scherag A, Adhikari NK, Hartog CS, Tsaganos T, Schlattmann P, *et al.* Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. *Am J Respir Crit Care Med* 2016;**193**:259–72. <https://doi.org/10.1164/rccm.201504-0781OC>
5. Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012. *JAMA* 2014;**311**:1308–16. <https://doi.org/10.1001/jama.2014.2637>
6. Marshall JC. Why have clinical trials in sepsis failed? *Trends Mol Med* 2014;**20**:195–203. <https://doi.org/10.1016/j.molmed.2014.01.007>
7. Shankar-Hari M, Harrison DA, Rowan KM. Differences in impact of definitional elements on mortality precludes international comparisons of sepsis epidemiology – a cohort study illustrating the need for standardized reporting. *Crit Care Med* 2016;**44**:2223–30. <https://doi.org/10.1097/CCM.0000000000001876>
8. Prescott HC, Calfee CS, Thompson BT, Angus DC, Liu VX. Toward smarter lumping and smarter splitting: rethinking strategies for sepsis and acute respiratory distress syndrome clinical trial design. *Am J Respir Crit Care Med* 2016;**194**:147–55. <https://doi.org/10.1164/rccm.201512-2544CP>
9. Force ADT, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, *et al.* Acute respiratory distress syndrome: the Berlin definition. *JAMA* 2012;**307**:2526–33. <https://doi.org/10.1001/jama.2012.5669>
10. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, *et al.* Incidence and outcomes of acute lung injury. *N Engl J Med* 2005;**353**:1685–93. <https://doi.org/10.1056/NEJMoa050333>
11. Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, *et al.* Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. *JAMA* 2016;**315**:788–800. <https://doi.org/10.1001/jama.2016.0291>
12. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, *et al.* The American–European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. *Am J Respir Crit Care Med* 1994;**149**:818–24. <https://doi.org/10.1164/ajrccm.149.3.7509706>
13. Shankar-Hari M, Rubenfeld GD. The use of enrichment to reduce statistically indeterminate or negative trials in critical care. *Anaesthesia* 2017;**72**:560–5. <https://doi.org/10.1111/anae.13870>

14. Shankar-Hari M, Summers C, Baillie K. In Pursuit of Precision Medicine in the Critically Ill. In Vincent J-L, editor. *Annual Update in Intensive Care and Emergency Medicine*. New York, NY: Springer; 2018. pp. 649–58. https://doi.org/10.1007/978-3-319-73670-9_48
15. Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, *et al*. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. *JAMA* 2016;**316**:509–18. <https://doi.org/10.1001/jama.2016.10485>
16. Gordon AC, Perkins GD, Singer M, McAuley DF, Orme RM, Santhakumaran S, *et al*. Levosimendan for the prevention of acute organ dysfunction in sepsis. *N Engl J Med* 2016;**375**:1638–48. <https://doi.org/10.1056/NEJMoa1609409>
17. McAuley DF, Laffey JG, O’Kane CM, Perkins GD, Mullan B, Trinder TJ, *et al*. Simvastatin in the acute respiratory distress syndrome. *N Engl J Med* 2014;**371**:1695–703. <https://doi.org/10.1056/NEJMoa1403285>
18. Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. *Trials* 2010;**11**:85. <https://doi.org/10.1186/1745-6215-11-85>
19. Senn S. Mastering variation: variance components and personalised medicine. *Stat Med* 2016;**35**:966–77. <https://doi.org/10.1002/sim.6739>
20. Scicluna BP, van Vught LA, Zwinderman AH, Wiewel MA, Davenport EE, Burnham KL, *et al*. Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study. *Lancet Respir Med* 2017;**5**:816–26. [https://doi.org/10.1016/S2213-2600\(17\)30294-1](https://doi.org/10.1016/S2213-2600(17)30294-1)
21. Davenport EE, Burnham KL, Radhakrishnan J, Humburg P, Hutton P, Mills TC, *et al*. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. *Lancet Respir Med* 2016;**4**:259–71. [https://doi.org/10.1016/S2213-2600\(16\)00046-1](https://doi.org/10.1016/S2213-2600(16)00046-1)
22. Bos LD, Schouten LR, van Vught LA, Wiewel MA, Ong DSY, Cremer O, *et al*. Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis. *Thorax* 2017;**72**:876–83. <https://doi.org/10.1136/thoraxjnl-2016-209719>
23. Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA, NHLBI ARDS Network. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. *Lancet Respir Med* 2014;**2**:611–20. [https://doi.org/10.1016/S2213-2600\(14\)70097-9](https://doi.org/10.1016/S2213-2600(14)70097-9)
24. Iwashyna TJ, Burke JF, Sussman JB, Prescott HC, Hayward RA, Angus DC. Implications of heterogeneity of treatment effect for reporting and analysis of randomized trials in critical care. *Am J Respir Crit Care Med* 2015;**192**:1045–51. <https://doi.org/10.1164/rccm.201411-2125CP>
25. Shankar-Hari M, Rubenfeld GD. Population enrichment for critical care trials: phenotypes and differential outcomes. *Curr Opin Crit Care* 2019;**25**:489–97. <https://doi.org/10.1097/MCC.0000000000000641>
26. Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, *et al*. Vasopressin versus norepinephrine infusion in patients with septic shock. *N Engl J Med* 2008;**358**:877–87. <https://doi.org/10.1056/NEJMoa067373>
27. Rochwerg B, Oczkowski SJ, Siemieniuk RAC, Agoritsas T, Belley-Cote E, D’Aragon F, *et al*. Corticosteroids in sepsis: an updated systematic review and meta-analysis. *Crit Care Med* 2018;**46**:1411–20. <https://doi.org/10.1097/CCM.0000000000003262>
28. Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, *et al*. Hydrocortisone plus fludrocortisone for adults with septic shock. *N Engl J Med* 2018;**378**:809–18. <https://doi.org/10.1056/NEJMoa1705716>

29. Venkatesh B, Finfer S, Cohen J, Rajbhandari D, Arabi Y, Bellomo R, *et al.* Adjunctive glucocorticoid therapy in patients with septic shock. *N Engl J Med* 2018;**378**:797–808. <https://doi.org/10.1056/NEJMoa1705835>
30. Annane D, Sébille V, Charpentier C, Bollaert PE, François B, Korach JM, *et al.* Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. *JAMA* 2002;**288**:862–71. <https://doi.org/10.1001/jama.288.7.862>
31. Calfee CS, Delucchi KL, Sinha P, Matthay MA, Hackett J, Shankar-Hari M, *et al.* Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. *Lancet Respir Med* 2018;**6**:691–8. [https://doi.org/10.1016/S2213-2600\(18\)30177-2](https://doi.org/10.1016/S2213-2600(18)30177-2)
32. Rothenberg FG, Clay MB, Jamali H, Vandivier-Pletsch RH. Systematic review of β blocker, aspirin, and statin in critically ill patients: importance of severity of illness and cardiac troponin. *J Investig Med* 2017;**65**:747–53. <https://doi.org/10.1136/jim-2016-000374>
33. Knaus WA, Harrell FE, LaBrecque JF, Wagner DP, Pribble JP, Draper EA, *et al.* Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. The rHL-1ra Phase III Sepsis Syndrome Study Group. *Crit Care Med* 1996;**24**:46–56. <https://doi.org/10.1097/00003246-199601000-00010>
34. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. *Crit Care Med* 1985;**13**:818–29. <https://doi.org/10.1097/00003246-198510000-00009>
35. Shankar-Hari M, Harrison DA, Rowan KM, Rubenfeld GD. Estimating attributable fraction of mortality from sepsis to inform clinical trials. *J Crit Care* 2018;**45**:33–9. <https://doi.org/10.1016/j.jcrc.2018.01.018>
36. Shankar-Hari M, Fan E, Ferguson ND. Acute respiratory distress syndrome (ARDS) phenotyping. *Intensive Care Med* 2019;**45**:516–19. <https://doi.org/10.1007/s00134-018-5480-6>
37. Seymour CW, Kennedy JN, Wang S, Chang CH, Elliott CF, Xu Z, *et al.* Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. *JAMA* 2019;**321**:2003–17. <https://doi.org/10.1001/jama.2019.5791>
38. Knox DB, Lanspa MJ, Kuttler KG, Brewer SC, Brown SM. Phenotypic clusters within sepsis-associated multiple organ dysfunction syndrome. *Intensive Care Med* 2015;**41**:814–22. <https://doi.org/10.1007/s00134-015-3764-7>
39. Gårdlund B, Dmitrieva NO, Pieper CF, Finfer S, Marshall JC, Taylor Thompson B. Six subphenotypes in septic shock: latent class analysis of the PROWESS Shock study. *J Crit Care* 2018;**47**:70–9. <https://doi.org/10.1016/j.jcrc.2018.06.012>
40. Sinha P, Delucchi KL, Thompson BT, McAuley DF, Matthay MA, Calfee CS, NHLBI ARDS Network. Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study. *Intensive Care Med* 2018;**44**:1859–69. <https://doi.org/10.1007/s00134-018-5378-3>
41. Delucchi K, Famous KR, Ware LB, Parsons PE, Thompson BT, Calfee CS, ARDS Network. Stability of ARDS subphenotypes over time in two randomised controlled trials. *Thorax* 2018;**73**:439–45. <https://doi.org/10.1136/thoraxjnl-2017-211090>
42. Famous KR, Delucchi K, Ware LB, Kangelaris KN, Liu KD, Thompson BT, Calfee CS, ARDS Network. Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. *Am J Respir Crit Care Med* 2017;**195**:331–8. <https://doi.org/10.1164/rccm.201603-0645OC>

REFERENCES

43. Thompson BT, Chambers RC, Liu KD. Acute respiratory distress syndrome. *N Engl J Med* 2017;**377**:562–72. <https://doi.org/10.1056/NEJMra1608077>
44. Santhakumaran S, Gordon A, Prevost AT, O’Kane C, McAuley DF, Shankar-Hari M. Heterogeneity of treatment effect by baseline risk of mortality in critically ill patients: re-analysis of three recent sepsis and ARDS randomised controlled trials. *Crit Care* 2019;**23**:156. <https://doi.org/10.1186/s13054-019-2446-1>
45. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, *et al.* Assessing the performance of prediction models: a framework for traditional and novel measures. *Epidemiology* 2010;**21**:128–38. <https://doi.org/10.1097/EDE.0b013e3181c30fb2>
46. Harrell F. *Regression Modeling Strategies*. New York, NY: Springer; 2001. <https://doi.org/10.1007/978-1-4757-3462-1>
47. Burke JF, Hayward RA, Nelson JP, Kent DM. Using internally developed risk models to assess heterogeneity in treatment effects in clinical trials. *Circ Cardiovasc Qual Outcomes* 2014;**7**:163–9. <https://doi.org/10.1161/CIRCOUTCOMES.113.000497>
48. Ioannidis JP, Lau J. Heterogeneity of the baseline risk within patient populations of clinical trials: a proposed evaluation algorithm. *Am J Epidemiol* 1998;**148**:1117–26. <https://doi.org/10.1093/oxfordjournals.aje.a009590>
49. Rubin D. *Multiple Imputation for Nonresponse in Surveys*. London: Wiley; 1987. <https://doi.org/10.1002/9780470316696>
50. Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. *JAMA* 2001;**286**:1754–8. <https://doi.org/10.1001/jama.286.14.1754>
51. Vermunt JK, Magidson J. Latent Class Cluster Analysis. In Hagenaars JA, McCutcheon AL, editors. *Applied Latent Class Analysis*. Cambridge: Cambridge University Press; 2002. pp. 89–106. <https://doi.org/10.1017/CBO9780511499531.004>
52. Masyn KE. Latent Class Analysis and Finite Mixture Modeling. In Little TD, editor. *The Oxford Handbook of Quantitative Methods in Psychology*. Oxford: Oxford University Press; 2013. p. 551. <https://doi.org/10.1093/oxfordhb/9780199934898.013.0025>
53. Taori G, Ho KM, George C, Bellomo R, Webb SA, Hart GK, Bailey MJ. Landmark survival as an end-point for trials in critically ill patients – comparison of alternative durations of follow-up: an exploratory analysis. *Crit Care* 2009;**13**:R128. <https://doi.org/10.1186/cc7988>
54. Cheung YB. A modified least-squares regression approach to the estimation of risk difference. *Am J Epidemiol* 2007;**166**:1337–44. <https://doi.org/10.1093/aje/kwm223>
55. Schwartz G. Estimating the dimension of a model. *Ann Stat* 1978;**6**:461–4. <https://doi.org/10.1214/aos/1176344136>
56. Lo YT, Mendell NR, Rubin DB. Testing the number of components in a normal mixture. *Biometrika* 2001;**88**:767–78. <https://doi.org/10.1093/biomet/88.3.767>
57. Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. *Circulation* 2016;**133**:601–9. <https://doi.org/10.1161/CIRCULATIONAHA.115.017719>
58. Calfee CS, Delucchi KR, Matthay MA, Hackett J, Shankar-Hari M, McDowell C, *et al.* *Consistent ARDS Endotypes Are Identified Using Minimal Data From a United Kingdom Clinical Trial*. American Thoracic Society International Conference, Washington, DC, USA, 2017.
59. Austin PC, Fine JP. Practical recommendations for reporting Fine–Gray model analyses for competing risk data. *Stat Med* 2017;**36**:4391–400. <https://doi.org/10.1002/sim.7501>

60. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. *BMJ* 2015;**350**:h2147. <https://doi.org/10.1136/bmj.h2147>
61. Rothman KJ, Greenland S. Causation and causal inference in epidemiology. *Am J Public Health* 2005;**95**(Suppl. 1):144–50. <https://doi.org/10.2105/AJPH.2004.059204>
62. Ioannidis JP, Cappelleri JC, Schmid CH, Lau J. Impact of epidemic and individual heterogeneity on the population distribution of disease progression rates. An example from patient populations in trials of human immunodeficiency virus infection. *Am J Epidemiol* 1996;**144**:1074–85. <https://doi.org/10.1093/oxfordjournals.aje.a008881>
63. Semler MW, Self WH, Wanderer JP, Ehrenfeld JM, Wang L, Byrne DW, *et al.* Balanced crystalloids versus saline in critically ill adults. *N Engl J Med* 2018;**378**:829–39. <https://doi.org/10.1056/NEJMoa1711584>
64. McKown AC, Huerta LE, Rice TW, Semler MW, Pragmatic Critical Care Research Group. Heterogeneity of treatment effect by baseline risk in a trial of balanced crystalloids versus saline. *Am J Respir Crit Care Med* 2018;**198**:810–13. <https://doi.org/10.1164/rccm.201804-0680LE>
65. Kuo CS, Pavlidis S, Loza M, Baribaud F, Rowe A, Pandis I, *et al.* T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED. *Eur Respir J* 2017;**49**:1602135. <https://doi.org/10.1183/13993003.02135-2016>
66. Lefaudeux D, De Meulder B, Loza MJ, Peffer N, Rowe A, Baribaud F, *et al.* U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. *J Allergy Clin Immunol* 2017;**139**:1797–807. <https://doi.org/10.1016/j.jaci.2016.08.048>
67. Maslove DM, Tang BM, McLean AS. Identification of sepsis subtypes in critically ill adults using gene expression profiling. *Crit Care* 2012;**16**:R183. <https://doi.org/10.1186/cc11667>
68. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, *et al.* Drotrecogin alfa (activated) in adults with septic shock. *N Engl J Med* 2012;**366**:2055–64. <https://doi.org/10.1056/NEJMoa1202290>
69. Antcliffe DB, Burnham KL, Al-Beidh F, Santhakumaran S, Brett SJ, Hinds CJ, *et al.* Transcriptomic signatures in sepsis and a differential response to steroids. From the VANISH randomized trial. *Am J Respir Crit Care Med* 2019;**199**:980–6. <https://doi.org/10.1164/rccm.201807-1419OC>
70. Shyamsundar M, McKeown ST, O’Kane CM, Craig TR, Brown V, Thickett DR, *et al.* Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. *Am J Respir Crit Care Med* 2009;**179**:1107–14. <https://doi.org/10.1164/rccm.200810-1584OC>
71. Bos LD, Scicluna BP, Ong DSY, Cremer OL, van der Poll T, Schultz MJ, *et al.* Understanding heterogeneity in biological phenotypes of ARDS by leukocyte expression profiles. *Am J Respir Crit Care Med* 2019;**200**:42–50. <https://doi.org/10.1164/rccm.201809-1808OC>
72. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. *Stat Med* 2002;**21**:2917–30. <https://doi.org/10.1002/sim.1296>
73. McAuley DF, Laffey JG, O’Kane CM, Cross M, Perkins GD, Murphy L, *et al.* Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in acute lung injury to reduce pulmonary dysfunction (HARP-2) trial: study protocol for a randomized controlled trial. *Trials* 2012;**13**:170. <https://doi.org/10.1186/1745-6215-13-170>

REFERENCES

74. Shankar-Hari M, McAuley DF. Divide and conquer: identifying acute respiratory distress syndrome subphenotypes. *Thorax* 2017;**72**:867–9. <https://doi.org/10.1136/thoraxjnl-2017-210422>
75. Russell JA, Lee T, Singer J, Boyd JH, Walley KR, Vasopressin and Septic Shock Trial (VASST) Group. The septic shock 3.0 definition and trials: a vasopressin and septic shock trial experience. *Crit Care Med* 2017;**45**:940–8. <https://doi.org/10.1097/CCM.0000000000002323>
76. Ferguson ND, Fan E, Camporota L, Antonelli M, Anzueto A, Beale R, *et al.* The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. *Intensive Care Med* 2012;**38**:1573–82. <https://doi.org/10.1007/s00134-012-2682-1>
77. Wong HR, Atkinson SJ, Cvijanovich NZ, Anas N, Allen GL, Thomas NJ, *et al.* Combining prognostic and predictive enrichment strategies to identify children with septic shock responsive to corticosteroids. *Crit Care Med* 2016;**44**:e1000–3. <https://doi.org/10.1097/CCM.0000000000001833>
78. Wong HR, Cvijanovich NZ, Anas N, Allen GL, Thomas NJ, Bigam MT, *et al.* Developing a clinically feasible personalized medicine approach to pediatric septic shock. *Am J Respir Crit Care Med* 2015;**191**:309–15. <https://doi.org/10.1164/rccm.201410-1864OC>
79. Williamson PR, Altman DG, Bagley H, Barnes KL, Blazeby JM, Brookes ST, *et al.* The COMET handbook: version 1.0. *Trials* 2017;**18**:280. <https://doi.org/10.1186/s13063-017-1978-4>

Appendix 1 Tables and figures

TABLE 19 Estimated class distribution, indicator means and separation for stage 1: the VANISH trial¹⁵

Parameter	Model											
	Two-class			Three-class				Four-class				
	Class		Separation	Class			Separation	Class				Separation
1	2	1		2	3	1		2	3	4		
Distribution (%)	51	49		27	44	29		32	13	34	21	
Organ dysfunction												
PaO ₂ /FiO ₂ ratio	0.342	-0.236	0.084	0.323	0.174	-0.351	0.084	0.343	0.515	-0.011	-0.522	0.157
Creatinine	-0.271	0.266	0.072	-0.748	0.363	0.133	0.229	-0.737	0.959	0.181	0.207	0.361
Platelets	0.189	-0.238	0.046	0.099	0.007	-0.178	0.013	0.114	0.413	-0.264	-0.095	0.064
Bilirubin	-0.147	0.234	0.036	-0.258	0.182	0.115	0.037	-0.124	-0.473	0.495	-0.123	0.122
Inflammation markers												
IL-1 β	-2.786	-1.088	0.721	-2.803	-2.08	-0.816	0.674	-2.608	-7.864	-1.592	-0.429	8.086
IL-6	-0.595	1.073	0.696	-0.763	-0.114	1.61	1.003	-0.706	-0.675	0.367	1.872	1.102
IL-8	-0.972	0.569	0.594	-1.208	-0.46	1.063	0.893	-1.078	-0.88	-0.097	1.268	0.85
IL-10	-1.008	0.604	0.65	-1.319	-0.343	0.964	0.875	-1.197	-0.83	0.15	0.984	0.728
IL-17	-2.943	-1.916	0.264	-3.002	-2.44	-1.997	0.169	-2.94	-3.649	-1.998	-1.754	0.573
IL-18	-0.440	0.252	0.12	-0.768	0.24	0.013	0.186	-0.604	-0.16	0.301	0.056	0.111
Leucocytes												
Myeloperoxidase	-0.394	0.432	0.171	-0.494	0.051	0.44	0.147	-0.477	-0.202	0.382	0.288	0.124
sICAM	-0.464	0.223	0.118	-0.583	0.088	-0.002	0.088	-0.518	-0.797	0.581	-0.277	0.266
Endothelial injury												
ANG II	-0.431	0.403	0.174	-0.809	0.288	0.275	0.264	-0.707	0.038	0.506	0.14	0.194
Cardiovascular												
Troponin	-0.35	0.346	0.121	-0.575	0.117	0.407	0.17	-0.558	0.357	0.187	0.356	0.143
NT-proBNP	-0.403	0.338	0.137	-0.808	0.28	0.222	0.25	-0.761	0.425	0.34	0.182	0.225
Other markers												
sTNFR1	-0.534	0.608	0.326	-1.055	0.316	0.629	0.535	-0.995	0.6	0.347	0.733	0.473
Lactate	-0.448	0.53	0.239	-0.671	-0.008	0.741	0.333	-0.596	-0.192	0.23	0.782	0.261

TABLE 20 Estimated class distribution, indicator means and separation for stage 2: the VANISH trial¹⁵

Parameter	Two-class model			Three-class model				Four-class model				
	Class		Separation	Class			Separation	Class				Separation
1	2	1		2	3	1		2	3	4		
Distribution (%)	51	49		40	29	31		29	18	26	28	
Organ dysfunction												
PaO ₂ /FiO ₂ ratio	0.314	-0.149	0.054	0.258	0.21	-0.188	0.04	0.337	0.38	-0.084	-0.174	0.061
Creatinine	-0.215	0.239	0.052	-0.809	0.582	0.085	0.331	-0.82	0.679	-0.484	0.174	0.337
Platelets	0.179	-0.223	0.04	0.173	-0.066	-0.102	0.015	-0.019	-0.172	0.398	-0.11	0.05
Bilirubin	-0.136	0.236	0.035	-0.101	0.151	0.082	0.011	-0.366	0.109	0.273	0.068	0.056
Inflammation markers												
IL-1β	-2.84	-1.085	0.77	-2.638	-2.571	-0.9	0.646	-2.818	-2.938	-2.098	-0.908	0.651
IL-6	-0.624	1.014	0.671	-0.58	-0.387	1.272	0.691	-0.974	-0.623	0.054	1.279	0.74
IL-8	-0.963	0.501	0.536	-0.982	-0.692	0.732	0.561	-1.426	-0.864	-0.36	0.706	0.616
IL-10	-1.04	0.601	0.673	-1.159	-0.637	0.833	0.711	-1.634	-0.856	-0.463	0.897	0.841
IL-17	-2.963	-1.806	0.335	-3.067	-2.446	-1.828	0.256	-2.914	-2.713	-2.664	-1.672	0.232
IL-18	-0.432	0.234	0.111	-0.592	0.068	0.132	0.107	-1.11	0.003	0.106	0.165	0.274
Leucocytes												
Myeloperoxidase	-0.414	0.454	0.188	-0.606	0.043	0.44	0.186	-0.67	0.173	-0.248	0.458	0.182
sICAM	-0.463	0.224	0.118	-0.691	0.175	0	0.14	-0.951	0.233	0.024	0.015	0.211
Endothelial injury												
ANG II	-0.431	0.371	0.161	-0.701	0.305	0.136	0.193	-0.867	0.194	-0.139	0.244	0.197
Cardiovascular												
Troponin	-0.335	0.348	0.117	-0.594	0.045	0.426	0.177	-0.579	-0.051	-0.245	0.384	0.121
NT-proBNP	-0.368	0.301	0.112	-0.803	0.421	0.145	0.275	-0.88	0.238	-0.265	0.234	0.211
Other markers												
sTNFR1	-0.524	0.598	0.315	-1.037	0.35	0.573	0.507	-1.317	0.331	-0.237	0.611	0.545
Lactate	-0.464	0.523	0.244	-0.636	-0.118	0.679	0.293	-0.76	-0.246	-0.225	0.618	0.244

TABLE 21 Estimated class distribution, indicator means and separation for stage 3a: the VANISH trial¹⁵

	Two-class model			Three-class model			
	Class 1	Class 2	Separation	Class 1	Class 2	Class 3	Separation
Distribution (%)	49	51		23	29	49	
Organ dysfunction							
PaO ₂ /FiO ₂ ratio	0.301	-0.142	0.049	0.199	0.306	-0.103	0.03
Creatinine	-0.235	0.255	0.06	0.609	-0.835	0.268	0.38
Platelets	0.166	-0.217	0.037	0.261	0.117	-0.221	0.041
Bilirubin	-0.099	0.193	0.021	-0.473	0.152	0.211	0.096
Inflammation markers							
IL-1 β	-2.012	-1.244	0.147	-2.431	-1.766	-1.205	0.251
IL-6	-0.607	1.036	0.675	-0.717	-0.484	1.048	0.613
IL-8	-0.948	0.479	0.509	-1.033	-0.841	0.508	0.47
IL-10	-1.036	0.605	0.673	-1.013	-0.995	0.625	0.59
IL-17	-2.947	-1.927	0.26	-2.778	-3.263	-1.863	0.337
IL-18	-0.404	0.204	0.092	-0.274	-0.452	0.235	0.085
Leucocytes							
Myeloperoxidase	-0.442	0.469	0.207	-0.15	-0.698	0.481	0.232
sICAM	-0.42	0.165	0.086	-0.078	-0.727	0.165	0.142
Endothelial injury							
ANG II	-0.415	0.372	0.155	-0.004	-0.669	0.331	0.173
Cardiovascular							
Troponin	-0.351	0.394	0.139	0.027	-0.661	0.448	0.209
NT-proBNP	-0.357	0.288	0.104	0.312	-0.764	0.277	0.249
Other markers							
sTNFR1	-0.513	0.593	0.306	0.042	-0.902	0.605	0.387
Lactate	-0.468	0.529	0.249	-0.216	-0.63	0.545	0.237

TABLE 22 Estimated class distribution, indicator means and separation for stage 3b: the VANISH trial¹⁵

Parameter	Two-class model			Three-class model				Four-class model				
	Class 1	Class 2	Separation	Class 1	Class 2	Class 3	Separation	Class 1	Class 2	Class 3	Class 4	Separation
Distribution (%)	54	46		22	46	32		23	38	15	25	
Organ dysfunction												
PaO ₂ /FiO ₂ ratio	0.233	-0.095	0.027	0.437	0.067	-0.208	0.07	0.439	0.028	-0.086	-0.272	0.068
Creatinine	-0.082	0.124	0.011	-0.567	0.009	0.108	0.089	-0.585	0.149	-0.314	0.143	0.098
Platelets	0.137	-0.185	0.026	0.138	0.04	-0.133	0.013	0.136	0.052	-0.072	0.151	0.008
Bilirubin	-0.062	0.141	0.01	-0.551	0.311	0.101	0.135	-0.535	0.384	0.326	-0.178	0.143
Inflammation markers												
IL-1β	-2.764	-1.037	0.746	-2.724	-2.204	-0.691	0.744	-2.608	-1.915	-2.583	-0.517	0.72
IL-6	-0.565	1.099	0.692	-1.122	0.05	1.411	1.071	-1.108	-0.034	0.509	1.568	0.932
IL-8	-0.93	0.603	0.588	-1.367	-0.443	0.895	0.862	-1.349	-0.569	0.208	0.993	0.761
IL-10	-1.004	0.717	0.74	-1.777	-0.414	0.942	1.232	-1.758	-0.541	0.575	0.865	1.069
IL-17	-2.88	-1.846	0.267	-2.563	-2.716	-1.677	0.21	-2.49	-2.315	-3.951	-1.371	0.853
IL-18	-0.314	0.176	0.06	-0.491	0.225	0.063	0.094	-0.507	0.261	0.37	0.032	0.114
Leucocytes												
Myeloperoxidase	-0.371	0.484	0.183	-0.527	-0.005	0.44	0.156	-0.547	-0.167	0.861	0.14	0.267
sICAM	-0.344	0.137	0.058	-0.763	0.16	0.038	0.168	-0.788	0.221	0.585	-0.503	0.302
Endothelial injury												
ANG II	-0.294	0.291	0.086	-0.635	0.18	0.165	0.145	-0.658	0.32	-0.202	0.032	0.128
Cardiovascular												
Troponin	-0.298	0.254	0.076	-0.614	0.149	0.071	0.117	-0.623	-0.054	0.991	0.009	0.337
NT-proBNP	-0.202	0.177	0.036	-0.377	-0.039	0.14	0.046	-0.403	0.129	0.002	-0.111	0.039
Other markers												
sTNFR1	-0.428	0.584	0.256	-0.787	0.045	0.609	0.329	-0.802	0.037	0.229	0.681	0.289
Lactate	-0.38	0.528	0.206	-1.013	-0.1	0.752	0.519	-1.012	-0.092	0.377	0.558	0.37

Note

In these models, indicators can be correlated within classes.

TABLE 23 Estimated class distribution, indicator means and separation for stage 3c: the VANISH trial¹⁵

Parameter	Two-class model			Three-class model			
	Class 1	Class 2	Separation	Class 1	Class 2	Class 3	Separation
Distribution (%)	44	56		29	23	48	
Organ dysfunction							
PaO ₂ /FiO ₂ ratio	0.16	0.008	0.006	0.423	-0.121	-0.032	0.057
Creatinine	-0.191	0.173	0.033	0.067	-0.332	0.132	0.042
Platelets	0.09	-0.082	0.007	-0.17	0.025	0.015	0.008
Bilirubin	-0.228	0.192	0.044	-0.377	0.493	0.093	0.126
Inflammation markers							
IL-1 β	-2.15	-1.332	0.167	-2.418	-2.475	-1.168	0.364
IL-6	-0.699	0.941	0.672	-0.631	-0.079	0.903	0.402
IL-8	-1.059	0.423	0.549	-0.802	-0.704	0.369	0.281
IL-10	-1.168	0.538	0.728	-1.023	-0.634	0.493	0.413
IL-17	-3.094	-1.991	0.304	-3.296	-3.956	-1.43	1.144
IL-18	-0.448	0.151	0.09	-0.275	-0.615	0.224	0.119
Leucocytes							
Myeloperoxidase	-0.39	0.339	0.133	-0.401	-0.028	0.36	0.097
sICAM	-0.25	-0.022	0.013	-0.238	-0.381	0.099	0.04
Endothelial injury							
ANG II	-0.335	0.223	0.078	-0.186	-0.24	0.216	0.041
Cardiovascular							
Troponin	-0.286	0.127	0.043	-0.228	-0.538	0.025	0.053
NT-proBNP	-0.263	0.138	0.04	-0.049	-0.29	0.082	0.024
Other markers							
sTNFR1	-0.501	0.474	0.238	-0.32	-0.202	0.382	0.094
Lactate	-0.482	0.457	0.22	-0.377	-0.042	0.323	0.082

Note

In these models, indicators can be correlated within classes.

TABLE 24 Differences in class assignment for main analysis and sensitivity analysis

Main analysis	Sensitivity analysis		
	Class 1	Class 2	Class 3
The LeoPARDS trial ¹⁶			
Class 1	180	11	0
Class 2	5	228	14
Class 3	0	0	55
The VANISH trial ¹⁵			
Class 1	87	3	
Class 2	2	84	

TABLE 25 Estimated class distribution, indicator means and separation for stage 1, two- to four-class models: the LeoPARDS trial¹⁶

Parameter	Two-class model			Three-class model				Four-class model				
	Class 1	Class 2	Separation	Class 1	Class 2	Class 3	Separation	Class 1	Class 2	Class 3	Class 4	Separation
Distribution (%)	61	39		33	53	14		35	23	29	13	
Organ dysfunction												
PaO ₂ /FiO ₂ ratio	0.144	-0.227	0.034	0.137	0.014	-0.367	0.046	0.12	0.045	-0.004	-0.389	0.039
Creatinine	-0.269	0.43	0.122	-0.562	0.203	0.562	0.22	-0.501	0.393	0.027	0.605	0.176
Platelets	0.262	-0.416	0.115	0.368	-0.053	-0.671	0.182	0.362	-0.359	0.164	-0.722	0.183
Bilirubin	-0.26	0.404	0.11	-0.409	0.188	0.247	0.088	-0.398	0.721	-0.222	0.284	0.193
Inflammation markers												
IL-1 β	-0.526	0.403	0.216	-0.782	-0.126	1.142	0.638	-0.751	-0.46	0.172	1.202	0.561
IL-6	-0.388	1.12	0.569	-0.715	0.23	2.265	1.546	-0.709	-0.186	0.679	2.28	1.283
IL-8	-0.503	0.873	0.473	-0.876	0.124	1.788	1.207	-0.875	-0.066	0.392	1.826	0.963
IL-10	-0.507	0.833	0.449	-0.873	0.167	1.493	0.938	-0.85	0.234	0.182	1.559	0.731
IL-17	-0.394	0.515	0.207	-0.555	0.037	0.86	0.337	-0.534	0.111	0.004	0.91	0.266
IL-18	-0.295	0.608	0.204	-0.477	0.218	0.682	0.227	-0.455	0.82	-0.25	0.764	0.333
Leucocytes												
Myeloperoxidase	-0.428	0.432	0.185	-0.659	0.075	0.578	0.258	-0.617	0.384	-0.182	0.66	0.245
sICAM	-0.221	0.642	0.186	-0.3	0.19	0.781	0.195	-0.272	0.954	-0.412	0.841	0.388
Endothelial injury												
ANG II	-0.48	0.786	0.401	-0.897	0.328	0.93	0.578	-0.832	0.778	-0.034	1.018	0.53
Cardiovascular												
Troponin	-0.087	0.139	0.013	-0.152	0.055	0.151	0.016	-0.122	0.259	-0.157	0.211	0.036
NT-proBNP	-0.42	0.168	0.086	-0.51	-0.141	0.356	0.126	-0.471	0.31	-0.514	0.387	0.178
Other markers												
sTNFR1	-0.44	0.694	0.321	-0.872	0.328	0.798	0.494	-0.812	0.596	0.119	0.849	0.402
Lactate	-0.422	0.661	0.293	-0.665	0.144	0.991	0.457	-0.652	0.264	0.102	1.036	0.359
CCL2	-0.494	0.925	0.503	-0.809	0.121	1.819	1.184	-0.795	0.026	0.288	1.874	0.936
Note	Bold font indicates the five indicators with the greatest separation (measured by the variance of the estimated class means) in each model.											

TABLE 26 Estimated class distribution, indicator means and separation for stage 1, five latent classes: the LeoPARDS trial¹⁶

Parameter	Five-class model					Separation
	Class 1	Class 2	Class 3	Class 5	Class 4	
Organ dysfunction						
PaO ₂ /FiO ₂ ratio	0.103	0.126	-0.062	-0.017	-0.455	0.044
Creatinine	-0.802	0.14	0.603	-0.121	0.584	0.27
Platelets	0.382	0.154	-0.666	0.193	-0.576	0.186
Bilirubin	-0.514	-0.011	0.999	-0.287	0.032	0.267
Inflammation markers						
IL-1 β	-0.907	-0.439	-0.114	0.234	1.407	0.611
IL-6	-0.891	-0.374	0.365	0.927	2.608	1.468
IL-8	-1.011	-0.427	0.342	0.563	2.048	1.075
IL-10	-0.98	-0.33	0.606	0.266	1.681	0.805
IL-17	-0.635	-0.228	0.332	0.019	1.068	0.329
IL-18	-0.579	0.051	1.015	-0.329	0.631	0.35
Leucocytes						
Myeloperoxidase	-0.678	-0.176	0.726	-0.281	0.426	0.256
sICAM	-0.415	0.124	1.124	-0.466	0.732	0.392
Endothelial injury						
ANG II	-1.145	0.048	1.015	-0.095	0.945	0.626
Cardiovascular						
Troponin	-0.317	0.214	0.253	-0.268	0.171	0.062
NT-proBNP	-0.736	0.027	0.267	-0.602	0.403	0.211
Other markers						
sTNFR1	-1.146	0.041	0.949	0.014	0.737	0.538
Lactate	-0.762	-0.312	0.669	0.22	0.985	0.403
CCL2	-0.957	-0.355	0.522	0.398	2.001	0.992

Note

Bold font indicates the five indicators with the greatest separation (measured by the variance of the estimated class means) in each model.

TABLE 27 Estimated class distribution, indicator means and separation for stage 2: the LeoPARDS trial¹⁶

Parameter	Two-class model			Three-class model				Four-class model				
	Class 1	Class 2	Separation	Class 1	Class 2	Class 3	Separation	Class 1	Class 2	Class 3	Class 4	Separation
Distribution (%)	58	42		32	56	12		26	41	21	12	
Organ dysfunction												
PaO ₂ /FiO ₂ ratio	0.109	-0.128	0.014	0.075	0.012	-0.23	0.017	0.072	0.045	0.148	-0.286	0.028
Creatinine	-0.248	0.314	0.079	-0.513	0.171	0.432	0.159	-0.715	0.13	0.289	0.428	0.198
Platelets	0.249	-0.331	0.084	0.363	-0.052	-0.595	0.154	0.352	0.194	-0.518	-0.513	0.159
Bilirubin	-0.276	0.338	0.094	-0.423	0.18	0.081	0.07	-0.509	-0.178	0.936	0.048	0.287
Inflammation markers												
IL-1 β	-0.575	0.396	0.236	-0.829	-0.111	1.327	0.804	-0.932	-0.116	-0.363	1.353	0.711
IL-6	-0.462	1.085	0.598	-0.759	0.278	2.42	1.752	-0.871	0.134	0.068	2.441	1.489
IL-8	-0.54	0.818	0.461	-0.891	0.154	1.909	1.335	-0.986	-0.03	0.174	1.921	1.101
IL-10	-0.533	0.774	0.427	-0.872	0.181	1.597	1.023	-0.961	-0.105	0.471	1.58	0.853
IL-17	-0.397	0.463	0.185	-0.538	0.054	0.845	0.321	-0.572	-0.149	0.236	0.885	0.287
IL-18	-0.277	0.503	0.152	-0.463	0.204	0.599	0.192	-0.515	-0.146	0.907	0.505	0.306
Leucocytes												
Myeloperoxidase	-0.385	0.317	0.123	-0.636	0.075	0.519	0.226	-0.64	-0.209	0.449	0.402	0.204
sICAM	-0.236	0.563	0.16	-0.293	0.172	0.754	0.183	-0.323	-0.243	1.122	0.69	0.378
Endothelial injury												
ANG II	-0.506	0.723	0.378	-0.914	0.327	0.876	0.561	-1.028	0.001	0.772	0.855	0.573
Cardiovascular												
Troponin	-0.041	0.052	0.002	-0.18	0.062	0.146	0.019	-0.235	0.038	0.126	0.144	0.023
NT-proBNP	-0.389	0.099	0.06	-0.465	-0.137	0.334	0.108	-0.591	-0.274	0.163	0.348	0.135
Other markers												
sTNFR1	-0.433	0.583	0.258	-0.862	0.313	0.701	0.442	-1.051	0.09	0.638	0.652	0.479
Lactate	-0.44	0.606	0.274	-0.675	0.172	0.904	0.416	-0.733	-0.144	0.542	0.891	0.392
CCL2	-0.527	0.863	0.483	-0.814	0.152	1.908	1.27	-0.913	-0.054	0.283	1.897	1.037

Note

Bold font indicates the five indicators with the greatest separation (measured by the variance of the estimated class means) in each model.

TABLE 28 Estimated class distribution, indicator means and separation for stage 3a: the LeoPARDS trial¹⁶

Parameter	Two-class model			Three-class model				Four-class model				
	Class 1	Class 2	Separation	Class 1	Class 2	Class 3	Separation	Class 1	Class 2	Class 3	Class 4	Separation
Distribution (%)	54	46		30	51	19		31	24	29	16	
Organ dysfunction												
PaO ₂ /FiO ₂ ratio	0.108	-0.091	0.01	0.092	0.057	-0.234	0.021	0.073	0.112	0.053	-0.269	0.023
Creatinine	-0.272	0.278	0.076	-0.524	0.148	0.349	0.139	-0.499	0.335	0.006	0.395	0.126
Platelets	0.323	-0.336	0.109	0.362	0.061	-0.693	0.197	0.379	-0.439	0.275	-0.533	0.168
Bilirubin	-0.298	0.305	0.091	-0.471	0.116	0.256	0.099	-0.454	0.687	-0.236	0.129	0.187
Inflammation markers												
IL-1β	-0.591	0.327	0.211	-0.834	-0.113	0.79	0.441	-0.798	-0.507	0.147	1.112	0.538
IL-6	-0.49	0.971	0.534	-0.819	0.18	1.932	1.293	-0.795	-0.274	0.56	2.233	1.316
IL-8	-0.602	0.744	0.453	-0.949	0.046	1.541	1.047	-0.932	-0.129	0.305	1.742	0.942
IL-10	-0.591	0.698	0.415	-0.925	0.066	1.371	0.884	-0.919	0.209	0.129	1.465	0.714
IL-17	-0.423	0.402	0.17	-0.564	-0.004	0.68	0.259	-0.546	0.124	-0.075	0.828	0.244
IL-18	-0.351	0.502	0.182	-0.477	0.162	0.518	0.169	-0.466	0.732	-0.199	0.48	0.237
Leucocytes												
Myeloperoxidase	-0.452	0.306	0.144	-0.641	0.037	0.377	0.179	-0.611	0.252	-0.127	0.455	0.165
sICAM	-0.26	0.518	0.151	-0.302	0.118	0.687	0.164	-0.276	0.919	-0.396	0.692	0.334
Endothelial injury												
ANG II	-0.563	0.648	0.367	-0.941	0.269	0.729	0.496	-0.884	0.631	-0.053	0.838	0.453
Cardiovascular												
Troponin	-0.051	0.041	0.002	-0.163	0.065	0.08	0.012	-0.143	0.214	-0.062	0.08	0.019
NT-proBNP	-0.44	0.095	0.072	-0.5	-0.159	0.229	0.089	-0.479	0.3	-0.667	0.35	0.206
Other markers												
sTNFR1	-0.48	0.523	0.252	-0.898	0.273	0.591	0.41	-0.857	0.493	0.115	0.622	0.336
Lactate	-0.469	0.523	0.246	-0.697	0.099	0.729	0.34	-0.693	0.142	0.159	0.82	0.288
CCL2	-0.57	0.763	0.444	-0.85	0.035	1.538	0.972	-0.832	-0.009	0.17	1.766	0.885

Note

Bold font indicates the five indicators with the greatest separation (measured by the variance of the estimated class means) in each model.

TABLE 29 Estimated class distribution, indicator means and separation for stage 3b: the LeoPARDS trial¹⁶

Parameter	Two-class model			Three-class model				Four-class model				
	Class 1	Class 2	Separation	Class 1	Class 2	Class 3	Separation	Class 1	Class 2	Class 3	Class 4	Separation
Distribution (%)	58	42		39	50	11		31	25	33	11	
Organ dysfunction												
PaO ₂ /FiO ₂ ratio	0.12	-0.15	0.018	0.098	-0.01	-0.252	0.021	0.076	0.109	-0.096	-0.232	0.019
Creatinine	-0.228	0.289	0.067	-0.368	0.155	0.451	0.115	-0.512	0.233	0.078	0.459	0.129
Platelets	0.238	-0.319	0.078	0.304	-0.087	-0.58	0.131	0.378	-0.335	0.119	-0.627	0.152
Bilirubin	-0.231	0.284	0.066	-0.295	0.196	0.021	0.041	-0.454	0.585	-0.01	0.054	0.136
Inflammation markers												
IL-1 β	-0.587	0.416	0.252	-0.774	-0.036	1.383	0.801	-0.825	-0.5	0.157	1.381	0.713
IL-6	-0.487	1.123	0.648	-0.746	0.428	2.506	1.808	-0.773	-0.369	0.795	2.456	1.571
IL-8	-0.552	0.838	0.483	-0.836	0.274	1.954	1.315	-0.925	-0.173	0.45	1.953	1.119
IL-10	-0.532	0.775	0.427	-0.779	0.283	1.601	0.948	-0.894	0.058	0.344	1.62	0.807
IL-17	-0.4	0.465	0.187	-0.499	0.106	0.9	0.328	-0.565	0.079	0.079	0.924	0.28
IL-18	-0.258	0.479	0.136	-0.358	0.246	0.569	0.148	-0.497	0.641	-0.053	0.605	0.226

continued

TABLE 29 Estimated class distribution, indicator means and separation for stage 3b: the LeoPARDS trial¹⁶ (continued)

Parameter	Two-class model			Three-class model				Four-class model				
	Class 1	Class 2	Separation	Class 1	Class 2	Class 3	Separation	Class 1	Class 2	Class 3	Class 4	Separation
Leucocytes												
Myeloperoxidase	-0.373	0.303	0.114	-0.531	0.125	0.461	0.17	-0.64	0.194	-0.008	0.49	0.172
sICAM	-0.2	0.515	0.128	-0.175	0.166	0.742	0.143	-0.312	0.823	-0.195	0.777	0.279
Endothelial injury												
ANG II	-0.486	0.696	0.349	-0.709	0.356	0.894	0.444	-0.896	0.556	0.152	0.933	0.467
Cardiovascular												
Troponin	-0.017	0.018	0	-0.034	-0.017	0.157	0.007	-0.09	0.126	-0.128	0.18	0.018
NT-proBNP	-0.368	0.07	0.048	-0.346	-0.184	0.361	0.091	-0.496	0.166	-0.359	0.359	0.126
Other markers												
sTNFR1	-0.414	0.56	0.237	-0.659	0.333	0.705	0.331	-0.865	0.404	0.229	0.719	0.355
Lactate	-0.425	0.59	0.258	-0.613	0.263	0.91	0.39	-0.684	0.048	0.342	0.898	0.326
CCL2	-0.533	0.873	0.494	-0.753	0.262	1.944	1.237	-0.817	-0.087	0.369	1.966	1.041
Notes												
In these models, the residual variance of each indicator can differ across classes.												
Bold font indicates the five indicators with the greatest separation (measured by the variance of the estimated class means) in each model.												

TABLE 30 Estimated class distribution, indicator means and separation for stage 3c: the LeoPARDS trial¹⁶

Parameter	Two-class model			Three-class model				Four-class model				
	Class 1	Class 2	Separation	Class 1	Class 2	Class 3	Separation	Class 1	Class 2	Class 3	Class 4	Separation
Distribution (%)	54	46		37	43	20		33	21	30	16	
Organ dysfunction												
PaO ₂ /FiO ₂ ratio	0.138	-0.132	0.018	0.08	0.063	-0.221	0.019	0.074	0.137	0.023	-0.261	0.023
Creatinine	-0.259	0.267	0.069	-0.39	0.116	0.375	0.101	-0.446	0.309	0.02	0.389	0.107
Platelets	0.316	-0.33	0.104	0.344	0.099	-0.771	0.229	0.394	-0.539	0.282	-0.518	0.189
Bilirubin	-0.247	0.242	0.06	-0.319	0.094	0.227	0.054	-0.42	0.706	-0.183	0.103	0.177
Inflammation markers												
IL-1 β	-0.612	0.367	0.24	-0.801	-0.027	0.734	0.393	-0.78	-0.521	0.15	1.096	0.526
IL-6	-0.513	1.015	0.584	-0.772	0.328	1.791	1.102	-0.765	-0.293	0.54	2.239	1.309
IL-8	-0.61	0.768	0.475	-0.882	0.17	1.416	0.882	-0.905	-0.141	0.293	1.757	0.94
IL-10	-0.591	0.714	0.426	-0.832	0.153	1.327	0.779	-0.885	0.219	0.141	1.459	0.69
IL-17	-0.436	0.425	0.185	-0.499	0.039	0.641	0.217	-0.528	0.065	0.013	0.793	0.221
IL-18	-0.331	0.477	0.163	-0.378	0.17	0.539	0.142	-0.459	0.804	-0.168	0.464	0.249

continued

TABLE 30 Estimated class distribution, indicator means and separation for stage 3c: the LeoPARDS trial¹⁶ (continued)

Parameter	Two-class model			Three-class model				Four-class model				
	Class 1	Class 2	Separation	Class 1	Class 2	Class 3	Separation	Class 1	Class 2	Class 3	Class 4	Separation
Leucocytes												
Myeloperoxidase	-0.447	0.308	0.143	-0.552	0.079	0.356	0.144	-0.614	0.304	-0.085	0.426	0.164
sICAM	-0.217	0.46	0.115	-0.15	0.061	0.693	0.128	-0.248	0.937	-0.334	0.662	0.308
Endothelial injury												
ANG II	-0.541	0.634	0.345	-0.736	0.289	0.707	0.368	-0.855	0.664	0.015	0.797	0.428
Cardiovascular												
Troponin	-0.033	0.018	0.001	-0.049	0.008	0.069	0.002	-0.13	0.264	-0.109	0.057	0.025
NT-proBNP	-0.416	0.074	0.06	-0.362	-0.242	0.265	0.074	-0.456	0.33	-0.609	0.315	0.186
Other markers												
sTNFR1	-0.458	0.511	0.235	-0.69	0.285	0.581	0.295	-0.799	0.485	0.158	0.601	0.303
Lactate	-0.454	0.512	0.233	-0.636	0.194	0.682	0.296	-0.677	0.174	0.151	0.792	0.273
CCL2	-0.571	0.779	0.456	-0.794	0.113	1.471	0.866	-0.818	0.005	0.16	1.772	0.88

Notes

In these models, the residual variance of each indicator can differ across classes.

Bold font indicates the five indicators with the greatest separation (measured by the variance of the estimated class means) in each model.

TABLE 31 Patient characteristics of the HARP-2 trial cohort¹⁷

Characteristic	Value
Age (years), mean (SD)	53.8 (16.5)
Male sex, <i>n</i> (%)	307 (57)
ARDS risk factors: direct, <i>n</i> (%)	
Aspiration	49 (9.1)
Pneumonia	295 (54.6)
Trauma	31 (5.7)
Other	28 (5.2)
None	137 (25.4)
ARDS risk factors: indirect, <i>n</i> (%)	
Sepsis	224 (41.9)
Pancreatitis	18 (3.3)
Other	33 (6.1)
None	265 (49.1)
APACHE II score (points), mean (SD)	18.8 (6.6)
SOFA score (points), mean (SD)	8.8 (3.1)
Vasopressor dependent, <i>n</i> (%)	356 (66.1)
PaO ₂ /FiO ₂ ratio (mmHg), mean (SD)	17.0 (7.4)
Tidal volume (ml/kg), mean (SD)	8.1 (2.7)
28-day mortality, <i>n</i> (%)	132 (24.5)
90-day mortality, <i>n</i> (%)	165 (30.6)
Ventilator-free days, median (IQR)	13 (0–22)
Non-pulmonary organ failure-free days, median (IQR)	25 (4–28)
Baseline plasma IL-6 (pg/ml) concentration, median (25–75%)	4.9 (4–5.9)
Baseline plasma sTNFR1 (pg/ml) concentration, median (25–75%)	8.5 (8–9.1)

TABLE 32 List of class-defining variables used in the LCA in the HARP-2 trial¹⁷

Variable name	Missing (<i>n</i>)
Age	0
Sex	1
Pulmonary ARDS (i.e. aspiration, pneumonia, trauma, other, none)	0
Extrapulmonary ARDS (sepsis, pancreatitis, other, none)	0
Bilirubin	37
Creatinine	22
Platelets	23
PaO ₂ /FiO ₂ ratio	1
Plateau pressure	245
Tidal volume	45
Vasopressor dependent	1
IL-6	30
sTNFR1	29




FIGURE 40 Separation plot for the stage 2 two-class model: the VANISH trial.¹⁵ P/F, PaO₂/FiO₂ ratio.




FIGURE 41 Separation plot for the stage 2 three-class model: the VANISH trial.¹⁵ P/F, PaO₂/FiO₂ ratio.




FIGURE 42 Separation plot for the stage 3b two-class model: the VANISH trial.¹⁵ P/F, PaO₂/FiO₂ ratio.




FIGURE 43 Separation plot for the stage 3 three-class model: the VANISH trial.¹⁵ P/F, PaO₂/FiO₂ ratio.




FIGURE 44 Separation plot for the stage 2 model: the LeoPARDS trial.¹⁶ P/F, PaO₂/FiO₂ ratio.




FIGURE 45 Separation plot for the stage 3a model: the LeoPARDS trial.¹⁶ P/F, PaO₂/FiO₂ ratio.




FIGURE 46 Separation plot for the stage 3b model: the LeoPARDS trial.¹⁶ P/F, PaO₂/FiO₂ ratio.




FIGURE 47 Separation plot for the stage 3c model: the LeoPARDS trial.¹⁶ P/F, PaO₂/FIO₂ ratio.

EME
HS&DR
HTA
PGfAR
PHR

Part of the NIHR Journals Library
www.journalslibrary.nihr.ac.uk

*This report presents independent research funded by the National Institute for Health Research (NIHR).
The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the
Department of Health and Social Care*

Published by the NIHR Journals Library